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ABSTRACT 
This study investigate the effects of four Chinese herbs for their potential therapeutic 
use as analgesics. It involved screening for inhibitors of enkephalin-hydrolysing 
enzymes, especially selective NEP inhibitors, mixed NEP/APN inhibitors and mixed 
NEP/ACE inhibitors. NEP was the key enzyme in the screening systems. 
Four Chinese herbs Yan (Corydalis yanhusuo 7: Wang); Gou (Nauclea siý7ensis 
Oliv. ); Qiang (Notopterygium incisum Ting ex H. T (7hang); and Chuan (Ligusticum 
chuanxiong Hort. ) were tested for their inhibitory effects on NEP activity measured 
in a rat kidney extract. Aqueous extracts of Gou and Qiang showed the significant 
inhibitory activity on NEP but results with organic extracts were not significant. Gou 
showed the strongest inhibitory activity on NEP. It was found that Gou also showed 
an inhibitory activity on the other two enkephalin-hydrolysing enzymes, APN and 
ACE in the microsomal mixture. 
A rat-brain opiate-receptor preparation (section 5.2.1) was used in ligand binding 
experiments with competition for the receptor sites between the aqueous Gou extract 
and tritium-labelled naloxone. For very small quantities of Gou there was a lowering 
of naloxone binding showing the antagonistical action of Gou. At higher 
concentrations (> 4 mg/ml of Gou) there was a tendency for naloxone binding to 
increase demonstrating potential agonistic activity. 
To test whether one compound in Gou had inhibitory activity on the three enzymes, 
or several compounds acting together, the aqueous extract of Gou was separated by 
HPLC. The HPLC-eluted fractions were pooled into seven parts and collected. The 
seven eluates were assayed for their effects on NEP proteolysis of 3H(leu)- 
enkephalin. Only six eluates showed inhibitory activity on NEP. The three single 
compounds already fractionated by others (rhynchophylline, mitraphylline and 
poteropodine) were shown to correspond in the Pool 7. An unexpectedly large 
number of active fractions suggest that many active compounds are present in Gou. 
It can be concluded that of the four herbs tested Gou (Nauclea sinensis Oliv) offers 
considerable potential as a novel analgesic agent. 
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A(nm) Absorbance or Absorption at some wavelength (nm) 
ACE Angiotensin-converting enzyme 
A° Angstron unit (10- 8 cm) 
APN Aminopeptidase N (APN E. C. 3.4.24.11.2) 
APS Aminopeptidase S 
ANP Atrial natriuretic peptide 
Bes Bestatin 
BFC Buffer control 
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cDNA Complementary DNA 
Cap Captopril 
CE/E Enzyme in a given mixture of rat kidney crude microsomal fractions 
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CPM Counts per minute 
°C centigrade 
Dap Dipeptidyl aminopeptidase 
DNA Deoxyribonucleic acid 
DPM Disintegrations per minute 
EDTA Ethylenediamine tetraacetic acid 
Gou Gouteng (Uncaria rhynchophylla. Miq. Jackson) 
Gn Gouteng undiluted (neat) 
Gwext Gou water (aqueous) extract 
HIC Hydrophobic interaction chromatography 
HPLC High performance liquid chromatography 
Hr Hour 
IC50 50% of inhibitory concentration 
i. p. Intraperitoneally 
IR Infra red spectrum 
i. v. Intra venous 
kDa kilo Dalton 
K» Equilibrium dissociation constant 
Ki Equilibrium inhibition constant 
McAb Monoclonal antibody 
MIC Minimal inhibitory concentration 
mg milli gram 
ml milli liter 
min Minutes 
mm Millimolar 
nM nano molar 
pmoles 10"12 moles 
Mw Molecular weight 
nm Nanometre 
NEP Neutral endopeptidase (E. C. 3.4.24.11) 
OD Optical density 
P Probability 
PCT Proximal convoluted tubule 
PBQ Phenyl-1,4-benzo quinone 
Qiang Qianghuo (Notopterygium incisum Ting ex H. 7. Chang) 
Qn Qianghuo undiluted (neat) 
Qwext Qiang water (aqueous) extract 
RAS Renin angiotensin aldosterone system 
RPM Revolutions per minute 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
TCM Traditional chinese medicine 
TCI-IM Traditional chinese herbal medicine 
TCA Trichloroacetic acid 
Thio Thiorphan 
TFA Trifluroacetic acid 
TLC Thin layer chromatography 
Tm Melting temperature 
Tris Tri-hydroxymethyl methylamine 
UV Ultra violet 
µl 10"6 liter 
µM 10-6 molar 
Yan Yan hu suo (Corydalis yanhusuo 7. Wang) 
Yn Yan hu suo undiluted (neat) 
% percent 
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CHAPTER I 
INTRODUCTION 
1.1 Research Background 
It has been known that the endogenous opioid peptides Met- and Leu-enkephalin are 
rapidly inactivated in vivo, by neutral endopeptidase (NEP E. C. 3.4.24.11) (Malfroy 
et al., 1978; Guyon et al., 1979) and aminopeptidase N (APN E. C 3.4.11.2) 
(Hambrook et al., 1976; Hersh, 1986); a further enkephalin inactivator is 
angiotensin-converting enzymes (ACE) (Waksman et al., 1984; Giros et al., 1986). 
In recent years the inhibition of enkephalin metabolism has been extensively 
investigated with the aim of testing the hypothesis that increasing the level of 
endogenous enkephalins in neuronal pathways implicated in pain transmission could 
lead to a "physiological" analgesia free of the major side effects of morphine (Roques 
and Fournie-Zaluski, 1986; Chipkin., 1986). These hypotheses have been 
demonstrated in experiments and the relationship among the NEP/APN versus 
enkephalin and analgesia can be briefly described in the following diagram (Figure 
1.1). 
According to Figure 1.1 inhibitors of NEP and APN increase the level of 
endogenous enkephalin, and potent physiological analgesic responses should be 
produced without major side effects in all animals in pain for which morphine is 
normally prescribed (Fournie-zaliski et al., 1984; Claude et al., 1984; Nobel e[ al., 
1991,1992,1997; Chen et al., 1998). In addition, specific inhibitors of NEP have 
been found to have the following uses as: (1) antidiarrheal without constipation; (2) 
treatment for acute cholecystitis; (3) diuretic and natri uretic (protection of atrial 
natriuretic peptide) and (4) antidepressant (Seymour et al., 1995; Roques, 1993). 
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Figure 1.1 Schematic Representation of the Spinal Localization of NEP in a 
Model of "Neuropeptide Extended Synaptic Area" (Roques et al., 1993). 
The enkephalins, released from the spinal interneurons, interact presynaptically 
with opioid receptors located on the afferent fiber terminals to modulate 
peptide secretion (SP, CGRP). The concentration of the peptides at the receptor 
level is dependent on both their passive dilution in the extended synaptic 
volume and the efficiency of the inactivation processes ensured by peptidases, 
such as NEP, mainly located on the enkephalin neurones. The fast enkephalin- 
induced responses observed in electrophysiological experiments could 
correspond to the release of the opioid peptide into a classical synaptic area at 
the cell body level of spinothalamic neurons. 
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Based the above background many scientists are interested in screening the inhibitors 
of the enkephalin-hydrolying enzymes (including NEP, APN and ACE) and have 
obtained much knowledge in this field. French scientists are concentrating on 
biosynthesis of the enkephalin-like compounds which are sensitive to NEP, APN, 
DAP and ACE (Adjroud, 1995; Nobel of al., 1991,1992,1997). So far they have 
developed a family of analgesics devoid of opioid side effects (Chen el al., 1998; 
Nobel et al., 1997), but no compound has actually been applied clinically. Japanese 
scientists are engaged in screening the natural inhibitors of these enzymes from 
micro-organisms (Kojima, 1990; Akiyama et al., 1998; Otani, 1991,1992; Tsurumi, 
1995; Kimura, 1990; Tsuru ei al., 1992). However, far from satisfactory results 
were obtained. As one kind of natural resource, plants are also worth investigating 
but so far no papers have been published. Traditional Chinese Herbs (TCH) have 
been used as analgesics for thousands of years (Yang et al., 1985). Even the most 
widely used analgesic---morphine, originates from a plant. Considering the above 
facts and the close relationship between NEP inhibitors and analgesics, it might be 
possible to find new analgesics by use of Chinese herbs clinically. This effect may be 
mediated by altering the metabolism of endogenous enkephalin, by inhibiting NEP 
and APN, thus making analgeia possible free of induced physical and psychic 
dependence. 
1.2 Nociception, Pain, Analgesia and Drug Addiction 
1.2.1 Nociception, Pain and Their Relationship 
Nociception refers to the reception of signals in the central nervous system evoked by 
activation of specialized sensory receptors (nociceptors) that provide information 
about tissue damage. Pain is the perception of an aversive or unpleasant sensation 
that originates from a specific region of the body. Not all noxious stimuli that 
activate nociceptors necessarily cause an experience of pain (Jessel and Kelly, 1991). 
The nociceptors can be activated by mechanical, thermal, or chemical stimuli. Tissue 
damage can also sensitize nociceptors. All perception of pain involves an abstraction 
and elaboration of sensory inputs. Usually local pain can be sensed when the 
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nociceptive pathways are damaged, but pain can also be modulated by the balance of 
activity between nociceptive and other afferent inputs. 
Pain is a highly complex perception. More than any other modality it is influenced by 
emotions and the environment. Because it is so dependent on experience, and 
therefore varies from person to person, pain is a difficult clinical problem. Moreover, 
the current understanding of the anatomy and physiology of specific pain circuits is 
still fragmentary. Nevertheless, recent advances in understanding the basic 
physiology of pain mechanisms have led to some effective pain therapies. 
First, the finding that the balance of activity in small and large fibers is important in 
pain transmission led to the use of dorsal column stimulation and transcutaneous 
electrical nerve stimulation for certain types of peripheral pain. Second, the 
experimental finding that stimulation of specific sites in the brain stem produces 
profound analgesia may eventually lead to better ways of controlling pain by 
activating endogenous pain modulatory systems. Third, the discovery that opiates 
applied directly to the spinal cord exert potent analgesic effects has led to the use of 
intrathecal and epidural administration of opiates for certain conditions. Finally the 
unravelling of the neurotransmitter systems underlying endogenous pain control 
circuits may provide a more rational basis for drug therapies in a variety of pain 
syndromes (Jessel and Kelly, 1991). 
1.2.2 Analgesia and Whole Animal Tests for the Analgesia 
Pain is an unpleasant sensory experience associated with actual or potential tissue 
damage. It may be acute or chronic in character; Both types are customarily treated 
by the administration of drugs known as analgesics. Analgesics used to treat pain are 
often classified into two categories: the narcotics that bind to opioid receptors, and 
the non-narcotics that lack an affinity for such receptors but work via other 
mechanisms (Tyler, 1980). The investigation of analgesics is a long-term project, 
and the research advances are relevant to our understanding of endogenous opioid 
systems in the human brain. So far the most direct tests of analgesic action are those 
carried out on whole animals. The following are typical tests in this category. 
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Writhing Test 
The writhing test was derived from that of Hendershot and Forsaith (1959). Mice 
received i. p. (intra peritoneally) 0.1 ml of a freshly prepared solution of PBQ (Phenyl- 
1,4-benzo quinone) per 10 g of body weight. 0.02% of PBQ was dissolved in 5% 
ethanol obtained by prior dissolution of PBQ in ethanol followed by addition of 
distilled water: the solution was kept out of the light and in a water bath set at 40°C. 
The injection produced the typical writhing reaction, which is characterized by 
contractions of the abdominal musculature followed by extension of the hind limbs. 
The mice were placed in individual transparent containers and the number of writhes 
per animal was counted during a 10-min period starting 10 min after the injection. 
The mean number of writhes for each treatment group was statistically analyzed with 
ANOVA, followed by Dunnett's t-test or Newman-Keuls test for multiple 
comparisons. 
Tail Flick Test 
The antinociceptive responses were determined by measuring the time required to 
respond to a painful radiating thermal stimulus, according to the method of D'Amour 
and Smith (1941). The rat was restricted so that the radiant heat source was focused 
onto the base of the tail. An automated tail-flick analgesymeter (Apelex, France) was 
used. The cut-off time was set at 15 seconds. For each rat, three determinations 
were carried out before drug injection (control latency). The tail-flick latency 
responses were expressed as a percentage of analgesia calculated by: percent 
analgesia = (test latency-control latency)/ (cut-off time-control latency) x 100. The 
intensity of the thermal stimulus was adjusted to obtain a control latency between 4 
and 6 seconds. Results were analyzed with ANOVA, followed by the Newman- 
Keuls test. 
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Hot Plate Test 
The test was based on that described by Eddy and Leimbach (1953). A glass cylinder 
(16 cm diameter) was used to keep the mouse at 55±0.5°C using a thermoregulated 
water-circulating pump. The latency period until the mouse jumped was registered 
by a means of a stopwatch (cut-off time 240 sec). Dose-response curves were 
established by expressing the data as a percent analgesia using the following equation, 
percent analgesia = (test latency - control latency) (cut-off time - control latency) x 
100. 
Statistical analysis was carried out with ANOVA followed by the Dunnett's t-test or 
the Newman-Keuls test for multiple comparisons. 
In this thesis the opioid receptor-binding assays were carried out so that the 
correlative mechanism between the analgesic activity of target herbs and their 
inhibitory activity on NEP/APN/ACE were to be clarified. In detail highly sensitive 
bioassays, antagonised by naloxone, a powerful morphine antagonist, provided the 
detection system. 
1.2.3 The Investigation of Analgesics and Drug Dependence 
Many of the analgesics applied clinically were found to induce drug dependence. 
The term "drug dependence" was defined as a state arising from repeated 
administration of a drug on a periodic or continuous basis and included both psychic 
and physical dependence (Warburton, 1975; Cooper et al., 1986). 
According to the definition, the dependence characteristics varied with the drug 
involved so that there would be drug dependence of the morphine type, of the 
amphetamine type, of the cannabis type, of the barbiturate type etc.. 
7 
Opiate (Morphine) Dependence 
Opiates have long been widely recognised as excellent analgesics, but with 
disadvantageous side effects such as physical dependence, appetite suppression, 
respiratory depression, and other behavioural effects that have limited their use. It 
has been shown that these effects are mediated through multiple receptors in the 
central nervous system (Akil et al., 1984; Watkins and Mayer, 1982; Chao et al., 
1996; Wang ei al., 1998; Abdulla and Smith, 1998). Medically, opiates have 
been used as analgesics and also they produce a sensation of euphoria and calmness 
in the patient. Recently Leventhal et al. (1998) found that opiates can induce 
hyperphagia and this effect was also mediated by distinct receptors. 
The principal active ingredient of opium is the alkaloid morphine, and the effects of 
morphine led to the synthesis of heroin and over 400 other derivatives, but the 
search has not revealed a compound superior to morphine in terms of analgesia and 
low-dependence properties, although recently a synthesized compound--RB 120 is 
possibly a break through (Nobel et al., 1997). Opioid dependence is often considered 
to be a long lasting form of neuronal plasticity. The molecular mechanism through 
which chronic opiate treatment induces states of tolerance and dependence in target 
neurons remains unknown. Recent studies have improved our knowledge of the 
molecular events linking transient activation of membrane receptors to genomic 
responses (Condorelli et al., 1994). A group of genes are believed to participate in 
the long-term plastic neuronal changes. Both activator protein-1 (AP-1) and nuclear 
factor KB (NF-KB) transcription factor complex is composed of dimers of c-fos and 
c-jun proto-oncogene products or closely related proteins (Chuang et al., 1995; 
Leventhal et al., 1998). Similarly the heterodimeric NF-KB complex is composed of 
two DNA-binding subunits p50 and p65, which share structural homology with the c- 
rel proto-oncogene product. Earlier studies have demonstrated that opiate treatment 
can stimulate brain region-specific expression of the fos and jun genes (Couceyro and 
Douglass, 1995; Hayard et al., 1990; Liu et al., 1994) increasing evidence suggests 
that NF-KB is also an inducible transcription factor present in the brain (Bakalkin el 
al., 1993; Guerrini et al., 1995; Kaltschimidt et al., 1993,1995). However, very 
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little is known about its (i. e. NF-KB) role in the neuronal plasticity associated with the 
administration of drugs of abuse (Hou et al., 1996). 
Dependence on these drugs develops even though the relief of pain is not involved, 
and this process seems to fall into two stages, the initiation phase and the physical 
dependence stage. The first dose of an opiate gives the subject an elevated mood 
with the amount of euphoria depending on the dose administered and the route of 
administration. The effects with other opiates are similar to those with perhaps more 
intense euphoria with heroin and less after other opiates like codeine, meperidine and 
methadone (Binz, 1985; Oswald, 1968; Lindesmith, 1970). 
Amphetamine Dependence 
The amphetamines are a group of drugs similar to epinephrine and they are used to 
control asthma. Amphetamine users report that the drug gives the feeling of 
excitement and omnipotence. The following account of the subjective experience of 
amphetamine comes from a paper by Gioscia (1972). 
According to the report of Gioscia (1972) the typical behavioural manifestations of 
amphetamine psychosis are stereotyped searching and examining movements 
(Ellenwood, 1967). Amphetamine psychosis is thought to be rare in Britain. 
Morgan (1991) investigated the biochemical consequences of injecting amphetamine 
into chicks every 12 hr for 5 days. This procedure resulted in increased activity of 
tyrosine hydroxylase, the synthesizing enzyme for norepinephrine, and choline 
acetylase, the synthesizing enzyme for acetylcholine in the brain stem of the chick. 
Thus, the euphoria seen in some patients after withdrawal from amphetamine may 
be due to the increased capacity of the nervous system for synthesizing 
norepinephrine as a result of the induction of tyrosine hydroxylase. 
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Abuse of Cannabis Derivatives 
The major "versions" of Indian Hemp (Cannabis sativa) are marijiuana and hashish, 
the latter being the stronger product because it is derived from the resin of the female 
plant. Both types are usually smoked, but marijuana is rolled into cigarettes 
('reefers') while hashish is always smoked in a pipe. The active ingredient which 
gives hashish and marijuana their particular properties is tetrahydrocannabinol. In the 
United States cannabis derivatives are the most frequently used illicit drugs 
(Warburton, 1968). 
It is only recently that the tetrahydrocannabinols have become available for research 
purposes (Mechoulam, 1970). Analysis of the brain chemistry has shown that 45 min 
after low doses of the drug there was a depletion of norepinephrine in the mouse 
brain (Holtzman, 1969; Dalton, 1968). Higher doses showed much less spontaneous 
activity. Injections of comparable doses in monkeys produced increased responses in 
continuous avoidance situations with the low doses, like amphetamine, but decreased 
responses in the later phases with higher doses (Scheckel, 1968, Dalton, 1968). It 
seems reasonable to suggest that the depletion of norepinephrine reflected the release 
of this transmitter by tetrahydrocannabinol, and it is this release, occurring in the 
median forebrain bundle, that produces the euphoric effects. So the behavioural 
effects of tetrahydrocannabinol are not the same as those of amphetamine 
(Warburton, 1968). 
Barbiturate Abuse 
The extent of barbiturate abuse is larger than the incidence of opiate abuse, but it has 
not been subjected to the same intensive study. The mechanism underlying 
barbiturate tolerance is not certain, but Seevers and Deneau (1963) have shown that 
there is markedly increased activity of the hepatic enzymes after chronic injections, 
suggesting that barbiturates are metabolized quicker in tolerant animals. In 
Warburton (1968) it was found that the recovery rate of tolerant and non-tolerant 
rats was not significantly different, suggesting that increased enzyme activity did not 
play a part in tolerance effect obtained after single doses, and that the effects were 
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probably due to changes in the sensitivity of the central nervous system. The nature 
of this change is unclear at the present time. 
Alcoholism 
Research suggests that the mechanism of tolerance or physical dependence are very 
similar to those found after chronic barbiturate use. Alcohol increased the release of 
norepinephrine in the brain stem (Gursey and Olsen, 1959,1960). 
Ideal analgesics which would not lead to both psychic and physical dependence have 
been investigated for thousands of years. No such analgesics have been obtained so 
far. RB 101 was reported to be such an analgesic (Honore el al., 1997; Nobel et 
al., 1992) but is only slightly active after oral administration. Recently (Nobel ei al., 
1997) the more active compound---RB 120 (RB 101 derivative) was synthesized and 
was selected for a complete study. After oral administration, in various assays 
commonly used to select analgesics (mouse hot plate test, rat tail-flick test, electrical 
stimulation of the tail in rats, paw pressure test on inflamed paws in rats, acetic acid- 
induced writhing test and the formalin test in mice), RB 120 induced potent dose- 
dependent antinociceptive responses in all these tests after oral administration. The 
differences between RB 101 and RB 120 in antinociceptive effects in the various 
assays are probably related to the amount of enkephalins and to the efficiency of 
peptidase inactivation in particular brain regions implicated in the control of a given 
nociceptive input. The goal of discovering orally active analgesics endowed with a 
potency similar to that of morphine but devoid of its major side-effects, seems now to 
have been reached with inhibitors of the enzymes NEP and APN. However RB 120 
still awaits clinical trials. 
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1.3 Opioid System : Opioid Peptides and Receptors 
1.3.1 Opioid Peptides 
In this thesis we screened Chinese herbs with the potential to be inhibitors of 
enkephalin-hydrolysing enzymes so that the endogenous opioid peptide (enkephalin) 
could be kept at high level in vivo. As endogenous opioid peptides and their 
receptors are located at key points in the pain modulatory system of the brain (as 
shown in Figure 1.1), the role of the opioid system is discussed. 
Two advances have greatly increased our understanding of the role of opioid systems 
in the modulation of nociception and pain perception. First was the demonstration by 
Solomon Snyder and Candace Pert ( Jessel and Kelly, 1991), and independently by 
Lars Terenius (1973) and by Simon (1973), that morphine and related alkaloids exert 
their physiological actions by binding to specific membrane receptors. Hughes and 
Kosterlitz (1975) also found that the brain contains endogenous opioid peptides. 
There are three classes of endogenous opioid peptides. The first, identified by 
Hughes and Kosterlitz (1979), are the enkephalins, two small peptides isolated from 
pig brain. The second class, discovered by Smythe and Chao Ho Li (Jessel and Kelly, 
1991), belongs to the proopiomelanocortin (POMC) family (Cooper et al., 1980). 
The POMC precursor is expressed in the pituitary, and its peptide products are 
released into the blood stream in response to stress. The third class, discovered by 
Avram Goldstein and colleagues (Jessel and Kelly, 1991), belongs to the dynorphin 
family. Many other peptides with opioid activity have now been discovered and are 
shown in Table 1.1. 
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Table 1.1 Amino Acid Sequences of Endogenous Opioid Peptides 
Name Amino acid sequence 
Leucine-enkephalin Tyr-Gly-Gly-Phe-Leu-OH 
Methionine-enkephalin Tyr-Gly-Gly-Phe-Met-OH 
Tyr-Gly-Gly-Ph e-Met-Thr-Ser-Glu-Lys-Ser-Gln- 
ß-Endorphin Thr-Pro-Leu-Val-Thr-leu-Phe-Lys-Asn-Ala-Ile-Val- 
Lys-Asn- Ala-His-Lys-Gly-Gin-OH 
Dynorphin Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys- 
Leu-Lys-Trp-Asp-Asn-Gln-OH 
a-Neoendorphin Tyr-Gly-Gly-Phe-Leu-Arg-lys-Tyr-pro-Lys 
Table 1.1 suggests that all of the discovered opioid peptides contain the sequence of 
Tyr-Gly-Gly-Phe. Morphine and the opioid peptides bind to distinct subclasses of 
opiate receptors that have been defined on the basis of their ligand binding properties. 
There are three major classes of opiate alkaloids, such as morphine, which are potent 
agonists of the mu receptor. The endogenous enkephalins are active at both the mu 
and kappa receptors. Each class of receptor is widely distributed throughout the 
central nervous system, suggesting that endogenous opioid systems are involved in 
physiological functions other than pain modulation. High levels of mu receptors are 
found in the periaqueductal gray region and in the superficial dorsal horn of the spinal 
cord, coincident with the distribution of enkephalin-containing neurones (Jessel and 
Kelly, 1991). Functional opioid systems are located in several regions of the brain 
involved in modulating nociception. Opiate antagonists that are used clinically, such 
as naloxone, are structural analogs of morphine and consequently are most effective 
in antagonizing opiate actions at mu receptors. There is a good correlation between 
analgesic potency and agonist affinity at the mu receptor. This is not surprising since 
the mu receptor was originally defined by its affinity for analgesic compounds. In 
experimental studies kappa agonists suppress nociceptive responses after noxious 
mechanical stimulation, where as mu agonists are most effective in analgesic tests 
that use noxious thermal stimuli. Different classes of opiate receptors may therefore 
be involved in modulating the activity of different classes of pain. 
13 
Each of the endogenous opioids derives from one of three genes that encode the 
large polyprotein precursors of the physiologically active peptides. These three genes 
are the POMC, proenkephalin and prodynorphin genes (Figure 1.2). 
Figure 1.2 The POMC Gene Structure (Cooper and Martin, 1980) 
A. Proopiomelanocortin (POMC) is so named because it gives rise to ß- 
endorphin(ß-endo), melanocyte-stimulating hormone (MSH) adrenocortico- 
tropic hormone (ACTH), and corticotropin-like intermediate lobe peptide 
(CLIP); 
B. Proenkephalin (pro-enk) gives rise to multiple copies of met-enkephalin 
(ME), a leucine-enkephalin (LE) and several extended enkephalins including 
ME-Arg-Leu (ME-RGL), ME-Arg-Phe (ME-RF), and peptidases E, F, and 
peptides E is further broken down into a family of large enkephalins that 
appear to be the most potent analgesic fragments derived from proenkephalin; 
C. Prodynorphin (Pro-dyn) gives rise to dynorphin (dyno), which contains the 
LE sequence, and neoendorphin(a-neo-endo). 
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Although the anatomical distributions of the peptides encoded by the three opioid 
genes differ, members of each family are located at sites associated with the 
processing or modulation of nociception. Enkephalin- and dynorphin-containing 
neuronal cell bodies and nerve terminals are found in periaqueductal gray matter and 
retroventral medulla and in the dorsal horn of the spinal cord, particularly in laminae I 
and II. In contrast, ß-endorphin has a more restricted distribution and is confined 
primarily to neurons in the hypothalamus that send projections to the periaqueductal 
gray region and to noradrenergic nuclei in the brain stem. 
15 
1.3.2 Distributions of Opioid Peptides 
Studies on the distribution of these peptides and their precursors in the central 
nervous system by direct assay and by immunohistochemistry have shown that the 
enkephalins are widely distributed in discrete pathways and that the ß-endorphin 
system is found in the brain stem, periaqeductal grey matter, locus ceruleus, and 
reticular formation (Enna and Yammura, 1980; Bloom et al., 1978; Waston et al., 
1978). It is also present in certain areas such as the corpus striatum, cudate, and 
globus pallidus. In the spinal cord, laminae I and II contain high levels of enkephalin 
but very little ß-endorphin (Figure 1.3). 
Figure 1.3 The Localization of Enkephalin in the Brain 
Enkephalin is localized in interneurons concentrated in the superficial dorsal 
horn, in the same region as afferent terminals containing substance P. 
The globus pallidus, in fact, seems to be the area richest in enkephalin. Enkephalins 
have been detected in amacrine cells of the retina and there is a rich enkephalinergic 
innervation of the gastrointestinal tract, emphasizing that they, too, are found in 
many different regions of the nervous system and particularly in those regions 
concerned with sensory transmission, endocrine control, respiration, motor activity, 
and behaviour (Stell et al., 1980). Enkephalin-containing neurons are often short, 
intrinsic interneurons, such as those found in the substantia gelatinosa of the spinal 
cord (Iversen ei al., 1978). 
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Enkephalins have a very short half-life in blood because of the action of peptidases, 
and they have not been thought to function as circulating agents. Instead, attention 
is concentrated on their likely neurotransmitter role. Enkephalins exist in nerve 
fibers and nerve-cell bodies in sympathetic ganglia of rat and guinea pig and in the 
adrenal medulla endocrine cells. They appear to be present throughout the gastro- 
intestinal tract of animals, including humans, with the myenteric plexus containing 
the highest concentrations (Iversen et al., 1978). 
Enkephalins have been detected in normal human blood (14-140 pg/ml) and human 
cerebrospinal fluid (5-29 pg/ml) by employing a specific radioimmunoassay for met- 
enkephalin. The high content of met-enkephalin in adrenal medulla and adrenal 
venous blood suggests that the adrenal medulla could be the source of the peptide 
found circulating in the blood (Rees, 1981; Clement el at, 1980). Opioid peptides 
met-(enkephalin), leu-(enkephalin) and ß-endorphin are distributed in the brain and 
can bind with receptor glycoproteins existing on the surface of each neuronal cell 
thus producing analgesia. These glycoproteins are commonly called `opioid 
receptors'. Some natural chemicals such as naloxone and morphine which have 
similar biological activities to the endogenous opioid peptides, also act as analgesics. 
1.3.3 Function of Opioid Peptides 
Enkephalins, methionine (Met)-enkephalin and leucine (Leu)-enkephalin, are the 
natural analgesics of the body, first isolated from pig brain by Hughes and Kosterlitz 
(1975). Figure 1.4 shows some important endogenous opioid peptides. CCK 
stimulate the gut to release enkephalin. Enkephalins exert their analgesic effects by 
acting on one or more of the three known opioid receptors; mu, delta and kappa. 
Binding of enkephalins to these receptors causes inhibition of the activity of 
nociceptive (pain sensitive) neurons, abundant in the grey matter of the brain. 
Another receptor thought to exist is the sigma receptor. This one is of particular 
interest as it appears that drugs of abuse can bind to it ( Roques et al., 1984). 
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Figure 1.4 Hypothetical Model of the Interactions Between CCK, CCK-A, 
CCK-B and the Receptors ( including the opioid system via S- opioid and µ 
opioid receptors) (Benoliel J. J. el al., 1991) 
1.4 The Opiate System: Opioid Receptors 
1.4.1 Classification of Opioid Receptors 
Opioid receptors are classified as indicated in table 1.2. 
Table 1.2 Classification of Opioid Receptors 
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1.4.2 The Interactions of Opioid Peptide and Receptors 
The brain contains at least three separate opioid receptor subcategories, mu, delta, 
and kappa. Current evidence suggests that each of the three large protein precurs- 
ors, pro-opiomelanocortin, proenkephalin, and prodynorphin, produces opioid 
peptides that interact differentially with mu, delta, and kappa receptors respectively. 
However, this is in no way exclusive. For instance, enkephalins that appear to 
interact predominantly with delta receptors can also interact with mu receptors 
mediating analgesia. It also seems that mu and delta receptors have an equal affinity 
for ß-endorphin, which has a strong analgesic action. In fact, ß-endorphin which has 
a strong analgesic action could well exert its actions through its own specific 
category of receptor (epsilon receptors). 
Opioid receptors in brain cells have been extensively studied and the gene sequences 
have been molecularly cloned (Reisine el al., 1993; Kong et al., 1993). Three major 
classes of opioid receptors have been defined according to their ligand binding 
affinities. mu for morphine, kappa for dynorphin and delta for enkephalin specificity 
(Atcheson, 1994, Bzdega, and Chin et al., 1993; Kozak, 1994). 
Although they are each synthesized from different genes with distinct chromosomal 
locations ( mu for chromosomal 10,8 for chromosomal 4, x for chromosomal 1), 
the three classes of opioid receptors all belong to the superfamily of G protein- 
coupled receptors which possess seven transmembrane domains. The three 
receptors have been successfully expressed in human lymphocytes (delta receptor); 
in human and monkey immune cells (mµ receptor) and in human and monkey 
lymphocytes (kappa receptor) (Chuang et al., 1991,1993,1994,1995). 
1.4.3 Opioid Receptor-type Specific Opiates 
During the past years, considerable experimental and theoretical effort has focused 
on the design of receptor-type opiates for the purpose of elucidating the 
physiological roles of various opioid receptor types and of developing improved 
opioid analgesics that have minimal side effects (Chao et al., Fan ei al., 1998; Yu 
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and Xie, 1998; Wang et al., 1998; Wenzlaff, 1998; Foxx et al., 1998; 
Abdulla, et al., 1998; Singh et al., 1998). For example Pilar et al (1996) used one 
strain of mouse, CXBK, which is deficient in supraspinal receptors µ1R and exhibits 
a poor response to morphine. They used this special strain of mice to screen for 
agents which produce antagonism or agonism action on µ2 receptor (µ2 R)-ligand 
binding reaction. Agents for agonism and antagonism other types of opioid 
receptors (including subtype receptors) have also been studied. As a whole the 
prototype agonists at the opioid receptors include: morphine, [D-Alai, Me Phe4, Gly- 
o15]-enkephalin (DAMGO) for µR; dynorphin, U-50 488H for KR; D-Pent, D-Pen5- 
enkephalin (DPDPE), ICI 174864 for 8R (Hemendra el a/., 1996). 
1.4.4 Opioid Receptor Binding Assay 
Based on an understanding of the endogenous or exogenous opioid peptide-receptor 
correlation, receptor binding assays were designed and applied to study the 
mechanism of some exogenous or endogenous analgesics (opioid peptide). 
Normally, there are three ways to study the interactions of analgesics with cells. 
The first procedure is to determine the biological response of an intact isolated 
organ, such as the guinea pig ilium, to applied agonists or antagonists. The 
disadvantage of this procedure is that one is obviously enmeshed in a cascade of 
events begining with transport, distribution, and metabolism of the agent before it 
even interacts with a receptor and ranging through an unknown multiplicity of steps 
before the final biological response of the tissue is measured. Thus, although studies 
with agonists may be interpretable, it is not difficult to envisage problems when 
antagonists are employed since these compounds may be competing at a different 
level from receptor binding. Despite the usual problem of a nonlinear relationship 
between receptor occupancy and biological response, this approach has yielded a 
considerable amount of information. The second approach to study receptors is by 
measuring ligand binding to a homogenate or slice preparation. This technique has 
become more feasible with a high affinity for the receptor (Gilean and Kosterlitz et 
al., 1980). The third procedure is applied to the site selective opioid receptor 
ligands to establish subtype receptor binding assay. The latter is suited to study the 
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molecular mechanism of some specified agonist or antagonist. The detailed 
procedure of subtype opioid receptor binding assay was described by Thom ei al. 
(1996) and Shen et al. (1995). 
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1.5 Enkephalin-Hydrolysing Enzymes 
The following sections will concentrate on introducing some of the basic concepts 
underlying the investigation of the inhibitors of the three enkephalin-hydrolysing 
enzymes: NEP, APN and ACE. 
1.5.1 Metallopeptidases 
Metallopeptidases comprise a large group of enzymes most of which contain zinc. 
All the Zn-metallopeptidases have similarities in their active sites and in their 
respective mechanisms of action. Based on the sequence and structural similarities, 
Hooper (1994) classified the Zn-metallopeptidases into the five families shown in 
Table 1.3. 
Table 1.3 shows that all the zinc metallopeptidases contain a HExxH or like peptide 
active site, where xx are amino acids such as LI, FL. FG. IG etc.. The specificity of 
the Zn-metallopeptidases is essentially ensured by Van der Waals and ionic 
interactions between their S2, S 1, S 1' and S2' subsites and the lateral chains of the 
corresponding P2, P 1, P 1' and P2' moieties of the substrate. 
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Table 1.3 The Family of Metallopeptidases and the Active Sequence 
(see Appendix. 1 for the single-letter code for amino acids) 
Enzyme 
_ 
Ammo acid sequence 
......... ._... I Gluzincins: HExxH........ E 
Neutral endopeptidase (NEP) VIGHEITHGF 
Rat thimet oligopeptidase HEFGHVMHQLCSQAEFAMFSGTHVE 
Aminopeptidase N (APN) VIAHELAHQWFG 
Angiotensin-converting enzyme (ACE) 
(N-terminal domain) HEMGHIQYYLQYKDLPVSLRRGANP 
(C-terminal domain) HEMGHIQYFMQYKDLPVALREGANP 
Endothelin-converting enzyme (ECE) 
Thermolysin (TLN) 
VVGHELTHAF 
HELTHAVTDYAGLIYQNESGAINE 
Clostridial neurotoxins 
Botulinum serotype A HELIHAGHRLYG 
B HELIHVLHGLYG 
C1 HELNHAMHNLYG 
D HELTHSLHQLYG 
E HELIHSLHGLYG 
Tetanus toxin HELIHVLHGLYG 
2 Metzincins: HEbxHxbGbxH........ M 
Crayfish astacin HELMHAIGFYHEHTRMDRDNYVTIN 
Mouse meprin (a-chain) HEILHALGFFHEQSRTDRDDYVNIW 
Rat meprin ((3-chain) HEFLHALGFWHEQSRADRDDYITIV 
Human 72-kDa gelatinase HEFGHAMGLEHSQDPGALMAPIY-T 
Human stromelysin HEIGHSLGLFHSANTEALMYPLYHS 
3 Inverzincins: HxxEH 
Human insulinase HFCEHMLFLGTKKYPKENEVSQFLS 
E. coli proteaselll (pitrilysin) HYLEHMSLHGSKKYPQADSLAEYLK 
4 Carboxypeptidase FHTYSE 
5 DD Carboxypeptidase HxH 
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Specificity is also determined by several well-positioned hydrogen bonds between the 
donor and the acceptor groups of the bound molecule and the polar residues of the 
peptidases (seen in Figure 1.5). 
Subsites of Zn-metallopeptidases 
\ 
FN-EP 
; UBSTRATE 
Figure 1.5 Schematic Representation of the Binding of Substrates to the 
Active Site of NEP (Rogues, 1993) 
Enkephalin-hydrolysing enzymes are the enzymes that cleave either methionine5- or 
leucines-enkephalin (ME or LE), they also act on other biomolecules such as 
endorphin, dynorphin and bradykinin. NEP was the first enzyme found to be able to 
degrade enkephalin in the human brain, therefore it is also called enkephalinase. It 
is now clear that APN, DAP and ACE as well as NEP have recognition sites on 
enkephalin and should also be called enkephalin-hydrolysing enzymes (seen in Figure 
1.6). 
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Figure 1.6 Recognition Sites of Enkephalin-hydrolysing Enzymes 
(Claude et al, 1984) 
1.5.2 Neutral Endopeptidase (NEP, EC 3.4.24.11) 
Neutral endopeptidase 24.11 (NEP) is the most important enzyme which was 
studied in this project. It acts on several natural substrates in vivo, such as 
enkephalins, endorphins, dynorphins etc.. All of these substrates have similar amino 
acid sequences in the region of their active site (Jessel and Kelly, 1991). Enkephalin 
or one of its analogues are usually used to establish the enzyme assay which allows 
selective inhibitors or mixed inhibitors of NEP/APN and NEP/ACE to be tested. 
Location and Distribution of NEP 
NEP is particularly abundant in the membranes of kidney, the lymph nodes and the 
placenta. It is found also at lower concentrations in lung, testis, prostate, fibroblasts, 
neutrophils, chondrocytes in articular cartilage, exocrine glands, various epithelial and 
endocrine glands and in various epithelial and endocrine cells (Sales et al., 1991). It 
is also found in eye and gut brush border. 
Several groups have studied the distribution of NEP in the spinal central nervous 
system (CNS) and peripheral organs. The first precise localization of NEP in the 
CNS was obtained by quantitative autoradiography using the tritiated inhibitor 
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['H]HACBO-Gly, which selectively interacts with the peptidase with a high affinity 
(KD = 0.5 nM) (Waksman et cd., 1984,1985b, 1986a). [3H]HACBO-Gly-binding 
sites were found to be discretely distributed in rat brain, with the highest 
concentrations in the choroid plexus, substantia nigra, caudate putmen, globus 
pallidus, olfactory tubercle, nucleus accumbens, and the substantia gelatinosa of the 
spinal cord. Moderate binding levels were found in the amygdana, the 
interpeduncular nucleus, the molecular layer of the cerebellum, the periaqueductal 
gray matter, and the hippocampus. 
NEP was also found to be discretely distributed in the spinal cord and meninges, high 
levels of NEP were found in rat and pig choroid plexus, the enzyme uniquely located 
on the brush border of the apical surface. The distribution of NEP on peripheral 
tissue was also observed. A soluble form of NEP has been found in various human 
physiological fluids such as plasma, cerebrospinal fluid, amniotic fluid, and seminal 
plasma (Spillantini et al., 1990) and its concentration seems to increase during 
inflammatory processes in the synovial fluid (Appelboom et al., 1991), in sarcoidosis, 
or in adult respiratory distress syndrome (Johnson et al., 1985). 
Substrate Specificity of NEP 
NEP has a broad substrate selectivity and can cleave various of the short linear or 
cyclic peptides such as endothelin (Fagny et al., 1991) or the ANP (Atrial Natri- 
uretic Peptide) (Stephenson and Kenny, 1987a), as well as polypeptides of 
intermediate or long length, such as the insulin-chain (approximately 3000 daltons) 
(Kerr and Kenny, 1974b) and interleukin-al (17000 daltons) (Pierart et al., 1988) 
(Figure 1.7). However, it sometimes acts more efficiently as a dipeptidyl 
carboxypeptidase than as a true NEP. Other than the enkephalins and Met- 
enkephalin-Arg-Phe, NEP shows little activity toward other opioid peptides. All of 
these peptides are characterized by the N-terminal sequence of Met or Leu- 
enkephalin, but the efficiency of NEP in cleaving their Gly3-Phe4 bonds is exquisitely 
sensitive to the length of the amino acid sequence added at the COON terminus 
(Turner et al., 1987). Thus dynorphin 1-9, dynorphin 1-13, a- and ß- neoendorphin, 
and ß-endorphin are poor substrates, suggesting a conformationally related hindered 
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access of the enzyme-sensitive bonds to the active site. This is an important 
observation because it indicates that the "opioid" pharmacological effects induced by 
NEP inhibitors are mainly due to the protection of the two endogenous enkephalins 
and perhaps partially to the protection of the extended hepatapeptide, met- 
enkephalin-Arg-Phe. As we mentioned for NEP, APN also has a broad specificity for 
its proteolytic action. (Mcdonald and Barrett, 1986), although hydrophobic residues, 
preferentially aromatic, in the NH2-terminal position are more rapidly removed. The 
SI' and SZ subsites of APN also seem to prefer hydrophobic residues (Hermandez, el 
al., 1988, Xie, et al., 1989a). 
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Figure 1.7 The Relative Substrate Selectivity of NEP and the Efficiency of 
Hydrolysis of Some Neuropeptides by NEP (Kenny, 1993) 
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Biochemical and Biophysical Properties of NEP 
NEP is a neutral glycoprotein which consists of a single polypeptide chain with a 
molecular weight of approximately 90 kDa (Rogues et al., 1993). It is a Zn- 
metallopeptidase and is located in many mammalian tissues. eg. kidney, brain and 
intestine. NEP is particularly abundant in the proximal convoluted tubule (PCT), 
located in the cortical region of the kidney (Booth, 1974; Corbeil, 1989). This is why 
the rat kidney was used to prepare the NEP sample in this thesis. 
Molecular Biology of NEP 
NEP has a short NH2-terminal cytoplasmic domain (27 amino acids), followed by a 
23-residue hydrophobic domain, which anchors the protein in the plasma membrane, 
and a large c-terminal extracellular domain that contains the active site (Figure 1.8 
and 1.9). NEP contains a consensus sequence VxxHExxH, which has been found in 
numerous other Zn-endopeptidases, such as human collagenase and human ACE 
(Soubrier et al., 1988). 
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Fig 1.8 Schematic Model of the Primary Structure of NEP. 
The intracellular domain (residues1 to 27) is followed by a membrane-spanning 
domain (M: residues 28 to 50) with the rest of the enzyme being in the extracellular 
space. C: 12 cysteine residues; "lollypops": putative glycosylation sites, hatched 
region : concensus sequence with residues at the active site of TLN(Roques et al., 
1993) 
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Figure 1.9 A Schematic Representation of the Binding of the NEP Inhibitor, 
Retrothiorphan, to the Active Site of the Enzyme, With the Sulphydryl Group 
of the Inhibitor Pointing Toward the Zn Atom ( Roques et al, 1993). 
Site-directed mutagenesis studies have confirmed the proposed roles of Glu5x 4 in 
catalysis (Devault et al., 1988b), His583, and His587, and Glu6` 6 in Zn-binding (Devault 
et al., 1988a; Le Moual et al., 1991), Arg747 (Beaumont et al., 1991) and Arg'02 
(Bateman et al., 1989; Beaumont et al., 1991,1992) in ligand binding, and His"' 
which may be involved in transition state binding (Bateman et al., 1990). Asn542 and 
Ala543 are probably involved in substrate binding (Benchetrit et al., 1988). All of 
these residues except Arg102 have their homologues in the active site of TLN 
(Matthew, 1988), and the binding mode of retrothiorphan is taken from data obtained 
by crystallization of the inhibitor with this enzyme (Roderick et al., 1989). 
The cDNA clone encoding human NEP in a A. gt 10 library was isolated from human 
placenta by Malfroy el al (1988). The complete 742 amino acid sequence of human 
NEP was obtained. The human enzyme displays a high homology with rat and rabbit 
NEP. Like the rat and rabbit enzyme, human NEP contains a single N-terminal 
transmembrane region and its carboxyl-terminus, is located extracellularly. The 
detailed amino acid sequences of NEP may be found in Appendix. 1. 
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Mechanism of Action 
NEP usually acts on NH2-amino sites of enkephalin. The enkephalins are degraded 
by APN, DAP, NEP and ACE. It is found that the inactivation of enkephalin takes 
place as follows! 
Tyr-Gly-Gly-Phe-Leu APN Tyr + Gly-Gly-Phe-Leu 
Gly-Gly-Phe-Leu NEP Gly-Gly + Phe-Leu 
Based the above mechanism, many assays (Rogues, 1982; Chipkin, 1986) were 
established to study the enkephalin-hydrolysing enzymes and their inhibitors. 
Physiological Function of NEP 
NEP has many important physiological functions. In brain it appears to participate in 
the inactivation of enkephalins. The reason for the presence of NEP in the kidney is 
that it degrades peptides and proteins in the PCT, which are filtered by the 
glomerulus, such as Atrial Natriuretic Peptides (ANPS) (Soleilhac, 1992; Seymour, 
1995). NEP is also seen to have an important role in the inactivation of peptide 
hormones. Recently NEP (Jane, 1988; Pierart et al, 1988) was found to be one of 
the many proteins used in immunology and leukemia research as lymphocyte markers 
where it was designated as CALLA (CD10) (Delikat, et al., 1994; Letarte et al., 
1988). 
1.5.3 Aminopeptidase (APN) and Angiotensin-Converting Enzymes (ACE) 
Besides NEP, there exist the metalloenzymes APN (aminopeptidase) and ACE 
(angiotensin-converting enzyme) which are also enkephalin-hydrolysing enzymes. 
They take part in the degradation of enkephalin and in that way they mediate the 
metabolism of the opioid system. Therefore it is necessary to include these enzymes 
when screening for the inhibitors of enkephalin-hydrolysing enzymes. In this project 
NEP was chosen as the first target enzyme and the NEP inhibitor was screened. 
Following this, the positive NEP inhibitors were assayed further for their activity on 
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APN and ACE. 
1.6 Inhibitors of Neutral Endopeptidase 24.11 (NEP), Aminopeptidase (APN) 
and Angiotensin-Converting Enzymes (ACE) 
Since the discovery of the peptidases, research on inhibitors commenced. So far 
thiorphan is the only commercially used NEP inhibitor. The best APN inhibitor is 
bestatin and ACE inhibitor is captopril (Roques el al., 1993). Until today scientists 
have obtained selective inhibitors for NEP(Roques et al., 1993) or mixed inhibitors 
for NEP/APN, NEP/ACE (Roques el al., 1993). Based on today's knowledge the 
above inhibitors are believed to have following pharmaceutical applications: 
a Selective NEP inhibitors 
Antidiarrhea agents without constipation (Roques, 1993), 
Treatment of acute cholecystitis (Wilkins, 1993), 
Diuretic and natriuretic agents (Protection of Atrial Natriuretic Peptide, ANP), 
(Krulan et at, 1993; Seymour, 1995 and Rob! cat al., 1996; Kenny, 1993) 
New antidepressants (Real et al., 1995); 
b Mixed NEP/APN inhibitors 
Analgesics devoid of tolerance and dependence (Protection of endogenous 
enkephalins) (Chen et al., 1998); 
c Mixed NEP/ACE inhibitors 
New antihypertensive agents (Gros et cri., 1991; Roques et al., 1993). 
In nature, NEP inhibitors have other special applications besides use as analgesics. So 
far all of the reported NEP inhibitors were obtained by one of the following three 
methods: (1) Biosynthesis; (2) Isolation from micro-organisms; (3) Isolation from 
plants (herbs). 
1.6.1 Biosynthetic Inhibitors of NEP 
All the biosynthetic inhibitors are designed by using enkephalin as a model as shown 
in Figure 1.10 (see also Figure 1.5). Modification of the inhibitors increases the 
reaction specificity and lowers the minimal inhibitory concentrations (MIC). 
32 
Figure 1.10 Proposed Model For the Interaction of Enkephalins and Inhibitors 
With the Active Site of "°Enkephalinase---enkephalin hydrolysing enzymes" 
( Schwartz el al., 1982). 
The Classification of Biosynthetic Inhibitors of NEP 
All the biosynthetic inhibitors of NEP have the general structure of X-AA, -AA2, 
where X= the zinc-complexing ligand and AA,, AA2 = different amino acids or amino 
acid-type structures. AA, is hydrophobic, uncharged, and can be large since 
cyclohexyl and biphenyl moieties are acceptable. But AA, is preferentially small with 
stereochemistry. Furthermore, a free carboxylic acid seems to enhance potency. 
Finally the bond between AA, and AA2 can be a retro-isomer but insertions of extra 
atoms leads to a decrease in potency. The Zn-complexing ligand, X, can be of 
several classes. Thus, mercapto, carboxyalkyl, phosphoryl and hydroxamates are all 
useful. Moreover proximity to AA, is important because carbonyl insertions here lead 
to decreases in activity. According to the difference between X/AA, /AA2, the 
biosynthetic inhibitors can be divided into following four types (Chipkin, 1986). 
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(1) Thio Inhibitors of NEP 
Extensive studies of enkephalin analogues and dipeptides have shown that the 
specificity of NEP for targeting the dipeptide is essentially ensured by the S, subsite 
(see Figure 1.5), which interacts preferentially with aromatic or large hydrophobic 
moieties. The S2 subsite has poor specificity for specific types of amino acid, proline 
at the S2 subsite leads to poor inhibition of NEP activity (Fournie-Zaluski et al., 
1979,1981 a). The above observations were used to design one class of inhibitor, the 
thio inhibitors (Tablel. 4) 
Table 1.4 The Thio Inhibitors of NEP 
Drug IC50 or K; (nM) References 
vs. 
Thiorphan** 
NEP ACE 
HS-CH2CH-(CH2-4)CO-Gly 4.7; 1.4 147; 480 Roques et al., 1980 
Retro-thiorphan 
HS-CH2-CH-(CH2-0-NHCO-CH2-COOH 6 
_>10,000 
Roques et al., 1983 
Modified Phe-Leu derivatives 
HS-CH2-CH(CH2-0)-NHCO-Leu 
Mercaptoacetyl-Leu-Phe 
Modified butyric acid derivatives 
HS-CH2-CH(CH2-0)-CONH- 
CH(CO2H)-(CH2)2SCH3 
495 
10 37 
15 1000 
9.1 - 
Gordon et al., 1983 1 
Altstein et al., 1983 1 
Bindra US 43291 
** Clinically used inhibitors; IC5() and Ki value are constants for inhibition of 
proteolytic action of NEP and ACE. They are defined in the list of abbreviations. 
In Tablel. 4 the first described synthetic potent NEP inhibitor is Thiorphan (HS-CH2- 
CH(CH2+-CONH-CH2-000H, N[(R, S) (3-mercapto-2-benzyl-propanoyl)] -glycine 
(Ki =4 nM) (Roques ei al., 1980). Thiorphan is about 50-fold more potent in 
inhibiting NEP activity than ACE activity. However, its two enationmers (R and S) 
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have the same inhibitory potency toward NEP but not for ACE (S-isomer =140 nM; 
R-isomer = 860 nM), indicating large differences in the stereochemical requirements 
for optimal interactions in the active sites of the two enzymes. 
(2) Carboxyl Inhibitors of NEP 
Introduction of a carboxyalkyl group at the NH2-terminus of the dipeptide Phe-Leu 
resulted in carboxyl-derived inhibitors of NEP and various N-carboxyl alkyl- 
dipeptide inhibitors were synthesized. The significant increase in potency obtained 
with these compounds and the influence of the chirality of the side chains suggested 
the existence of a S, subsite that could exhibit some selectivity for the NEP 
recognition site. However, nonspecific Van der Waals interactions and bidentate 
coordination of the carboxyl group are more probable explanations for the specificity 
of the carboxyl inhibitors (Roques et al., 1982a, b; Elliot et al., 1985; Ksander el al., 
1995). Three carboxyl NEP inhibitors have so far been extensively studied, and the 
following compounds were already biosynthesized (Seen in the Tablel. 5). 
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Table 1.5 Carboxyalkyl Inhibitors of NEP 
Drug 
Phe-Leu derivatives 
HOOCCH(CH2-OCO-Leu 
ICS() or K; 
vs 
NEP ACE 
0.7µM 
Refernces 
>1000 µM Zaluski et al., 1982 1 
20 µM Zaluski ei at, 1983 HOOCCH2CH(CH2-O)CO-Leu 0.8. tM 
HOOC-CH2-CH2-NH-Phe-Leu 11 µM 
Phe-ßAla derivatives 
I ý-CH2-CH(CO2H)-Phe-ßAla 
ý-CH2-CH(CO2H)-Phe-Ala 
N-Carboxyphenylethyl derivatives 
CO2H-CH(CH2+-Phe-PABA 
>100 µM Zaluski ei al., 
20 nM >100,000 nM Mumford et al., 1982 
300 nM 1850 nM Mumford et al., 1982 
71 nM Murthy et al., 1984 
NB: ICs() and Ki see Table1.4 
(3) Bidentate Inhibitors (Hydroxamate) of NEP 
A detailed analysis of NEP inhibition by NH2-terminal hydroxamates was performed 
by Bouboutou et al. (1984), using a series of four novel dipeptide analogues. This 
study showed that (a) hydroxamates were more efficient than N-formal-N- 
hydroxyamino derivatives; (b) a study of the insertion of a methylene spacer between 
the Zn-chelating group and the benzyl-bearing carbon increased the inhibitory 
potency for NEP proteolysis of the molecules; and (c) all of the inhibitors have poor 
affinities for ACE (IC5 >10,000 nM). Studies using HACBO-Gly (Fournie-Zaluski 
el al., 1985; Xie, et al., 1989a, b) have shown that the absolute configuration of the 
P1' residue (see Figure 1.5), as well as the size and the hydrophobicity of the P2' 
residue, does not greatly influence NEP recognition by the inhibitor. However, these 
two parameters have played an important role in the design of selective or mixed 
inhibitors of NEP, APN, and DAP; The retroinversion of the amide bond in 
dipeptide hydroxamates led to very efficient NEP inhibitors with compounds 
containing a methylene spacer between the hydroxamate group and the carbon 
bearing the P l' benzyl side chain (Fournie-Zaluski et al., 1989). The first retro- 
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HACBO-Gly is a highly potent and selective NEP inhibitor with a concentration of 
0.5 nM. An increase in NEP affinity was also obtained by monosubstitution of the P2' 
residue. Thus, the inhibitor (S, S) HONH-CO-CCH (CH24)-NHCO-CH2-CH 
(CH3)-COOH (JFH19), is more than 100- and 2000-fold more selective for NEP 
(IC50 approximately 0.15 nM) than for APN and DAP, respectively (Fournie-Zaluski 
et at, 1989). The replacement of Gly in retro-HACBO-Gly by a highly hydrophobic 
aromatic moiety in RB104 led to a large increase in NEP affinity. [125I]RB104 is 
more potent than RB 101 (K» = 0,03 nM), a property that has been used directly. 
But RB 104 can not pass through the blood brain barrier. 
Hydroxamaic acid derivatives have a general structure: OH-NHCO-X-Ala-Gly, 
where X=Phe, Leu or Gly. These compounds potently inhibited NEP (seen in the 
Table 1.6). 
Table 1.6 Bidentate Inhibitors of NEP 
Drug IC50 or K; References 
vs 
NEP ACE 
Ala-Gly derivatives 
OH-NHCO-Phe-Gly 8.4 nM - Hudigin et al., 1981 
OH-NHCO-Leu-Ala-Gly 3.1 nM - Hudigin el al., 1981 
OH-NHCO-Gly-Ala-Gly 41 µM - Hudigin et al., 1981 
BOC '-Hydroxamates 
BOC-Leu-NHOH 40 nM - Blumberg et al., 1981 
BOC-Phe-NHOH 200 nM - Blumberg et al., 1981 
` BOC = benzyloxycarbonyl 
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(4) Phosphorous-containing Inhibitors of NEP 
Another interesting series of inhibitors are the phosphorus-containing dipeptides, 
among which is the natural competitive inhibitor of NEP, phosphoramidon, produced 
by Streptomyces tanashiensis; This compound was initially described as a TLN 
inhibitor (Umezawa, 1972). Phosphoramidon [rhamnosyl-O-P(O)(OH)-Leu-Trp] is a 
potent NEP inhibitor (IC5o = 2-5 nM). Based on the hypothesized similarity of 
thermolysin and NEP, the phosphorus containing complexing ligands were designed 
(Kukkola et al., 1995) and various potent phosphorylated inhibitors of NEP have 
been described (Altstein et al., 1982; Garcialopez el al., 1985). More recently, 
phosphoramidon derivatives have also been reported (Elliot ei al., 1985). The other 
phosphorus-containing complexing ligands were tried and newer NEP inhibitors were 
made. The inhibitors are given in Table 1.7. However, these compounds, although 
potentially able to interact with the SI, S 1', and S2' subsites of NEP (see Figure 1.5), 
are less efficient than the phosphyl dipeptide. Nevertheless, this series of potential 
inhibitors deserves further investigation. 
Table 1.7 Phosphoryl-Based Enkaphalinase Inhibitors 
Drug ICso or K; References 
Enka'se 
Natural compounds 
Rhamnosyl-O-P(O)(OH)-Leu-Trp 1.1 nM 
Phosphoryl compounds 
PO(OH)2-Leu-Phe 0.3 nM 
Phosphoamidates 
vs 
ACE 
150 µM Altstein et al., 1983 
ýtM Malfroy et al., 1982 
CH3-CONH-CH2-PO2-Na'-Phe-Met 140 nM 3.4 µM Elliott et all, 1985 
Phosphonic acids 
PO(OH)2-CH2-CH(CH24)CO-0Ala 20 nM >100 pM Chipkin, 1986 
PO(OH)2-CH(CH2-ý)CO-Leu 1 30 nM - Wilkinson e/ al., EP75334 
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Present attempts for chemists are to find a compound with high affinity both to NEP 
and APN, but so far this has not been successful (Chen et al., 1998). Roques and his 
colleagues (1995) obtained one compound (RB 101)---N-ý (R, S)-2-benzyl-3 [(S)(2- 
amino-4-methylthio) butyl dithio]-1-ox- opropyl ý -L-phenylalanine benzyl ester which 
showed dual inhibitory activity on both NEP and APN. Periodic clinical trials 
demonstrated that RB 101 gave a strong analgesic response without inducing 
antinociceptive tolerance nor cross-tolerance with morphine. RB 101 is also active in 
the tail-flick and tail-electric stimulation tests in rats. The pain-alleviating effect of 
RB 101 was suppressed by naloxone, RB 101 therefore is the first compound allowing 
analgesia to be critically evaluated, and the side effects assessed for treatments which 
elevate the extracellular level of enkephalins as opposed to analgesia produced by 
morphine. RB 101 easily crossed the blood-barrier and so the above properties made 
RB101 become interesting for treating pain. Unfortunately, it is only slightly active 
after oral administration. Based on above facts Chen et al. (1998) designed dual 
competitive inhibitors of both enzymes with Ki values in the nanomolar range. These 
have been obtained by selecting R-1, R-2, R-3 determinants in aminophosphophilic- 
containing inhibitors: NH2-CH(R-1) P(O)-(OH)CH2-CH(R-2) CONH-CH(R- 
3)000H. For optimal recognition of the two enkephalin inactivating enzymes, 
active site peculiarities being determined by site-directed mutagenesis, have been 
taken into account. The best inhibitors were ten times more potent than dual 
inhibitors described before in alleviating acute and inflammatory nociceptive stimuli in 
mice, thus providing a basis for the development of a family of analgesics devoid of 
opioid side effects. Nobel ei al. (1997) also chemically modified RB 101 and a new 
compound--RB 120 was obtained. RB 120 has already passed through all the pre- 
clinical trials and showed excellent analgesic activity without major side effects. It 
still awaits clinical trial. 
1.6.2 Inhibitors of Peptidases From Micro-Organisms (See Table 1.8) 
In addition to the biosynthetic compounds described above, inhibitors of enkephalin- 
hydrolysing enzymes can also be isolated either from micro-organisms or from plants 
as well as animals and insects. The Japanese have done lot of work in screening new 
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NEP inhibitors from Streptomyces (Kojima, 1990; Otani, 1991; Tsurumi, 1995) and 
other micro-organisms (Kimura, 1990; Tsuru el al., 1992; Akiyama, et al., 1998). 
So far they have made significant progress but without marketable products. The 
inhibitors isolated from micro-organisms are summarised as given in Table 1.8, but 
the work has not really yet been effective. 
Table 1.8 Inhibitors of Enkephalin-hydrolysing Enzymes From 
Micro-organisms 
Inhibitors Producing strains Activity 
Staurosporine Steptomyces staurosporeus Anti-fungi, anti-amnesic 
effect 
W S75624 A and B Saccharothrix sp. No. Inhibition of NEP, ECE 
75624 (Endothelin-converting 
enzyme) and collagenase 
Metalloprotease inhibitor Streptomyces ni reg scens Inhibition NEP isolated 
(SMPI) (SMPI) from Bacillus subtilis var. 
am losacchriticus 
Streptomyces subtilisin Inhibition of trypsin 
inhibitor (SSI) activity 
Fluostatins A and B Streptomyces sp. TA-3391 Inhibition of DAP 
(dipeptidyl peptidase III, 
EC 3.4.14.4 
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1.7 Research Advances of Chinese Herbs For Use As Analgesics 
1.7.1 Introduction 
Herbal medicine, acupuncture, moxibustion, and massage are the four major 
constituent parts of traditional Chinese medicine (TCM). Although acupuncture is 
well known in many western countries (Janet, 1995; Sher, 1998), Chinese herbal 
medicine, is less well known in the west (Zhu et al., 1995; Berry and Tinorua, 
1993). However in recent years it has become increasingly popular with its 
application in treating dermatological diseases such as psoriasis (Koo and Arain, 
1998), atopic dermatitis (Rustin e1 al., 1994; Li, 1995), and atopic eczema 
(Galloway et al., 1991; Atherton et al., 1990; Allen e1 al., Hollman et al., Harper 
et al., Davies et al., 1990; Latchman et al., 1994,1996; Kirby, 1997). Some 
biotechnology companies are beginning to explore the potential of ancient remedies 
such as Chinese herbs in the hunt for sources of new therapies (Mack, 1997). 
However, systematic study of Chinese herbs in the western world still has a long way 
to go. 
In China systematic study of Chinese herbs has been made for about twenty years 
(Yang, 1998). Most of the work has concentrated on isolating single compounds 
from herbal crude extracts. Less work has been done on pharmacolo-gical 
applications and many compounds have been purified without assaying their 
pharmacological effects. Even less work has been done on the molecular 
pharmacology of Chinese herbal extracts and so it is now of great interest to study 
the molecular pharmacological activity of the traditionally-used Chinese herbs 
especially for herbs which have already been well characterised. According to 
traditional Chinese-herbal medicine (TCHM), quite lot of Chinese herbs are found to 
be useful as: analgesics (Yang, 1985,1986; Sher, 1998), treatments with diuretic 
and antidepressant activity (Chan, 1995; Li, el al., 1994), treatments of nephrotic 
syndrome (Jiang, 1994) and treatments of neurological disorders (Ding and He, 
1986). Such functions suggest that it should be possible to find some inhibitors of 
NEP, NEP/APN or NEP/ACE from Chinese herbs. 
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1.7.2 The Use of Chinese Herbs as Analgesics and Anaesthetics 
The following is a list of Chinese herbs currently used as analgesics or anaesthetics in 
clinics; 
Aconitum carmichaeli Debx; Aconitum brachypodum Diels; Aconitum 
szechenyianum Gay; Daphne ; iraldii Nitsche; Rhododendron molle (Bl) G. Don; 
Hyoscyamus niger; Datura metel L.; Corydalis decumbens (thumb)1 ers; Alangium 
chinese(Lour Rehd; Zanthoxylum nitidum (Roxb) Dc; Cynanchum paniculatum 
(Bunge) K. Schum; Hemsleya amabilis Diels; Uncaria rh ny choph. ylla (Mig. Jackson; 
Notpterygium incisum Ting; Li usticum chuanxiong Hort; Corydalis bulbosa De; 
Corydalis Yahusuo T. Wang. 
Many of these herbs have already been used as analgesics for thousands of years. 
And indeed the best clinically-used analgesic, morphine, originated from herbs. On 
the other hand, Chinese scientists have done much work in the last 20 years on 
screening new analgesics free of major side effects of morphine. Yang and his 
colleagues (1985) have successfully investigated the effects of three hundred cases of 
Chinese herbs on drug addiction in vino. They used whole-animal tests to investigate 
the analgesic activity of twenty herbs, combined with data from treating opium and 
heroin addicts in Hong Kong. The results of three hundred cases were analysed and 
evaluated. The effects of Chinese herbs on withdrawal behaviour in morphine- 
addicted rats were also investigated. Four herbs (Qiang huo, Gou teng, Chuan xiong, 
Yan husuo) were found to reduce the three main withdrawal symptoms significantly. 
The effect of the above four herbs in combination on the morphine-withdrawal signs 
were also compared with that of endogenous opiate-like peptides (endorphin, 
enkephalin, dynorphin) and acupuncture. The analgesic effects of the above herbs 
were also studied in mice where in the writhing test (a standard analgesic 
experiment-see section of 1.2) they caused a reduction of the writhing sign. Tests 
on the contraction of guinea pig ileum showed that the inhibition of the enzymes 
caused by the herbs was not blocked by naloxone. This suggested that none of the 
above herbs contained morphine-like substances showing that the analgesic activity 
was by a different mechanism. Based on the study of Yang et al (1985), it was 
decided in this thesis to investigate the effects of the above four listed herbs on 
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enkephalin-hydrolysing enzymes (NEP, APN and ACE), so that the molecular 
mechanism for the analgesic activity of the above four herbs might be clarified and 
the active ingredients identified. 
1.7.3 Brief Introduction For the Selected Four Chinese Herbs 
The four selected Chinese herbs Yan, Gou, Qiang and Chuan have been clinically 
used as analgesics according to traditional Chinese herbal medicine (TCHM). Keys 
(1975) described the above four Chinese herbs in his book as follows and being 
quoted. 
Descriptions of the crude drugs, as used in commence, are available in the Chinese 
Pharmacopoeia, and in each case reference is made to the relevant monograph. The 
crude drugs were checked for authenticity against these monographs by staff at the 
Institute of Medicines Plant Development, Chinese Academy of Science, Beijing, 
China. 
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(1) Yan hu suo (van)---the latin name is CORYDALIS AMBIGUA Cham. et 
Schlecht. (Fumariaceae) or CORYDALIS YANHUSUO T. Wang. (Keys, 1975) 
It is an herbaceous perennial, the stem erect, tender, 20 cm. high. Leaves alternate, 
compound, the last leaflet larger than the others and tridentate at the tip. 
Inflorescence a multifloral cluster; April-May. Sepals 2; Corolla irregular, with 4 
erect, connivent petals, one of which is spurred, greenish violet; stamens 6; ovary 2- 
celled. Fruit an oblong, linear capsule. Siberia. Manchuria, Japan. 
The root is officinal. It occurs as a small, flat tuber 17 cm. thick by 20 mm. in 
diameter, hard, ochre-yellow, the exterior covered with a thin, wrinkled cuticle, the 
interior light yellow, semi-transparent, cirrose. The taste is bitter. A large number of 
alkaloids have been isolated from the tube. It was prescibed as sedative, 
antispasmodic, analgesic in headache, gastralgia, menstrual colic. Dose 3-5 gm. " 
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(2) "Gou tens---the latin name is NAUCLEA SINENSIS Oliv. (Rubiaceae) or 
UNCARIA RHYNCHOPHYLLINE (MIQ. ) JACKSON. (Keys, 1975) 
Rubiaceae is a shrub, the branches small, bearing compressed, curved spines 
occasionally. Leaves oval-elliptical, tip acute, base rounded, 10-14 cm. long by 5.0- 
7.5 cm. Wide. Inflorescence an axillary capitulum. Flowers white; Calyx in 5 
segments; corolla infundibular, with 5 lobes which are much smaller than the tube; 
stamens 5; ovary 2 celled. Fruit a dry capsule. central China. 
The stem and spines are officinal. The taste is bitter and astrigent. The drug 
contains the alkaloid rhynchophylline (C22H28 N204; crystal; m. p. 216°; freely 
soluble in organic solvents except petroleum ether). Rhynchophylline lowers blood 
pressure and paralyzes sympathetic nerve endings. 
Employed as sedative, antispasmodic in infantile nervous disorders. dose, 5-10 gm. " 
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(3) "Qiang huo--the latin name is NOTOPTERYGIUM INCISUM Ting ex H. 
T. Chang (Yang et al., 1993) 
Root bitter, very fragrant. 1-25 essential oil. emmenagogue, 
About 15 compounds were obtained. They are isoimperatorin, bergapten, cnidinin, 
notopterol, notoptol, nodakenin, bergaptol, decuroside etc. 
Sedative, analgesic. dose, 4-11 gm. " 
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(4) "Chuan xiong ---the latin name is LIGUSTICUM CHUANXIONG Hort. 
(Tsao et al., 1983; He and Zhang, 1957) 
Herbaceous, high 40-70 cm. Fragrant root. About 20 compounds were obtained 
from chuan xiong. They are 3-sec-butyl-6-isopropyl-2,5-piperazinedione; 
perlolyrine; chuanxingol; ferulic acid; chrysophannol ; sedanic acid etc. Sedative, 
analgesic. be effective in treating nephropathy, antihypertension. " 
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1.7.4 Extraction of Active Ingredients From Chinese Herbs and 
Traditional Method of Studying Pharmacological Activity 
The isolation and structure determination of pharmacologically active substances 
from Chinese herbs may be followed by determination of their pharmacological 
profile. 
Standardising herbal extracts is problematical because the properties of herbal 
extracts depend on the season and location of growth and the herbal extraction 
method. Usually the herbal extracts contain quite a few components which may 
interact in their medicinal effects. To combat this, scientists have adopted the 
following strategies to study Chinese herbs (Chan, 1995; Zhu et al, 1995). 
(1) Selection of the herbal prescriptions which have been used clinically to treat the 
target disease; 
(2) Identification of target herb and establishment of all the decoction methods, 
(3) The extraction of the active ingredients from crude drugs and clarification of 
their pharmacological activity. 
1.8 Overall Objectives of The Thesis Work 
The overall objectives of the work involved in the project of this study were as 
follows: 
(1) Design and utilization of an enkephalin-hydrolysing enzyme assay to 
screen NEP inhibitors from Chinese herbs 
Although some laboratories (Nortier ei al., 1997; Kabanda, 1995) have reported 
use of NEP assay to monitor the proximal tubular injury induced by Chinese herbs in 
vivo, so far there are no reports of work to screen NEP inhibitors from Chinese 
herbs. Therefore, we believe that this laboratory is the first to use NEP assay as a 
primary model to screen selective NEP inhibitors from Chinese herbs. In this project, 
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the 'H(leu)-enkephalin was used as the competitive substrate to establish an NEP 
assay 
(2) Design and utilization of opioid receptor binding assay to investigate the 
effect of target herbs on naloxone - opioid receptor reaction 
(3) Partially purification of selected herbal extracts 
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CHAPTER II 
METHODS 
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General methods, such as enzyme preparation, enzyme assays, enzyme purification 
etc. are introduced in this chapter. However specific methods which apply to the 
contents of a particular chapter are introduced with that related chapter. Therefore, 
in particular, nuclease treatment of herbs is described in section 6.4 of Chapter 6 and 
buffer treatments of herbs are dealt with in section 4.5. The preparation of opiate 
binding receptors from rat-brain membrane is described in section 5.2.1, the 
experimental methods of opiate binding is described in section 5.2.2, the effect of 
Gou on ligand-receptor binding activity is described in section 5.4 . 
2.1 Methods for the Extraction of Chinese Herbs 
All the Chinese herbs studied in this project were either supplied by East & West 
Herbs LTD (in Kingham, Oxfordshire, U. K. ) as powders, or dried pieces of the 
plants. In the case where whole pieces of plant were supplied, the plant was ground 
into a coarse powder by a pestle and mortar. For studies of the different effects of 
Chinese herbs it was necessary to solubilise or extract the active ingredients from the 
Chinese herbs by water extraction or by organic-solvent extraction. Before use for 
research all the Chinese herbs were identified by the Institute of Medicinal Plant 
Development, Chinese Academy of Medical Sciences, Beijing, China. 
(a) Water Extraction 
"Fire-water" extraction involves boiling the Chinese herbs in water to extract the 
active components. 3 grams of herbs were mixed with 100 ml of distilled water and 
this suspension was boiled for 3 hours to aid solubilisation. The extract was then 
filtred and the filtrate was concentrated to dryness in a microcentrifuge concentrator 
(HOWE GYRO VAP) and the dried extract was kept at 4°C for enzyme assay and 
opioid receptor-binding assay. 
(b) Organic Solvent Extraction 
An amount of 100 mg of Chinese herbs was mixed with 10 ml of an organic solvent 
(methanol in this experiment). The mixture was centrifuged at 1000 g for 5 minutes 
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to remove any undissolved particles from solution. The supernatant was 
concentrated to dryness by the centrifugal concentrator (HOWE GYRO VAP) and 
the dried extract was kept at 4"C for further study. 
2.2 Characterisation of the Chinese Herbs 
2.2.1 Spectral Analyses of Gou Crude Extract 
Dried extracts of herbs (Gou etc. ) were dissolved in 50 mM of Tris-HCI buffer at pH 
7.0 until the final concentration was 100 µg/ml. Tris-HCI buffer was used as a 
control and the absorption spectrum was measured by scanning between 200 nm and 
900 nm. 
2.2.2 The Fractionation of Gou By Sephadex G-10 Gel Filtration 
Absolute ethanol was mixed with the Gou aqueous solution in the ratio of 1: 1 to a 
final concentration of 50% ethanol. The solution was kept at room temperature for 
10 minutes and centrifuged at 13,000 rpm (Microcentaur, MSE) for 20 minutes. The 
pellet and the supernatant were separated and stored in the cold room for further 
study. 
The prepared Sephadex G-10 column (NAP-10, length: 10 cm, diameter: 1 cm) was 
washed and the void volume was measured by means of blue dextran. The maximum 
loading volume was calculated and the 0.25 ml of Gou crude sample was applied 
onto the column and washed by 0.5 M Sodium Chloride. The elution fractions (200 
µl / tube) were collected and their activities assayed. 
2.2.3 Reversed-phase Preparative HPLC Analysis of Gou Crude Extracts 
(1) The mobile phase was prepared for reversed-phase preparative HPLC analyses as 
follows: 500 ml of a solution of 0.07% trifluroacetic acid (TFA) in 100% acetonitrile 
was prepared and also a solution in distilled water of 0.07% of TFA. 
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(2) The sample preparation and running on the HPLC column (S5 ODS2 , CIS 
column) was done by taking a Gou solution at a concentration of I mg/ml and 
filtering it. The solution (50 µl) was then loaded onto the HPLC column to analyse 
the components of Gou. The flow rate was 1.0 ml/min. The gradient was 0% to 
100% acetonitrile over 60 minutes. 
2.3 Enzyme Preparation, Purification and Characterisation 
Ethical approval was obtained to use animals in this study. 
2.3.1 Preparation of NEP Samples From a Rat Kidney Crude 
Microsomal Fraction of NEP 
This preparation was essentially that of Booth and Kenny (1974). Twelve wistar rats 
were killed by the inhalation method (CO2 for 5-10 minutes) and their kidneys were 
removed rapidly and chilled. The adipose tissue was removed and the kidneys were 
washed with 0.3 M sucrose, chopped finely, and filtered with cleaned gauze. The 
pellet left in the gauze was collected, dried and weighed. 
The pellet was resuspended in 0.3 M sucrose (in the ratio of 1 gram to 9 mis) and 
homogenised until a fine suspension was obtained. This was centrifuged at 8000 g 
for 15 minutes at 4°C (Beckman Centaur JA10), the pellet was discarded and the 
supernatant was centrifuged at 26000 g for 2 hours at 4°C (Beckman Centaur JA20); 
The supernatant was removed and the pellet resuspended in one third of the 
homogenised initial volume of 50 mM Tris-HCI, pH 7.4 with 1% of Triton-X-100; 
This was then stirred at room temperature for 60 minutes before being centrifuged at 
26000g for 90 minutes at 4°C. The supernatant, or "solubilised microsomal fraction" 
was retained and subsequently stored at 4°C. 
2.3.2 Protein Determination of the Rat-Kidney Crude-Microsomal Fraction 
Protein determination was carried out by using BSA (Bovine Serum Albumin) as the 
standard for the Lowry's assay and the HA (Human Albumin) for the Bradford 
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assay. The details of this are described in the section 3.4 (Bradford, 1976; Lowry ei 
al., 1951). 
2.3.3 Bio-Bead Column Preparation 
Bio-bead column preparation (SM-Z, BIO-RAD, Absorbent 100-200 meshes) was 
carried out following Vogel and Altsein (1977) with slight modification. A small 
amount of glass wool was pushed tightly into the necks of 12 pasteur pipettes, 12x80 
mg of Bio-beads in 50 ml of ethanol was washed for 60 minutes then distributed 
equally between the pipettes, the Bio-beads were then washed with lox I ml of 
distilled water and were ready for use. After each use the column was washed with 
2x 1 ml of ethanol and l Ox 1 ml of distilled water. 
2.3.4 Measurement of the Efficiency of 3H(leu)-enkephalin 
Binding to Bio-beads 
20 µl of 5 nM 3H(leu)-enkephalin was loaded at the top of prepared columns of Bio- 
beads. The columns were then eluted twice with I ml of distilled water. Substances 
bound to the column were removed by eluting twice, each time with I ml of absolute 
ethanol (this was more hydrophobic than water and thus it removed substances bound 
to the Bio-beads). A volume of I ml of eluent was collected each time (for the two 
distilled water elutions and for the two alcohol elutions) directly into scintillation vials 
containing 4 ml of Ecoscint H. Scintillation counts were taken of the four I ml 
samples. Two separate 20 pl aliquots of 5 nM of 
3H(leu)-enkephalin were also 
counted to act as controls. 
2.3.5 Assay for 3H(leu)-enkephalin Hydrolysis of NEP 
The assay for 3H(leu)-enkephalin hydrolysis was carried out as described by as 
Maifroy et al (1978) and Roques (1980), with some modifications: 
The following mixture was prepared and incubated at 37°C for 30 minutes 
54 
40 µl of diluted crude microsomal sample or eluate 
or 50 mM of Tris-HCI buffer, pH 7.4; 
20 pl of 200 nM non-isotopic (leu)-enkephalin; 
20 µl of 5 nM 3H(leu)-enkephalin; 
20 µl of 10 mM Bestatin (APN inhibitor); 
20 µl of 10 pM Captopril (ACE inhibitor); 
80 µl of 50 mM Tris-HCI at pH 7.4; 
Final volume was 200 µl. 
A volume of 50 µl of 0.1 M HCl was added immediately and the solutions were put 
into a 95°C water bath for 5 minutes to denature the protein and then centrifuged at 
13000 rpm for 20 minutes (Microcentaur, MSE). 200 µl of supernatant was applied 
to the washed Bio-bead columns and eluted with 2x l ml of distilled water. This was 
followed by 2x] ml of absolute ethanol. I ml of the eluted solution was collected 
directly into scintillation vials with 4 ml of Ecoscint H before being counted. 
2.3.6 The Purification And Identification of Enzymes By Hydrophobic- 
Interaction Chromatography (HIC) on Phenyl Agarose 
The following method is according to Almenoff and Orlowski (1983). 
The additional method of HIC purification involves the use of hydrophobic 
interactions in high salt. The binding buffer was 2M ammonium sulphate in 20 mM 
potassium phosphate buffer, pH 7.0. 
The column was pre-equilibrated with binding buffer at a flow rate of 0.5 ml/minute 
and 5 ml of kidney microsomal protein was loaded and run into the column. The 
protein was allowed to bind for 30 minutes. 
The unbound protein was removed from the column by elution with binding buffer at 
0.5 ml/min; 1 ml fractions were collected and all the unbound protein was removed 
(monitored at 280 nm). 
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A decreasing salt gradient was then applied to the column using a gradient former, 
The gradient was from 20 mM potassium phosphate pH 7.0 + 2.0 M (NH4)SO4 to 20 
mM potassium phosphate buffer pH 7.0. 
Following this gradient, 20 mM potassium phosphate buffer was run through until all 
the bound protein was eluted from the column. 
I ml fractions were collected through-out and their absorbance at A28() nm taken to 
plot an elution profile (shown in Chapter 3). 
2.3.7 Use of Polyacrylamide Gel Electrophoresis (PAGE) to Identify NEP 
Based on the elution profile protein estimation was performed on selected peak and 
plateau fractions by the Bradford method and samples were run on SDS-PAGE to 
evaluate the protein content of the elution peaks. 
The detailed method used is a variation on that used by Laemmli (1970) 
Glass plates for electrophoresis was washed in detergent, rinsed in distilled water, 
sprayed in 95% ethanol and dried with a paper towel. For silver staining the plates 
should be soaked in nitric acid before use. 
30.0 g of acrylamide was dissolved in water, the volume adjusted to 100 ml, and 5.0 
g of decolourising charcoal added. This was left at room temperature for 2 hours. 
The solution was filtered and stored in a brown bottle. 1.0 g of methylene 
bisacrylamide was dissolved in water and the volume adjusted to 100 ml. This was 
stored at 4°C. 1.5 M of Tris-HCI pH 8.8,1.0 M of Tris-HC1 pH 6.8 and 10% SDS 
were prepared; Together with freshly prepared 10% ammonium persulphate (APS), 
an electrode buffer was prepared containing 28.8 g of glycine, 6.06 g of Tris base and 
1.0 g of SDS, make up to 1 000 ml with distilled water. 
The sample buffer contained 0.77 g of dithiothreitol, 1.0 g of SDS, 4.0 ml of 1.0 M 
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Tris-HCI pH 6.8,5.0 ml of glycerol and 0.2% bromophenol blue, adjusted to 50 ml 
with distilled water. 
Solution `A'which contained 16.66 ml of 30% acrylamide, 13.33 ml of 1.0 % 
methylene bis-acrylamide and 20.0 ml of distilled water. Solution 'B' which 
contained 12.5 ml of 1.0 M Tris-HCI pH 6.8,1.0 ml of 10% SDS and 36.5 ml of 
distilled water. The resolving gel is prepared, as shown in Table 2.1 
Table2.1 Volume of Reagents for SDS PAGE Resolving Gel 
Percentage gel 
5.0% 10.0% 12.5% 17.5% 20.0% 
30% acrylamide 5.0 10.0 12.5 17.5 20.0 
1% bisacrylamide 7.8 3.9 3.1 2.2 2.0 
1.5 M Tris pH 8.8 7.5 7.5 7.5 7.5 7.5 
10% SDS 0.3 0.3 0.3 0.3 0.3 
Water 9.2 8.1 6.4 2.3 0.0 
TEMED ( eil) 20.0 20.0 20.0 20.0 20.0 
10% APS (pi) 200 200 200 200 200 
The stacking gel has been prepared by mixing 5.0 ml of solution 'A' , 
5.0 ml of 
solution 'B', 0.01 ml of 10% APS and 10.0 pl of TEMED. The gel was run at 25.0 
mA constant current, negative to positive. 
The gel was stained in 0.03% Coomasie Brilliant Blue R-250,45% methanol and 
10% glacial acetic acid, destain in 25% methanol and 10% glacial acetic acid. The 
procedure of Silver staining was shown in Appendix 2. 
2.4 Inhibition Experiments of Herbs on Enkephalin-hydrolysing Enzymes 
A defined volume (0-80 pd) of herbal extracts or controls was mixed as follows to a 
final volume of 160 µl. 
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40 pl of'rat kidney crude microsomal sample (L20). 
20 Id of 10 mM Bestatin: 
20 ftl of 10 pM Captopril, 
80 Eil of' 50 mM Tris-HCI, pH 7.4; 
I }it mixture «as incubated at room temperature for 15 minutes and 
200 til of 200 nM non-isotopic (Leu)-enkephalin, 
20 pA ot'5 Al 'H(leu)-enkephalin, 
ý%ere added Hic solution as incubated at 37°C for a further 30 minutes. The 
enzvmc %ti as assayed as in section of 2.3.5 _ to 
determine the inhibition effects of the 
Chinese herbs on the enkephalin-hydrolysing; enzymes. 
2.5 Statistical Analyses 
In this report the results of statistical calculations are presented as mean values ± 
Standani deviations iiom at least three experiments. The data were analysed with an 
unpaired t«u tailed Student's t-test. The statistical differences were considered 
significant according: to detailed situation. P stands for "probability". The detailed 
principle and related information is given in the Appendix. 3. 
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('IIAPTER 111 
Tiff, DESIGN AND ESTABLISHMENT OF THE 
SCREENING MODEL 
Preparation And Partial Purification of NEP 
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INTRODUCTION 
3.1 Screening model 
The first step for screening bioactive molecules is to design a efficient screening in 
vitro model such as enzyme assay. As discussed in Chapter 1, NEP has been 
implicated in pathways of analgesia, NEP has a broad substrate specificity and is a 
widely distributed enzyme (Gee et al., 1985). In the nervous system, the enzyme has 
been implicated in the metabolism of the enkephalins which are hydrolysed at the 
Gly3-Phe4 bond with the release of Tyr-Gly-Gly. Because of its broad substrate 
specificity, the enzyme may also participate in the degradation of tachykinins (e. g. 
Substance P), neurotensin, cholecystokinin and other neuropeptides. One Zn2+ is 
bound at the active site of the enzyme which is essential for its catalytic activity. 
NEP hydrolyses peptide bonds involving the amino groups of hydrophobic residues, 
(X-Ywhere Y is Phe, Leu, Ile, Ala, Val, Tyr, or Trp). Recently (Hersh and Morihara, 
1986), the optimum substrate sequence for NEP has been elucidated as, 
P3 P2 Pi ri P'z P03 
Phe Phe Ala Phe Leu Ala 
Ala Gly Leu 
Several specific inhibitors of the enzyme exist, of which the most widely used are 
Phosphoramidon and Thiorphan (For review see Turner et al., 1987). The effective 
concentration of both inhibitors, where controls containing them are suggested, is 1 
µM. In this thesis the Thiorphan was used as inhibitors of NEP, Bestatin was used to 
be inhibitor of APN and Captopril as that of ACE. 
3.2 The Principle of the Assay Used for NEP 
Three different kinds of NEP assay have been established in recent years and were 
widely used for different purposes. 
They are (1) Radiometric assay; (2) HPLC assay; (3) Fluorimetric assays. 
Compared with the other two methods, the radiometric assay allowed the assay of 
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more samples at one time and was suited for large-scale screening of new medicines. 
Therefore in this study the radiometric assay was adopted to investigate the inhibitory 
effects of the selected four Chinese herbs on NEP and then on APN/ACE. 
Radiometric Assay ( The actual method used is fully described in section 2.3. The 
discussion here relates to the principles behind this method only. ) 
The basic principle of NEP/APN/ACE degradation of the above substrate can be 
found in Chapter 1. The initial assays of enkephalin degradation employed 
radiometric methods and was reported by Malfroy (1978) and Vogel and Altstein 
(1977). Both thin layer chromatography (TLC) and polystyrene beads have been used 
to separate quantitatively intact enkephalins from the N-terminal tripeptide produced 
on incubation with NEP. 
In the normal method used, the incubation mixture in Eppendorf tubes consists of 
[3H-Leu5]-enkephalin (10 nM final concentration), the enzyme source (50 µl) and 
buffer (50 mM Tris-HCI, pH 7.4) made up to a final volume of 100 µl. After 30-60 
minutes at 3 7°C the reaction is stopped by the addition of 25 j il of 0.2 M HC 1. 
In the thin layer chromatography method, aliquots of the acidified incubation mixture 
(40-100 p l) are spotted on to silica-gel plates or sheets along with marker peptides. 
The chromatogram is developed with acetic acid: ethyl acetate: butanol: H2O 
(1: 2: 1: 1) and then stained with ninhydrin to reveal the marker peptides (e. g. 
Tyr-Gly-Gly). The sample spots are scraped off or cut out and their radioactivity 
determined by liquid-scintillation (Harman, 1989). 
Another method of analysing the breakdown of enkephalin is based on the 
observation that in aqueous solutions the pentapeptides are quantitatively retained on 
polystyrene beads (Vogel and Altstein, 1977) but the radiolabelled reaction products 
(e. g. Tyr, Tyr-Gly, Tyr-Gly-Gly) are not. Aliquots of the acidified incubation mixture 
(750) are transferred to pasteur pippettes containing 60 mg polystyrene beads, 
previously washed with 6x2 ml ethanol and 10x2 ml H20. The [3H]Tyr-Gly-Gly is 
directly eluted into scintillation vials with 2x2 ml H2O, and the radioactivity 
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determined by liquid scintillation (Llorens et al., 1982). The columns may be washed 
and stored in ethanol, and re-used several times. 
[3H-Leus]enkephalin is also a substrate for Aminopeptidase S (APS), dipeptidyl 
peptidases and peptidyl dipeptidases, and even Angiotensin-converting enzymes 
(ACE). To prevent the production of [3H]Tyr, which is also not absorbed to 
Bio-beads, Puromycin (100 µM) or Bestatin (100 µM) or Amastatin (10 µM) are 
included as APS inhibitors and Captopril (10 µM) is used as an ACE inhibitor. A 
more selective susbtrate is [Tyrosyl-3,5 3H-DpAla2, Leus]enkephalin, which has been 
synthesized but is not available commercially (Llorens et al., 1982). 
The radiometric methods are generally less satisfactory than fluorimetric or HPLC 
assays, since substrate concentrations substantially below K. are employed. The 
methodology also led to anomalously low K. values for enkephalin hydrolysis 
(Malfroy et al., 1978). However, the high sensitivity and operation scale means that 
the radiometric assay still has advantages for certain applications, for example, being 
used as a primary screening model to screen for novel medicines from natural 
resources. 
3.3 The Preparation and Purification of NEP Samples 
3.3.1 The Preparation of NEP Samples 
The preparation procedure for this enkephalin-hydrolysing enzyme sample was as 
described in section 2.3.1 of chapter 2. In chapter 1 it was also shown that the NEP 
is widely distributed in many kinds of tissues but most concentrated in the kidney. 
This is the reason that the rat kidney was used to prepare enkephalin-hydrolysing 
enzyme samples in this study. 
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3.3.2 Use of Hydrophobic-Interaction Chromatography (HIC) 
to Purify The NEP 
Hydrophobic-interaction-affinity chromatography relies on the fact that interaction 
occurs when the hydrophobic sites of proteins undergo differing degrees of 
hydrophobic interaction with an uncharged matrix containing hydrophobic groups. 
This method can provide a general systematic approach to the purification of both 
water-soluble and lipophilic proteins. In this thesis, hydrophobic phenyl-agarose was 
used to achieve resolution and purification of NEP from other enzymes. This method 
was according to Almenoff and Orlowski (1983). The detailed procedure is dealt in 
section 2.3.6 of chapter 2. 
3.3.3 Use of Polyacrylamide Gel Electrophoresis (PAGE) to Identify NEP 
At any pH other than at their isoelectric point, proteins carry a net electrical charge. 
If the charged proteins are placed in an electrical field they will migrate at a rate 
dependent on their charge density, i. e. the ratio of their charge to their molecular 
mass. Electrophoresis uses a semi-rigid porous matrix through which molecular 
sieving can occur, and so two molecules of similar charge density may be separated 
by a difference in their size. The extent of the molecular sieving is dependent on the 
pore size of the matrix, this can be reproducibly selected for the range of molecular 
weights under consideration (Names and Rickwood, 1983). 
Polyacrylamide gels have a working range of concentrations from 2.5% to 30%. As 
the concentration increases the effective pore size decreases. Pore size is varied by 
adjusting the proportion of cross-linker present in the gel, this is generally methylene 
bis-acrylamide. Pore size decreases as the concentration of methylene bis-acrylamide 
increases, reaching a minimum when the cross-linker reaches about 5% of the total 
acrylamide monomer present (Laemmli, 1970). 
Polymerisation of the gel requires an activator in the form of free radicals, these are 
usually obtained from ammonium persulphate, but riboflavin can be used. Light 
causes the decomposition of riboflavin into the free radicals necessary to initiate poly- 
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merisation. The polymerisation process can be accelerated by the addition of a 
catalyst. This is usually N, N, N', N'-tetramethyl ethylenediamine (TEMED), which 
catalyses the formation of the free radicals from ammonium persulphate which initiate 
polymerisation (Hames and Rickwood, 1983). 
Polyacrylamide gels were prepared immediately before use from an acrylamide 
monomer (CH2=CHCONH2) copolymerised with a cross linking agent, N, 
N-methylenebisacrylmide [CH2(NH000H CH2)2] in the presence of an initiator 
(ammonium persulphate) and a catalyst N, N, N, N', -tetramethyl ethylenediamine 
(TEMED). Polyacrylamide gel electrophoresis (PAGE) is usually carried out as slab 
gels sandwiched between glass plates. The gap between the plates is usually between 
0.5 and 3.0 mm. A major advantage of this system is that several samples and 
standards can be run at the same time, therefore the results are comparable. For a 
higher degree of separation between proteins of similar molecular weight and charge 
density, systems such as Triton-acid-urea or two-dimensional gels ( Davie, 1982 ) 
may be run. 
The majority of the buffering systems used are denaturing in nature and are designed 
to dissociate protein complexes into their constituent subunits. They are designed to 
give the proteins a similar overall charge so that they will be separated according to 
molecular weight. Exceptions to this do occur. Because of the basicity of histones, 
the overall negative charge induced by sodium dodecyl sulphate (SDS) is reduced so 
that the histones migrate at a slower rate, when compared with molecular weight 
markers, than their molecular weight would suggest. 
In this study the SDS-PAGE was used to identify the NEP band of the pooled 
fractions. Both Coomassie brilliant blue and Silver were compared for staining the 
gel. The detailed procedure for SDS-PAGE was shown in section 2.3.7. and silver 
staining was given in Appendix 2. 
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RESULTS AND DISCUSSION 
3.4 Assay of Protein Concentration in the Rat Kidney Crude Microsomal 
Fraction 
After obtaining the crude microsomal fraction prepared as in Chapter 2, the 
concentration of proteins was measured. In order to find a best method, two 
different methods were compared. All the results in this report were repeated at least 
three times. 
3.4.1 The Lowry Method (Rosebrough et al., 1951) 
The Lowry method is based on measuring the content of tyrosine and tryptophan in a 
protein using Folin-Ciocalteau reagent as the dye. BSA (Bovine serum albumin) (10 
mg/ml) was used as the reference to prepare a standard curve, from which, by 
comparison the concentration of protein in experimental samples could be calculated. 
The results were as shown in Table 3.1 and in Figure 3.1 
Table 3.1 Result of The Lowry Method to Determine the Protein 
Concentration of the Rat-Kidney Crude Microsomal Fraction 
(see section 2.3.2) 
The cone itration of BSA (pg/ml) A650 
0 0.000±0.000 
100 0.173±0.008 
200 0.305±0.004 
300 0.454±0.018 
400 
500 0.563±0.006 
Crude microsomal fraction: 
0.657±0.005 
next 1.861±0.013 
1: 10 0.508±0.015 
1: 100 0.044±0.004 
Based on the data presented in Table 3.1 the standard curve was plotted in Figure 
3.1. 
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Figure 3.1 The Standardisation Curve for the Lowry Method Used to 
Determine the Protein Concentration of the Rat Kidney 
Crude Microsomal Fraction 
From the standard curve in Figure 3.1, the A650 of the rat kidney crude microsomal 
fraction could be read against the protein concentration, so that the protein content 
could be obtained. For dilution at 1: 10 of rat kidney crude microsomal fraction, the 
reading taken from the Figure 3.1 was 351 µg/ml, for 1: 100 dilution the reading was 
250 pg/ml. Then the concentration of protein in the crude microsomal fractions was 
calculated, which was 3.01±0.71 mg/mi. 
3.4.2 The Bradford Method (Spector, 1977) 
The difference between the Bradford and the Lowry's method is that Coomassie 
brilliant blue is used as the dye for the Bradford assay and the absorbance is measured 
at 595 nm. The dye-binding capacities can affect the As9, value and finally affect the 
estimation of the protein concentration in the samples. However this method is easier 
and quicker to manipulate than the Lowry method. Therefore the protein 
concentration was also measured by the Bradford method so that the most 
appropriate method could be chosen in the following experiments. The sample 
contained 10-100 µg of protein in 0.1 ml and 5.0 ml of Coomassie brilliant blue G- 
66 
250 was added and mixed with protein sample quickly. After 5 minutes and before 1 
hour, the absorbance at 595 nm was read against a reagent blank. Protein 
concentration was calculated by comparison with the results as presented in Table 
3.2 and in Figure 3.2. 
Table 3.2 Bradford Method Used to Determine the Protein 
Concentration of Crude Microsomal Fraction 
The concentration of human albumin 
HA (nigh 
Args 
0.0 0.000±0.000 
0.2 0.156±0.014 
0.4 0.250±0.014 
0.6 0.387±0.012 
0.8 0.474±0.010 
1.0 0.555±0.007 
Crude sample dilution: 1: 5 0.445±0.010 
1: 10 0.219±0.008 
Tris-HCI buffer, (pH 7.4) control 0.002±0.000 
0.6 
Y= -0.1799x2 + 0.7322x+ 0.0035 0.5 
0.4 
0.3 
0.2 
0.1 
0 
0 0.2 0.4 0.6 0.8 
Concentration of HA (mg/ml) 
Figure 3.2 The Standard Curve For the Bradford Method Used to Determine 
the Protein Concentration of the Crude Microsomal Fraction, prepared as 
section 2.3.2. 
Human Albumin (HA) stock: 10 mg/ml; The crude microsomal sample was tested at 
two dilutions: 1: 5 and 1: 10. 
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Based on the data in Table 3.2 the standard curve was produced in Figure 3.2. The 
A595 of the crude microsomal fraction could be read against the protein concentration 
so that the protein content of the samples could be obtained. The protein 
concentration from the Bradford assay of the crude microsomal fraction was 
calculated (by means of the equation in the figure) which is 0.7365 mg/ml at the 
dilution of 1: 5 and 0.32 mg/ml at the dilution of 1: 10, then the protein concentration 
in the undiluted crude microsomal fraction was 3.44±0.34 mg/ml. The statistical 
significance of difference between the Bradford and the Lowry was determined by 
Student's t-test. P<0.05 was considered as the criterion of significance (The detail of 
Student's t-test is described in Chapter 2 and Appendix. 3). This suggested that the 
two results had no statistical significance in their difference (P>0.05). The Bradford 
assay was easier to operate than the Lowry's assay and so it was the chosen method 
to measure the protein concentration in the following experiments. 
3.4.3 The Stability Determination of the Rat Kidney Crude Microsomal 
Fraction 
After the rat kidney crude microsomal fraction was stored in the cold room at 4°C for 
two months, some white precipitate was observed on the bottom of the sample tube. 
In order to determine if it was the inactivated enzyme and if this would affect the 
effective concentration of protein, the concentration of the protein in our sample was 
remeasured periodically by carrying out the protein assay at two-monthly intervals. 
The results were as shown in Table 3.3. 
Table 3.3 The Monitoring of the Stability of the Crude 
Microsomul Fraction (Bradford Method) 
Dilution of sample The concentration of protein (m ýW) 
I day after prepared 2 months after 
ared 
Significance 
1: 5 3.88 3.50 P<0.01 
1: 10 3.30 3.35 P<0.01 
The results presented in Table 3.3 indicated that the concentration of protein was 
still about 3.4±0.1 mg/ml (P<0.01). The NEP assay also showed that the enzyme 
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activity was stable enough (see in the section 3.5.3 in this chapter). These two results 
suggested that the white precipitate would not affect the NEP activity significantly 
and so the white precipitate could be neglected. 
3.5 Assay of NEP Activity in the Crude Microsomal Fraction 
3.5.1 The Binding Efficiency of the Column 
After the crude microsomal fraction was obtained and the protein concentration was 
determined by the Bradford assay, the NEP assay had to be established. Firstly, the 
binding efficiency of the Bio-beads column was investigated so that the most efficient 
Bio-beads columns (the principles of the method was introduced in section 3.2 of this 
chapter) could be chosen for NEP assay. The results were as shown in Table 3.4. 
Table 3.4 The Binding Efficiency of Bio-beads Column 
Number of columns Total DPM Binec 
1 40082.2 87.0 (DPM) 90.5 CP 
2 65352.2 93.2 (DPM) 92.5 CP 
3H leu -enke halin control 
13508.9±8239 
Ecoscint H control 29.9±2.8 
DPM: Disintegrations per minute 
The binding efficiency of the randomly-selected two bio-beads columns were 
therefore 87% and 93.2%, giving an average binding efficiency of 90.1±4.4%. This 
suggested that the columns' binding efficiency was higher than 90'/0. Normally if the 
binding efficiencies of randomly-selected beads were above (85-90)%, the beads 
could be used to carry out the effective NEP assays. 
3.5.2 Concentration Curve of the Crude Microsomal Fraction For 50% 
Hydrolysis of 3H(leu)-enkephallin 
In order to establish a stable and reasonable NEP assay for primary screening of the 
Chinese herbs, the concentration of the crude microsomal fraction required to 
produce 50% hydrolysis of 3H(leu)-enkephalin needed to be investigated. The buf er 
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containing 50 mM of Tris-HCl pH 7.4 was used to dilute the crude microsomal 
sample according to the following ratios 1: 5,1: 10,1: 20,1: 30,1: 40,1: 60,1: 100 then 
in each case the enzyme was assayed. The results were as shown in Table 3.5 and in 
Figure 3.3. 
Table 3.5 Determination of the Concentration of the Crude Microsomal 
Fraction Required to Produce a 50% Hydrolysis of 3HOeu)-enkephalin 
Dilution of 
enzyme sample 
Conc. of protein 
in sample (µg/ml) 
Total 
DPM 
Specific 
DPM 
Hydrolysis% 
of 3H(leu)- 
enk halin 
undiluted 3400 68460.5 66269.76 96.8 
1: 5 680 79051.1 72647.96 91.9 
1: 10 340 89852.7 55169.55 61.4 
1: 20 170 85908.0 44414.44 51.7 
1: 30 113.3 84105.8 27166.17 32.3 
1: 40 85.0 93543.8 22076.34 23.6 
1: 60 56.7 82227.6 14389.83 17.5 
1: 100 34.0 81711.1 8334.53 10.2 
Tris-HC1 buffer control 52311.3 4760.33 9.1 
Ecoscint H control 28.8±0.2 
NB: HD% = (Specific DPM / Total DPM) X 100%; DPM means disintegrations per 
minute; Digestion was taken to completion in these experiments for which a 
digestion time of 30 minutes was considered sufficient. 
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Figure 3.3 Determination of the Concentration of the Crude Microsomal 
Fraction Required to Produce 50% Hydrolysis of 3H(leu)-enkephalin. 
Based on the data in Table 3.5 the dilution curve was as plotted in Figure 3.3. The 
curve indicated that the optimum dilution for 50 % hydrolysis of 3H(leu)-enkephalin 
was 1: 20. Since the original concentration of protein in the rat-kidney crude 
microsomal fraction was 3.4 mg/ml, the enzyme concentration required to produce 
50% hydrolysis of 3H(leu)-enkephalin was therefore 165.6 µg /ml. 
3.5.3 The Time Course for Hydrolysis of 3H(leu)-eukephalin by the Rat 
Kidney Crude Microsomal Fraction 
The above experiment demonstrated that the concentration of the rat kidney crude 
microsomal fraction for 50% hydrolysis on 3H(leu)-enkephalin was 165.6 µg/ml. The 
time course for digestion of 3HOeu)-enkephalin by the rat-kidney crude microsomal 
fraction was then determined. 
The reaction mixture (40 µl of crude microsomal fraction -protein concentration at 
165.6 p. g/ml, being mixed with 20 µ1 of 200 nM cold (leu)-enkephalin, 20 µl of 5 nM 
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3H(leu)-enkephalin, 20 µl of 10 mM Bestatin, 20 µ1 of 10 pM Captopril and 80 µ1 of 
50 mM Tris-HCI, pH7.4 ) was incubated at 37°C and aliquots of volume were taken 
out at 0,10,20,30,60,90,120,180 minutes separately, and 50 0 of 0. IN HCI was 
added to stop the reaction for each aliquot. Each aliquot was denatured at 95°C for 
15 minutes, and centrifuged at 13000 rpm for 20 minutes. The supernatant was 
applied to Bio-beads and counted for DPM(disintegration per minute) in a liquid 
scintillation counter. The results were as shown in Table 3.6. and as plotted in 
Figure 3.4. 
Table 3.6 Determination of the Time Course of 3H(leu)-enkephal n 
Hydrolysis for Crude Microsomal Fraction 
Incubation 
time 
Hydrolysis % of 3H(leu)-enkephalin (HD%) 
min E erimeirt 1 E erimeut 2 Average 
DPM HD% DPM HD% HD% 
0 78231.5 4.3 78784.0 6.5 5.4±1.5 
10 84999.4 21.5 89890.0 20.8 21.2±0.5 
20 92246.4 35.7 90253.6 34.5 35.1±0.8 
30 87490.2 47.9 91282.8 46.2 47.1±1.2 
60 95414.4 68.7 96340.5 67.7 68.2±0.7 
90 93514.8 82.1 94166.5 81.3 81.7±0.6 
120 95026.9 88.1 99856.8 85.8 87.0±1.6 
180 95515.0 93.8 100389.7 92.9 93.4±0.6 
BC* 89322.8 7.4 
Ecoscint H control 30.0±0.3 
NB: * BFC: 50 mM Tris-HC1 (pH 7.4) control; HD%: Hydrolysis percent of 
3H(leu)-enkephalin (see Table3.5 for definition) 
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Figure 3.4 Determination of the Time Course of 3H(leu)-enkephaln 
Hydrolysis For the Rat Kidney Crude Microsomal Fraction. 
The graph of the time course of the hydrolysis was produced from the data in Table 
3.6. This indicated that for 50% hydrolysis at 1: 20 dilution, the incubation time was 
33.5 minutes. In the detailed experiments the incubation time was chosen to be 30 
minutes. A t-test showed that 33.5 minutes incubation time was not significantly 
different from 30 minutes (P > 0.05). 
Based on the above experiments the characterisation of the rat kidney crude 
microsomal extract was carried out. Up to this stage of the work an optimum 
enkephalin-hydrolysing enzyme assay was established as follows: 
40 µ1 of crude microsomal fraction (protein concentration at 165.6 µg/ml) was mixed 
with: (1) 20 d of 200 nM cold (leu)-enkephalin, (2) 20 µl of 5 nM 3H(leu)- 
enkephalin, (3) 20 µl of 10 mM Bestatin, (4) 20 µl of 10 pM Captopril. The 
solution was made up to 200 .d with 
50 mM Tris-HCI buffer, pH7.4. The reaction 
mixture was incubated at 37°C for 30 minutes and digestion was stopped with 0.1 N 
HC1 and denatured at 95°C for 15 minutes. The digestion solutions were then 
centrifuged at 13000 rpm for 20 minutes and the supernatants were applied to Bio- 
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beads and counted for DPM in the liquid scintillation counter. All the following 
screening experiments were carried out using the optimum assay (as described in this 
section). 
3.5.4 Final Calculation of the Enzyme Activity of NEP in the Rat Kidney 
Crude Microsomal Fraction 
In order to understand the enkephalin-hydrolysing enzyme assay better, the NEP 
activity was calculated as follows. According to the Table 3.6,47.1 % of 20.5 nM 
(leu)-enkephalin added into the incubation mixture, was hydrolysed in a total volume 
of 200 0 in 30 minutes. 
Thus 20.5x47.1%=9.656nM 
9.6555/5000 = 1.93 x 10 3 nmols 
. *. In 1 minute hydrolysed 1.93 x 10 
3/ 30 = 6.4 x 10-5 nmoles/min 
Thus 6.4 x10-5 nmoles/min of (leu)-enkephalin are hydrolysed by 40 µl of 1: 20 
dilution of the enzyme solution. Therefore using 1 ml of 1: 20 dilution of the 
enzyme solution, hydrolysis of ii (leu)-enkephalin should be 6.4 x10-5 nmoles/min 
x 25 = 1.6 pmoles/min per ml of the crude microsomal fraction. 
Enzyme Activity 
One SI unit of enzyme activity is that amount of enzyme which will catalyse the 
conversion of 1 pmole of substrate under given assay conditions. 
Thus 16 enzyme units/ml of 1: 20 dilution (From the dilution curve it could be 
found that the dilution was 20) of enzyme solution. Thus in original solution: 
1.6 x 20 = 32 enzyme units/nil of original solution 
Specific activity = units of enzyme activity/mg of protein 
= 32 / 3.4 = 9.41 units of enzyme activity/mg of protein 
Total activity = specific activity x total protein 
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As the volume of the obtained rat kidney crude microsomal fraction is 47.5 ml, the 
protein concentration is 3.4 mg/ml; Therefore the total activity = 9.41 x 47.5 x 3.4 = 
1.52 x 103 units. 
Therefore under the experimental conditions, for 1 mg of protein in the crude 
microsomal fraction the specific activity of NEP is 9.41 units. Totally 1.52 x 103 units 
of NEP was harvested. This was compatible with the reported results of Roques 
(1984). 
3.6 The Purification of NEP By Hydrophobic-Interaction Chromatography 
Purification of NEP was essential in order to study NEP activity quantitatively. 
Hydrophobic-Interaction Chromatography (HIC) was therefore chosen for partial 
purification of the enzymes. 
The detailed HIC method for purification of NEP was described in section 2.3.6. 
Eluted fractions were collected in 1 ml aliquots in separate tubes for protein assay 
and enzyme assay. 
3.6.1 Protein Assay 
The collected fractions from the Hydrophobic-Interaction Chromatography (HIC) 
were measured at ODZ50 by Ultra-violet absorption spectrophotometry from which 
the protein concentration was calculated. A plot of the fraction-tube number on the 
abscissa against the average protein concentration as ordinate, the elution curve, was 
made and was as shown in Figure 3.5. 
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Figure 3.5 Elution Profile For NEP from the HIC Purification Procedure 
The elution curve of Figure 3.5 showed 8 peaks. They were in the positions: Peak 1: 
# 3, Peak 2: # 9, Peak 3: # 81, Peak 4: # 113, Peak 5: # 166, Peak 6: # 185, 
Peak 7: # 193, Peak 8: # 199, where # indicates fraction number. 
3.6.2 Enzyme Assay 
Based on the Figure 3.5, the enzyme activity was assayed for each of the selected 
five fractions, and the corresponding activity curve was calculated as plotted in 
Figure 3.6. The result presented in Figure 3.6 suggested that the elution curve for 
protein (OD280 peak) was compatible with the enzyme activity curve (hydrolysis 
percent peak). i. e. there is a strong correlation between the chromatographic peaks 
and the levels of enzyme activity. The fractions corresponding to the peaks were 
then pooled for further study. 
76 
1.5- 100 
OD280; + Hydrolysis percen x 
a ö 
80 ' 
La . 
1"0 1 
6 0 
8 40 I- 
ö 0.5 c 
O -- 
20 
CD 
- 0.0 0 
0 20 40 60 80 100 120 140 160 180 200 
P= Pool No. ) T P1 1P2 TP3 T P4 
TP5 I P6 TP7 
T 
P8 IP9 
Fraction number 
Figure 3.6 The OD2*o (- " -) Measurements of the HIC Fractions and the 
Related Enzyme Activity as Indicated by the Percentage Hydrolysed (- + -). 
Each tube contained a1 ml elution fraction which was tested for OD2gO and enzyme 
activity. 
3.6.3 Determination of the Protein Concentration and the Enzyme Activity 
in Pooled Fractions 
By carefal consideration of the two curves in Figure 3.6 fractions were pooled so 
that the maximum yield of individual fractionated proteins were collected. The pooled 
fractions were taken as indicated in the following table. 
No. of Pools Fraction numbers No. Pools Fraction numbers 
(#) (#) 
Pool 1 1-15 Pool 2 16-80 
Pool 3 81-95 Pool 4 96-110 
Pool 5 111-125 Pool 6 126-135 
Pool 7 136-160 Pool 8 161-175 
Pool 9 176-200 
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Then the protein concentration and the enzyme activity in the pooled fractions were 
measured. The results were as shown in Table 3.7. 
Table 3.7 Determination of the Protein Concentration of Pooled 
Fractions and Related Enzyme Activity 
Pooled 
fractions 
Volume 
of pools 
ml 
Protein conc. 
(mg/ml) 
Total DPM Hydrolysis% 
of 3H(leu)- 
enk halm 
Total NEP 
activity 
(unit) 
Pool 1 10.0 0.900 26049.5 81.7 27.91 
Pool 2 47.0 0.048 28661.9 6.5 10.44 
Pool 3 11.0 0.125 26287.8 19.3 7.25 
Pool 4 12.0 0.142 23591.9 17.3 7.09 
Pool 5 10.2 0.510 22583.3 71.4 24.88 
Pool 6 12.0 0.307 24164.2 20.7 8.49 
Pool 7 17.0 0.291 25472.3 22.0 12.78 
Pool 8 14.5 0.152 21632.4 13.8 6.84 
Pool 9 14.6 0.188 23830.8 7.7 3.84 
Crude Enzym 
sample 
-20°C 
26363.9 48.1 164.34 
Fresh enzyme 
sample 
-4°C 
20987.5 56.5 193.04 
The data presented in Table 3.7 was used to calculate the recovery percent of 
enzyme activity as follows; 
The total activity of pooled fractions are: 
20 .5x 
hydrolysis% of subs x 25 x 103 x V. of pools x protein conc. 
5000 x 30 xprotein conc. 
Thus the total loading enzyme activity is: 164,34 units; The total recovery enzyme 
activity is: 109.52 units. 
So, Recovery % of enzyme actv'tY =109.52 =164.34 x 100 % 
= 66.6 % 
Therefore about 66.6 % of the OnzYine activity was recovered. 
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3.6.4 Using Polyacrylamide Gel Electrophoresis (PAGE) to Analyse the Pooled 
Fractions 
As shown in the SDS polyacrylamide gels in Figure 3.7, Pool 1 (P1), Pool 3 (P3), 
Pool 6 (P6) seemly contained the 90 kDa band as calculated by comparison with the 
standards run in the first alley. 90 kDa should be the band of NEP according to the 
work of Kenny et al. (1992). The gel profile of Figure 3.7 showed that the NEP had 
not been purified completely. This suggested that HIC was useful but not good 
enough to purify the NEP completely. HIC still needed to be combined with other 
methods so that completely purified NEP could be obtained. The detailed procedures 
for obtaining completely purified NEP was described by Almenoff and Orlonski 
(1983). According to Roques (1993), affinity chromatography using monoclonal 
antibodies raised to the NEP would be the most efficient way to obtain purified NEP. 
In future this method will be considered for use if circumstances allow it. 
Markers P1 P2 P3 P4 P5 P6 
kDa 
205 -- r 
kDa 
116-- k, 
97 
.. Tý s. 66 
45 
Figure 3.7 Silver Stained SDS-acrylamide Gel of the Pooled Fractions of Rat 
Kidney Crude Microsomal Fractions, where P Denotes Pool Number. 
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Figure 3.8 An Rf Plot For the Above Gel Showing a 90 kDa Value for 
the Indicated Band. 
Figure 3.8 was based on the SDS-PAGE gel result of pooled fractions of rat kidney 
crude microsomal fractions. The result suggested that P1, P3 and P6 do contain the 
NEP band. Coomassie brilliant blue staining was also done (gel not shown) in order 
to compare it with silver staining. The result showed that silver staining was more 
sensitive and it was important under this experimental conditions because the 
amounts of the enzymes were quite limited, silver staining therefore was chosen as 
the preferred staining method. 
3.6.5 Conclusion 
CONCLUSION AND SUMMARY 
The hydrophobic-interaction chromatography (HIC) method proved to be useful to 
purify NEP from the crude rat-kidney fraction from the above experiments and the 
gels showed the presence of a 90 kDa band consistant with NEP but indicated that 
impurity proteins were also present. In future a more detailed purification method 
will be needed to isolate NEP. The McAb method is reported to be the most efficient 
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method to obtain completely purified NEP (Roques, 1993). The NEP enzyme did not 
fractionate in a unique fraction of the HIC column but was observed in several 
fractions. However in the total pooled fractions 66.6% of enzyme activity was 
recovered and the NEP was not observed in pools of fraction numbers 16-80,96- 
110,111-125 but was observed in pools of fractions 1-15,81-95 and 126-135. 
Clearly fractions were not taken where there was 33.4% of the enzyme activity, 
however the above 33.4% of enzyme were not in the region which would expect to 
contain NEP. 
3.7 Summary 
At this stage of the work the enkephalin-hydrolysing enzymes assay had been 
established. According to the results in the Figure 3.3 the optimum dilution for 50% 
hydrolysis of 3H(leu)-enkephalin was 1: 20, the protein concentration was 165.6 
µg/ml and the incubation time was 33.5 minutes. 
In the experiments which are described in the later sections of this study, by changing 
the inhibitors of the three enkephalin-hydrolysing enzymes, the activity of three 
enkephalin-hydrolysing enzymes (NEP, APN, ACE) could be assayed separately. By 
using selective NEP inhibitors or mixed inhibitors of NEP/APN, APN/ACE, and 
NEP/ACE, the activity of specific enzymes or groups of enzymes could be screened. 
The protocol for the assays for the activities of the specific enzymes was as given in 
Table 3.8 
Table 3.8 The Protocols of the Assays for the Activities 
of the Specific Enzymes 
Enzyme inhibited Inhibitors' name and 
concentration 
Remaining uninhibited enrymes 
therefore being assayed 
NEP Thiorphan (2.0 APN ACE DAP 
APN, DAP Bestatin (10 NEP, ACE 
ACE C ril (10 NEP, APN, DAP 
APN DAP, ACE Bestatin, C ril NEP 
NEP, ACE Thiorphan, Captopril APN/DAP 
NEP, APN, DAP Thiorphan, Bestatin ACE 
NEP, APN, DAP, ACE Thiorphan, Bestatin, 
Captapril 
N/A 
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CHAPTER IV 
THE EFFECTIVE USE OF GOU AND QIANG AS 
INHIBITORS OF PROTEOLYTIC ENZYMES NEP, APN AND 
ACE IN THE CRUDE MICROSOMAL FRACTION 
PRIMARY SCREENING EXPERIMENTS 
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INTRODUCTION 
After the assay for proteolytic enzymes had been established and the partially purified 
NEP had been obtained as described in Chapter 3, Chinese herbs were assayed for 
their inhibitory effects on NEP. The crude microsomal fraction contained two other 
enzymes (APN and ACE) which also have proteolytic action on enkephalin. The 
standard inhibitors of enzymes other than NEP were therefore used to ensure that 
screening was specifically for NEP (see Table 3.8 of chapter 3). The screening work 
was done on NEP first, then the effect of target herbs on APN or/and on ACE were 
investigated in subsequent experiments. All the results in this chapter were repeated 
at least three times. 
RESULTS AND DISCUSSION 
4.1 The Optimum Inhibitory Concentration of Standard Inhibitors 
In order to establish an optimum screening model, the optimum concentrations for 
inhibition of enkephalin proteolysis in Table 4.1 had to be investigated first. Three 
concentrations of each inhibitor were assayed for their inhibitory activity on the rat 
kidney crude microsomal fraction. The results were as presented in Table 4.1. and 
the experiments were carried out as following steps: (1) Preparation of the 
preincubation mixture: Bestatin (final concentration: 1mM , 10mM, 100 mM) or 
Thiorphan (final concentration: 0.2 mM 2.0 mM, 20 mM) or Captopril (final 
concentration: 10µM, 1mM, 10 mM) was usually mixed with 40 µl of rat kidney 
crude microsomal fraction (diluted at 1: 20), then the 50 mM Tris-HCI buffer, pH7.4 
was added until the final volume was 140 pl , preincubated at room temperature for 
15 minutes; (2) NEP assay : The NEP assay was run by mixing above 140 µl 
solution with 20 . tl of 200 nM cold (leu)-enkephalin, 20 pl of 5nM of 3H(leu)- 
enkephalin, and 20 W of 10 mM Bestatin, then final volume (200 µl) solution were 
incubated at 37°C for 30 minutes, then 50 µl of 0.1 M HCl was added to stop the 
reaction immediately and inactivated at 95°C for 15 minutes. (3) The mixture was 
centrifuged at 13000 rpm for 20 minutes and the 200 µl of supernatants were loaded 
onto Bio-beads column and washed with 2x1 ml distilled water to elute and 
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followed with 2x1 ml absolute ethanol to elute, the eluates were counted using a 
liquid scintillation counter. 
Table 4.1 Determination of the Optimum Inhibitory Concentration Standard 
Inhibitors of NEP, APN and ACE in the Crude Microsomal Fraction 
Classified group HD% Enzyme 
inhibited 
Enzyme active 
still 
Bestatin 1 mm 86.1 
(Bes) 10 mm 44.9 * APN NEP, ACE 
100 mm 16.7 
Bes (10mM) 10 Jim 30.4 
+ 100 28.2 
Captopril 1 mm 27.9 APN, ACE NEP 
10 mm 16.4 
Bes (10 mM) 0.2 mM 30.8* 
+ 2.0 mM 22.9 APN, NEP ACE 
Thiorphan 20 mM 13.0 
CE only 94.5 None NEP, NEP, 
ACE 
BFC 6.7 Buff er control 
NB: BFC: buffer control; CE: Rat kidney crude microsomal sample 
*: The optimum concentration under this experimental condition 
HD% : Hydrolysis percent of 3H(leu)-enkephalin (see Table3.5 for definition) 
The results presented in Table 4.1 suggested that 10 mM of Bestatin, 10 µM of 
Captopril and 0.2 mM of Thiorphan could be considered as the optimum inhibitory 
concentrations under laboratory conditions for these studies. Firstly the 
concentration of Bestatin that led to 50% of 3H(leu)-enkephalin to be degraded by 
NEP was obtained, then the minimum inhibitory concentration MC) of Captopril 
and Thiorphan was assayed. Under these experimental conditions the 0.2 mM of 
Thiorphan could significantly decrease the hydrolysis of 3H(leu)-enkephalin and was 
used as the inhibitory concentration. 10 mM of Bestatin could significantly decrease 
the hydrolysis of 3H(leu)-enkephalin and was chosen to inhibit APN in the following 
screening experiments. While 10 µM of Captopril was used to inhibit ACE. By 
controlling the use of the three inhibitors, the activity of three enzymes (NEP, APN 
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and ACE) could be assayed. In this way the effects of Chinese herbs on NEP APN 
and or ACE individually could be investigated. 
The 50 percent inhibitory concentration (IC50) value of Thiorphan was reported by 
Roques (1980) to be 4.7±1.2 nM. Bestatin was reported to be 0.2 µ. M (Barclay, 
1980) and Captopril was reported to be 1 pM (Ondetti, 1977,1979). These results 
were obtained by assaying the rat kidney crude microsomal fraction, not the pure 
enzymes, and of course it also contained proteins other than NEP, APN and ACE. It 
is known that none of these other proteins act as peptidases against enkephalins but 
they will affect the calculation of the enzyme inhibitory concentration. Therefore the 
optimum concentration used in this experimental condition was much higher than the 
reported Minimum Inhibitory Concentration (NHC) of the three standard inhibitors 
(Roques, 1980). In fact a higher concentration of standard inhibitors was necessary 
in order to obtain complete inhibition of enzymes combinations (APN, ACE and 
DAP) so that the effect of the herbal extract on NEP could be properly investigated. 
4.2 The Effect of Four Chinese Herbal Extracts on the Activity of NEP 
in the Crude Microsomal Fraction 
Yang (1985) identified four herbs which were clinically found to have different 
degrees of analgesic activity on patients. They were: Yan; Gou; Chuan; and Qiang. 
The molecular mechanism for the analgesic activity of the above herbs has not yet 
been reported. In view of the relationship between NEP and opioid peptides (see 
Figure 1.1), it was worthwhile to test the activity of above four herbs on NEP in the 
crude microsomal extract. Both the aqueous and organic extracts (see section 2.1 of 
Chapter 2) of above four herbs were tested for their inhibitory activity on NEP in 
vitro. The results were as given in Table 4.2 and plotted in Figure 4.2. The 
detailed experimental procedure was described in section 2.4. and section 2.3.5. 
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Table 4.2 Determination of the Effects on the Percentage of Hydrolysis 
of 3H(leu)-enkephalin in the Presence of Four Herbs to Show Their 
Inhibition of NEP in the Crude Microsomal Fraction 
Enzyme activity group Organic extract Aqueous extract 
HD% HD% 
NEP active (CB) 44.6 47.8 
NEP active (CB) plus: neat 28.5 31.7 
Yan 1: 10 45.6 37.9 
Gou neat 22.2 * 6.0 
1: 10 37.8 25.8* 
Qiang neat 23.7 * 7.8 *** 
1: 10 38.7 39.4 
Chuan neat 32.9 15.3 
1: 10 54.0 39.2 
Tris-HCl buffer control 5.8 
HD% means Hydrolysis% of 3H(leu)-enkephalin; CB means Captopril plus Bestatin 
which inhibit APN and ACE, leaving NEP active (see Table 4.1). Then the four 
selected herbal extracts were mixed with the NEP-active preparation (CB) and 
assayed for proteolysis of (leu)-enkehalin. Student's t-test was used to analyse the 
significant differences between the NEP only active (CB) preparation and other NEP 
active (CB) plus herbs preparation. Probability "P" was expressed as follows: *: 
P<0.05; **: P<0.01; ***: P<0.001. 
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Figure 4.2 Determination of the Influence of the Four Herbs on NEP Activity In 
the Rat Kidney Microsomal Fraction. 
CB: Captopril, Bestatin (NEP active) no herbs; BFC: Buffer Control; All herbal 
extracts were tested at 2 dilutions: neat (n) and 1: 10. The herbs are Yan (Y), Gou 
(G), Qiang (Q) and Chuan (C). 
The results presented in Figure 4.2 indicated the following facts. 
(1) For the aqueous extract case, the hydrolysis percent of 3H-(leu)-enkephalin in 
the rat kidney microsomal fraction was 47.8% in the case where NEP only was active 
without herbs (CB). All the digestion experiments with herbal extract present 
showed a lower hydrolysis percent of 3H-(leu)-enkephalin than was the case with 
NEP in the crude microsomal extract without herbal extracts. However only Gou, 
Qiang (undiluted only) and Chuan (undiluted only) showed statistically significant 
inhibition on NEP ( P<0.05). The undiluted Gou and Qiang decreased the hydrolysis 
of 3H-(leu)-enkephalin significantly (P<0.001). This suggested that the Gou aqueous 
extracts (Gwext) and Qiang aqueous extract (Qwext) had strong inhibitory activity 
on NEP activity in the crude microsomal fraction. Under experimental conditions 
the two standard inhibitors could reduce the hydrolysis percent to 16.4% (Table 4.1), 
However the undiluted Gwext could even reduce the hydrolysis percent to 6%. This 
suggested that Gwext showed the strongest inhibition on NEP activity from the crude 
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microsomal fraction. And Gou's inhibitory activity was stronger than the 
combinatorial inhibitory activity of both Bestatin and Captopril (Table 4.1). 
(2) In the case of the organic extract the result shown in Figure 4.2 indicated that 
Yan, Gou and Qiang at neat dilution showed only a limited inhibition of NEP activity 
(P<0.05). Chuan did not show significant inhibition on NEP activity (P > 0.05). The 
aqueous extracts of Gou (Gwext) and Qiang (Qwext) showed effects which were ten 
fold as strong as their organic extracts (Gmext and Qmext). Therefore the Gwext 
and Qwext were chosen for further study. 
(3) The above herbs are already used as analgesics in Chinese Traditional Medicine 
(TCM), but they showed different inhibitory activity on NEP. It seems possible 
therefore that the above four herbs might have their analgesic activity by different 
mechanisms (see the description in section 1.7.3 of chapter 1). 
4.3 Concentration Dependence of The Effect of Gwext And Qwext on The 
Activity of NEP in The Crude Microsomal Fraction 
Based on the above results, the effects of Gwext and Qwext were studied further. 
In this experiment, four concentrations of Gwext and Qwext were observed for their 
effects on NEP. The results were as given in Table 4.3 and graphed in Figure 4.3. 
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Table 4.3 Determination of the Effect of Different Concentrations 
of Herb Aqueous Extracts on the Activity of NEP in the Crude 
Microsomal Fraction 
Active enzyme group HD% a Inhibiting %b 
NEP active CB 45.1 62.5 
NEP active (CB) 
plus: 
dilu- Conc. 
tion (mg/ml) 
neat, 40 8.2 81.8 *** 
Gwext 1: 2 20 9.7 78.5 *** 
1: 4,10 17.2 61.9 ** 
1: 8 5 27.5 39.0 * 
neat, 40 15.4 65.9 ** 
Qwext 1: 2,20 26.2 41.9 * 
1: 4,10 27.4 39.2 
1: 8,5 33.3 26.2 
Tris-HC1 buffer control 4.2 
a: HD% =Hydrolysis percent of 3H(leu)-enkephalin. 
b: Inhibiting %=( HD% of all the group minus HD% of CB group) divided 
by (M% of CB group) x 100%. Ecoscint H control : 28.4± 0.2. 
Student's t-test was used to do statistical analysis. Probability "P" was as 
follows. *: P<0.01; **: P<. 001 
Table 4.3 indicated that the Gou aqueous extract (Crwext) decreased the hydrolysis 
percent (HD%) more significantly than Qiang aqueous extract (Qwext) while being 
added at the same concentrations in the range of 40-20 mg/ml. This suggested that 
Gwext was more worthy of investigation in the future. 
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Figure 4.3 Determination of the Effects of Different Concentrations of Herbs 
on the Activity of NEP in the Crude Microsomal Fraction 
CB: NEP active (Captopril and Bestatin were added) group without adding herbs ; 
BFC: buffer control; Captopril and Bestatin were presented in all samples to inhibit 
APN and ACE and without herbal extracts have CE; Gn: Gou undiluted (neat) 
group; G1: 2, G1: 4 and G1: 8 : dilutions of Gou were 1: 2,1: 4 and 1: 8; Qn: Qiang 
undiluted (neat) group; Q 1: 2, Q 1: 4 and Q 1: 8: The dilutions of Qiang were 1: 2,1: 4 
and 1: 8. 
The more direct evidence was as presented in Figure 4.3. It demonstrated fully that 
the Gwext truly showed very strong inhibitory activity on NEP while being compared 
with the rat kidney crude microsomal fraction where no herbal extract was present, 
(student's t-test showed P<0.001). Qwext also showed strong inhibitory activity on 
NEP, but its inhibitory potency was not as strong as that of Gou. Considering the 
time limitation, Gwext was chosen for further study in the following experiments. 
4.4 The Effect of pH on NEP in The Crude Microsomal Fraction 
The results in Table 4.3 showed that Gwext produced inhibition of NEP activity on 
3H(leu)-enkephalin. However the pH of the Gwext solution was found to be lower 
than pH 7.0 and so it was possible that Gwext's inhibitory activity was due to a 
lowering of the pH, which inhibited the NEP activity. The following experiments 
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were designed to check the effect of pH on NEP activity and indeed it showed that 
the lowering of the pH below 7 does produce an inhibition on NEP activity and so 
fiuther work was added to prove the inhibitive effects of Gwext. 
In this experiment a series of Tris-HC1 buffers having each a known pH from 6 to 9 
were prepared and used to dilute the rat kidney crude microsomal fraction until the 
dilution was 1: 20. The final pH of the crude microsomal fraction was measured by 
pH meter and the fractions were assayed (a) for the effect of NEP in the crude 
microsomal fraction using captopril and bestatin as inhibitors of ACE and APN on 
enkephalin; (b) For the effect of NEP, ACE and APN combined, with no peptidases 
inhibitors present. The results were as presented in Table 4.4a and graphically in 
Figure 4.4. 
Table 4.4a The Dependence on pH of the Hydrolysis of 
3H(leu)-enkephalin By NEP in the Crude Microsomal Fraction 
pH of enzyme solution On endopeptidase 
only (CB) 
On NEP, APN and 
ACE (CE only)- 
no inhibitors 
pH of 50 mM 
Tris-HC1 buffer 
Final pH of 
enzyme solution 
HD % of H(leu)- 
enkephalin 
HD% of (leu)- 
enk halm 
6 6.27 5.6 97.4 
7 7.12 82.3 95.2 
8 7.91 49.5 95.5 
9 8.72 34.0 95.6 
7.4 7.40 61.6 
95.6 
BFC 61.5 
NB: BFC: Buffer Control. 
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Figure 4.4 The pH Curve of the Activity of NEP in the Crude 
Microsomal Fraction 
The buffers were 50 mM of Tris-HC1 at the different pHs (undiluted between pH 6 
and 9). The enzyme assay was the same as section 2.3.5 of chapter 2. 
Figure 4.4 indicated that pH seemed to have no inhibitory effect on the mixtures of 
the crude microsomal fraction (red curve), but showed inhibitory activity on NEP. 
The optimum pH of NEP was 7.12. Lower than 6.27 and higher than pH 8.0 would 
reduce the NEP activity. This result suggested that 50 mM of Tris-HCl buffer (pH 
7.4) can be used as the solvent of enkephalin-hydrolysing assay. Our result about the 
optimum pH of NEP was compatible with that of Roques et al. (1990) who reported 
an optimum pH for NEP activity was 7.0. 
The Effect of DH on the inhibition of the NEP vdrolvtis 
of 3H(leu)-enkeohalin by Gwext 
Since Tris-HCl buffers could only buffer properly from pH 7.5-8.5, the results of 
Table 4.4a and Figure 4.4 are reliable over the 7.5-8.5 pH range. The fall off below 
of pH 7.2 in enzyme activity (hydrolysis percent) could be due to the loss of the 
buffering effect of Tris ions. This means that pH might have some effect on NEP 
activity but not completely affect the activity of NEP. In order to find an optimum 
pH for the Crwext-NEP reaction, two specific pHs were chosen in order to study the 
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effect of Gwext on NEP activity. The stock enzyme sample was diluted by Tris-HC1 
buffer at either pH 7.4 or 8.0 until the dilution was 1: 20 and then the Gwext's 
solution was mixed with following mixture: 
20 µ1 of 10 µM Captopril (pH 7.0), 20 µ1 of Bestatin (pH 7.0), 40 µl of enzyme 
solution (1: 20, pH 7.4 or 8.0), 40 µl of Tris-HC1 buffer (pH 7.4 or 8.0). 
Under these experimental conditions the maximum volume of the Gwext solution was 
80 W. Gwext solution was mixed with the crude microsomal fraction which was 
already diluted in 1: 20 in buffer at two pHs for about 15 minutes and combined with 
above mixtures. The hydrolysis percent of 3H(leu)-enkephalin was measured and the 
results were as presented in Table 4.4b. 
Table 4.4b Determination of the Effect of pH on Gwext-NEP Reaction 
Classified Group Hydrolysis percent of H(leu)- 
enke halin 
E8.0+50 mM Tris-HCI, pH 8.0 45.1 
E8.0+50 mM Tris-HCI, pH 7.4 51.7 
E7.4+50 mM Tris-HCI, pH 8.0 49.3 
E7.4+50 mM Tris-HCI, pH 7.4 56.7 
Gwext(100mg/ml)+E8.0 10.4 
Gwext(100mg/ml)+E7.4 10.3 
Buffer Control 8.4 
NB: F-1.0: The stock crude enzyme sample (NEP active) was diluted to 1: 20 by 50 
mM Tris-HC1, pH 8.0; F. 7.4: The stock crude enzyme sample was diluted to 1: 20 by 
50 mM Tris-HCI, pH 7.4. 
The result in Table 4.4b indicated that no matter what the pH of the buffer used, to 
dilute the enzyme, the hydrolysis percent of 3H-(leu)-enkephalin remained at 50% 
approximately and there was no significant difference while being compared with 
each other by means of Student's t -test ( see section 2.5 of Chapter 2 and Appendix. 
3) over the range of pHs studied. The Gwext solution was pre-mixed with different 
buffer-diluted enzyme samples and then the activity of NEP was measured. The 
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result indicated that Gou still showed strong inhibitory activity on NEP no matter 
which buffer was used. This directly demonstrated that the pH of the Gou solution 
itself was definitely not the only influence on the activity of NEP. So primarily it was 
the active ingredients existing in the Gou solution that inactivated the NEP activity, 
4.5 Selection of the Best Buffer to Carry Out the Inhibition of Proteolysis 
Experiments on Gou Aqueous Extract (Gwext) 
In the experiments described earlier, the conditions were established for the 
hydrolysis-inhibition experiments on Gou and on the fractions of the components of 
the Gou aqueous extract (Gwext) involved in Tris-HC1 buffer (a buffering range 7.4 
to 8.5). However, all the work by others used pHs of 7.4, where the buffering 
capacity of Tris is not high. Therefore, other buffers for lower pHs were tried to 
dissolve up the powder in order to find a suitable buffer. 50 mM Tris-HC1 buffer and 
50 mM phosphate buffer pH at 7.0 and 7.4 were prepared and then samples of Gwext 
were dissolved in the buffer at a concentration of 100 mg/ml. The pH was measured 
to see how effective the buffer had been in stabilising the pH. The results were as 
shown in Table 4.5a. 
Table 4.5a Determination of the pH of Goo in Different Buffers. 
Classified group 50 mM Tris-HC1 Buffer 50 mM Phos hate Buffer 
Original pH of buffer 7.0 7.4 7.0 7.4 
pH of the Grwext 
solution 100m ml 
5.4 6.8 6.7 7.3 
The results presented in Table 4.5a indicated that phosphate buffer was more able to 
maintain its pH in the presence of Gwext than Tris-HC1 buffer. It was necessary to 
consider the effect of buffer on NEP also, besides the effectiveness of buffering. The 
enzyme assay was done to check if Phosphate buffer was really suited to be Gwext's 
solvent and used in our reaction mixture. The results were as presented in Table 
4.5b. 
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Table 4.5b The Effect of Dissolved Gou in Different Buffers 
on the Crude Microsomal Fraction 
Classified group Hydrolysis percent of Heu -enk halm HD% 
50 mM Tris-HC1 buffer, 
pH 7.4 
50 mM Phosphate buffer, 
pH 7.4 
DPM HD% DPM HD% 
Buffer only 58361.3 55.5 53579.9 38.9 
Gwext+buffer 53775.6 27.9 54715.5 36.7 
coscint H control 160.0±2.0 
NB: The Gwext was diluted at 1: 16. The dilution of the enzyme sample: 1: 20. 
The results in Table 4.5b suggested that phosphate buffer itself had an inhibitory 
activity on NEP and so it was not suited to be a solvent for Gwext. Combining this 
result with the result presented in Figure 4.4 and Table 4.4b, 50 mM of Tris-HC1 
buffer (pH 7.4) was still chosen to be used as the solvent of Crwext. 
4.6 The Concentration Curve of Gwext 
After the inhibitory activity of CYwext itself had been confirmed, the dilution curve of 
Gwext was then tested. The results were as given in Table 4.6 and as a graph in 
Figure 4.6. 
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Table 4.6 Determination of the Concentration Curve of Gwext 
For its Inhibition of the Hydrolysis of 3H(leu)-eukephalin in 
the Crude Microsomal Fraction 
Classified group HD% of H(leu)- 
enkephalin 
Inhibitory activity 
% 
NEP active (CB) 50.1 
NEP active (CB) 
plus : 
Conc. of Gwext 
(Mg/ml) 
- 40 3.6 92.8 ** 
20 6.8 86.4 ** 
10 9.3 81.4 ** 
Gwext 5 19.6 60.9 * 
2.5 29.0 42.1 * 
1.25 31.3 37.5 
0.625 46.7 6.8 
Buffer control 4.7 
NB: The inhibitory activity %= (HD% of CB -HD%of Crwext) /HD% of CB 
x 100%. 
The concentration of stock solution of Gwext was 100 mg/ml; Student's t-test was 
used to analyse the statistically significant difference between each sample group 
and the CB group. The Probability "P" was shown as follows :*: P< 0.01; 
** : P< 0.001. Ecoscint H control: 30.30 ± 4.45. 
The results shown in Table 4.6 indicated that Gwext significantly decreased the 
hydrolysis percent of 3H(leu)-enkephalin over a range of concentrations between 2.5 
and 40 µg/ml. Gwext could not further significantly decrease the hydrolysis percent 
while the concentration was lower than 2.5 mg/ml (P>0.05). This suggested that the 
minimum inhibitory concentration (MIC) of Gwext was 2.5 mg/ml (P< 0.01). 
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Figure 4.6 The Concentration Curve of Enkephalin Hydrolysis by NEP 
in The Crude Microsomal Fraction in The Presence of Gwext 
Figure 4.6 indicated that the larger the concentration of Gwext the stronger was the 
inhibition potency. While 0.625 mg/ml of Gwext only induced 6.8% inhibition. 40 
mg/ml of Gwext could inhibit 96% of hydrolysis while compared with the CB group. 
The Inhibitory Concentration (IC5o ) of Gwext was 2.7 mg/mi. Therefore the 
Minimum Inhibitory Concentration (MIC) of Gou was 2.5 mg/ml and IC50 of Gwext 
was 2.7 mg/ml. 
4.7 The Effect of Gwext on The Other Enzymes (ACE and APN) in 
The Crude Microsomal Fraction 
It was known that there existed three enkephalin-hydrolysing enzymes in the crude 
microsomal fraction. They were: Aminopeptidase (APN), Angiotensin Converting 
Enzyme (ACE), and Neutral Endopeptidase 24.11 (NEP). By controlling the use of 
the three specific inhibitors of the above three enzymes the activity of each enzyme 
specifically could be studied (see Table 4.1). In order to analyse the mechanism of 
the inhibitory activity of Gwext, its effect on the above three enzymes was observed 
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and compared with the inhibitory activity of Qwext. The results were as shown in 
Table 4.7 and graphed in Figure 4.7. 
Table 4.7 Comparison of the Effect of Gwext and Qwext in Inhibiting 
the Enzymes, NEP ACE and APN Present in the Crude Microsomal 
Fraction 
Classified groups H drol sis% of 3H(leu -enke halin 
Without adding 
herbs 
Adding Gwext 
(20 m ml) 
Adding Qwext 
(20 mg/ml) 
No enzyme active CBT 18.7 14.0 12.8 
NEP active (CB) 47.7 8.3 ** 11.0 ** 
APN active (CT) 94.6 46.4 ** 34.0 ** 
ACE active (B 20.1 8.7 ** 14.2 * 
NEP ACE active (B) 49.6 6.9 ** 13.8 ** 
NEP APN ACE active (E) 92.0 17.2 ** 14.9 ** 
Buffer control 5.8 
Ecoscint H Control 37.09±2.40 
NB: Student t-test was used to analyse the significant difference between the 
sample group and CB group. Probability P was shown as follows: 
*: P<0.01; **: P< 0.001 
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Figure 4.7 Determination of the Effect of Gwext and Qwext on the 
Different Enzymes in the Crude Microsomal Fraction (mean of n=3) 
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CBT: Cap+Bes+Thio (no enzyme active); CB: Cap+Bes( NEP active); CT: 
Cap+Thio (APN active); B: Bes only (NEP, ACE active); E: No inhibitors (Three 
enzyme active); BFC: Buffer control 
The results presented in Table 4.7 and Figure 4.7 indicated the following four facts: 
(1) Both Gwext and Qwext could decrease the hydroysis percent of 3H(leu)- 
enkephalin significantly, no matter whether one used CB enzyme (NEP active) or 
CT(APN active) or BT(ACE active) or B (NEP/ACE active) and even E (Three 
enzyme active in the crude microsomal fraction). This suggested that both Gwext 
and Qwext showed inhibitory activity on three enzymes but the mechanism seemed to 
be different, because Qwext showed lower inhibitory activity on ACE / NEP. 
(2) Gwext and Qwext showed significant inhibitory activity on the crude microsomal 
fraction in this experiment. This result was of importance because it reminded us of 
the possible side effect of pH on NEP. The results presented in Fig 4.4 indicated 
that the pH had no complete inhibitory activity on the crude microsomal fraction, or 
in other words on the total enzymes existing in the crude microsomal fraction mixture 
as pHs between 7.14 and 8.7. Also we had reason to believe that Gwext and Qwext 
really contained some active ingredients which showed inhibitory activity on all the 
three enkephalin-hydrolysing enzymes. 
(3) The three standard inhibitors together decreased the hydrolysis percent of 
3H(leu)-enkephalin to 18.7%, while the 20 mg/ml of Gwext could reduce it to 14.0 
%. For CB (NEP active) the 20 mg/ml of Gwext reduced the hydrolysis percent to 
8.3%, as low as in the case of the buffer control (5.8). These encouraging results 
indicated that it may be possible to find some promising enkephalin-hydrolysing 
enzyme inhibitors in future experiments. 
(4) Gwext and Qwext decreased the inhibitory activity of Bes (NEP/ACE active) 
which suggested that Gwext and Qwext also behaved as the mixed inhibitors of 
NEP/ACE. These results provided evidence that it may be possible for us to develop 
new peptidase inhibitors. Therefore more experiments were needed with the 
intention of extracting new inhibitors of peptidases. 
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Indeed, the recent studies have shown that co-administration of selective ACE and 
NEP inhibitors is more effective in animal models of hypertension and congestive 
heart failure than treatment with either enzyme inhibitor given alone (Seymour et al, 
1991). On the basis of this premise, a number of groups, have been active in the 
pursuit of a dual-acting ACE/NEP inhibitor (Gros et al, 1991; Roques et al, 1993; 
Trippodo et al., 1995; Fink et al., 1995). It was found that NEP can degrade the 
atriuretic peptide to mediate the blood pressure change (Krulan et al, 1993; Seymour, 
1995 and Robl et al, 1996). Therefore the above results are of importance 
theoretically and practically. 
(5) Gwext and Qwext have also been shown to be the triple inhibitors of NEP/APN 
and ACE. In the three enzyme active (E) group, the hydrolysis percent of 3H(leu)- 
enkehaplin decreased from 92.0% to 19.2% (Gwext case) and 14.9% (Qwext case) 
respectively. Qwext also showed stronger inhibitory activity than Gwext in this 
case. According to Chen et al. (1998), inhibition of APN and NEP involved in the 
inactivation of the opioid peptides enkephalin completely, produce potent 
physiological analgesic responses, without major side-effects, in all animal models of 
pain in which morphine is always active. Dual inhibitors of both enzymes could fill 
the gap between opioid analgesics, until now, the attempts to find a compound with 
high affinity both for NEP and APN have failed. They therefore have tried to design 
dual competitive inhibitors of both enzymes with K-1 values in the nanomolar range. 
So far the best inhibitors they obtained were 10 times more potent than the described 
dual inhibitors in alleviating acute inflammatory nociceptive stimuli in mice, thus 
providing a basis for the development of a family of analgesics devoid of opioid side 
effects. Nobel et al. (1997) also obtained a new compound---RB 120 which has 
passed through all the pre-clinical trials and are now on clinical trials, according to 
Nobel et al. (1997), RB 120 is the best reported dual inhibitor of NEP/APN. Our 
experiment showed that Gwext and Qwext were not only dual inhibitors but also 
triple inhibitors of NEP/APN/ACE. This suggested that Crwext and Qwext are 
promising to be investigated further. Of course Gou's MIC was 2.5 mg dried extract 
of Gou per ml, IC50 was 2.7 mg dried extract per ml. The above data are far from 
nanomolar range, but as both Gwext and Qwext are mixtures of compounds at this 
stage, the individual compounds in Gwext and Qwext should have much lower MIC 
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and IC5o. On another hand the direct analgesic effect of Gwext and Qwext has not 
yet been investigated. Unfortunately because of limitation of time, only Gwext was 
further investigated in the following experiments. 
4.8 The Inhibitory Activity of Gou on the Partially Purified Enzymes 
(pooled fractions) from the Crude Microsomal Fraction 
In order to estimate the inhibitory potency of Gou on NEP, the effect of Gou on 
pooled fractions of the crude microsomal fractions (see section 3.7 of Chapter 3) 
further purified on Hydrophobic Interaction Column (HIC) was assayed. Some of 
these pooled fractions contained partially purified enzymes. All the pooled fractions 
were diluted at 1: 2 and 40 µl of Gou was added into the reaction mixture before 
carrying out the enzyme assay. The results were as shown in Table 4.8 and plotted in 
Figure 4.8. 
Table 4.8 The Inhibitory Activity of Gou on The Partially Purified 
Enzymes (pooled fractions) From The Crude Microsomal Fraction 
Classified group Hydrolysis percent of H leu -entre halin 
NEP active (Pool 1+CB 68.1 
NEP active (Pool 3+CB) 12.5 
NEP active (Pool 6+CB) 33.6 
NEP active CE+CB 64.1 
NEP active (Pool 1+CB+Gou 4.9 
NEP active (Pool 3+CB+Gou) 3.7 
NEP active (Pool 6+CB+Gou) 3.3 
NEP active (CE+CB+Gou) 6.9 
Tris-HC1 buffer control 5.5 
Ecoscint H control 36.08±8.8 P 
Note that the presence of Bestatin and Captopril (CB) as ussual leaves NEP only 
active in the fractions (see Table 4.1). All the pooled fractions were added into the 
reaction mixture at 40 W. The concentration of the stock solution of Gou was 100 
mg/ml. The ilution of the crude microsomal sample was 1: 20 and 40 µl of this was 
used in the reaction mixture. 
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Figure 4.8 The Inhibitory Activity of Gou on the Partially Purified 
Enzymes (pooled fractions). 
Px : Pool number; The dilution of Gou was 1: 2 and that of the crude enzyme sample 
(CE) was diluted at 1: 20; BFC was the buffer control. In Figure 3.7 it was shown 
by PAGE that fractions P1, P3 and P6 contained a gel band (90 kDa band) 
corresponding to the molecular weight of NEP. 
The above results showed that Gou had an inhibitory effect on the partially purified 
NEP. Because the fractions were pooled and in them the NEP was only partially 
purified, the above result was not enough to demonstrate the exact inhibition of the 
hydrolysing activity of NEP. Completely purified NEP was needed in order to obtain 
the direct evidence for the inhibitory activity of Gwext on NEP. However due to the 
limitation of time, such an experiment had to be left for the future. 
CONCLUSION AND SUMMMARY 
Gwext was found to display strong inhibitory activity on NEP. Its minimum 
inhibitory concentration (MIC) was 2.5 mg dried extract of Gou per ml, and 50% 
inhibitory concentration (IC50) was 2.7 mg dried extract of Gou per ml for a digestion 
time of 30 minutes. The inhibitory effect of Gwext was compared with standard 
inhibitors and it was found that Gwext in the experiment showed stronger inhibitory 
102 
activity than that was produced by the chemical inhibitor Thiorphan and it was even 
stronger than the combinatorial effects of Bestain and Captopril. Therefore Gwext 
was worthy of further study. 
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CHAPTER V 
THE OPIOID RECEPTOR BINDING ASSAY 
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INTRODUCTION 
5.1 Review of the Principles of the Receptor Binding Assay 
The receptor binding assays in this study concerned binding to the opiate-peptide 
receptor in rat brain. The study involved the isolation and characterisation of the 
receptor and the establishment of a sensitive and specific assay to determine the 
pharmacological specificity of the retention site of the receptor for binding of 
naloxone (Holt et al., 1995). The investigation of the effect of some drugs on 
naloxone binding to the opiate-peptide receptor was then studied. By far the most 
widely used general method for opioid-receptor-binding assays involves the use of 
radiolabelled ligand. This inherently simple procedure, first described by Paton and 
Rang in 1965 has developed into a major activity in both basic research and in the 
pharmaceutical industry where such assays offer the prospect of a simple rapid screen 
for the evaluation of drugs which bind to a receptor. In this chapter the naloxone 
(morphine-antagonist) receptor-binding assay is established in order to study the 
effect of one Chinese Herb (Gou) on naloxone binding activity. 
5.1.1 General Strategies for Isolation and Purification of Receptors 
Normally receptor isolation and purification can be considered in three basic stages. 
Firstly the tissue is homogenized in a homogeniser (normally the Potter-Elvejhem 
type of homogeniser) and the homogenate processed by differential centrifugation to 
obtain the membranes; The homogenate is then treated with detergent in order to 
solubilize the receptor which is thirdly purified in an affinity-chromatography step. 
The successful purifications of the vertebrate n-acetylcholine (nAChR) and the y- 
aminobutyric acid receptor complex (GABAR) are based on this general procedure 
(Lunt, 1980). However it should be emphasized that receptor purification is a 
relatively young science and there is no guarantee that these methods can be 
successfully applied to all neuroreceptors. In this chapter only the first step was 
adopted in order to obtain a crude but fairly reproducible opioid-membrane fraction 
for the naloxone-binding assay. 
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5.1.2 The Factors Which Affect the Final Results of Opioid Binding Activity 
The opioid binding assay usually follows a pattern in which a receptor preparation is 
exposed to a radiolabelled ligand until an equilibrium is reached, after which time free 
ligand is separated from the receptor-bound ligand. Such an apparently simple 
procedure can unfortunately pose a number of practical problems. For example the 
number of opioid receptor sites with which the radioligand will interact in a specific, 
physiologically-relevant manner is likely to be a small proportion of the total number 
of potential binding sites in the tissue preparation (Lunt, 1980). The great majority 
of non-opiate receptors may well be physiologically irrelevant but may be defined as 
`specific' binding sites within the terms of reference of many binding assays. The 
problem then is not simply to separate specific from non-specific binding but to 
distinguish between physiological receptors and `other' binding sites. Therefore a lot 
of factors have their effects on the final results and so in our experiments these 
needed to be considered in the detailed design of the experiments. 
5.1.2.1 Specific And Non-specific Binding Sites 
Firstly the number of receptor binding sites is usually small compared with the total 
number of sites with which the radiolabelled ligand can interact as shown above. 
This latter class of sites encompasses binding to the tissue preparation, to assay tubes, 
to filters and indeed to any part of the experimental system other than the receptor 
recognition site. The general procedure for distinguishing between the opiate- 
receptor and other binding sites is to use the `cold ligand excess' method. In this 
procedure parallel measurements are made of the binding of radiolabelled ligand in 
the absence and presence of a large excess of unlabelled ligand (Lunt, 1980). 
Specific binding is then defined as total binding of radio-labelled ligand (in the 
absence of unlabelled ligand), minus the non-specific binding of radio-labelled ligand 
that remains in the presence of unlabelled ligands. The method is based on two 
assumptions; Firstly that the concentration of non-receptor-binding sites is greatly in 
excess of that of the receptor-binding sites and, secondly the receptor-bound 
radioactivity of the radiolabelled ligand is drastically reduced by addition of a large 
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excess of cold ligand, so becoming insignificant, but the level of non-receptor binding 
is essentially unchanged. The major shortcoming of the method is that `specificity' is 
defined in terms of the relationship between the concentration of radiolabelled ligand 
and the KD (equilibrium dissociation constant) of the binding site (Briley et al, 1981). 
Thus any site whose KD is lower than or comparable with the concentration of 
radioligand used will emerge as a specific site. It is quite possible therefore that if 
differing concentration ranges of radiolabelled ligand are used then different `specific' 
sites will appear. It frequently is the case that as ligands of higher specific 
radioactivity become available so workers use them at lower concentrations and find 
new specific binding sites. In our experiment nM concentration of radiolabelled 3H- 
naloxone were used as the radioactive ligand which is compatible with the 
concentration usually used in such experiments (Gillan et al, 1980). 
Another aspect of the opiate-receptor-binding versus the non-opiate-receptor-binding 
problem is the saturability of the sites. It is often stated rather loosely that non- 
specific sites are unsaturable (Bielkiwicz, 1985). Clearly this can not be entirely true 
because no matter what the nature of the site there must be a finite number of them in 
the particular experimental system that is used. However, it is probable that there are 
many more non-specific sites than there are specific sites such that, when using 
concentrations of radiolabelled ligand in the generally used range of 10"9-10-4 M, 
saturation of the non-specific sites is not approached. Therefore in our experiments 
we chose pM concentration of cold naloxone and nM concentration of radiolabelled 
naloxone as the experimental condition. 
To some extent this can be achieved by a modification of the assay system so that 
specific binding of the radiolabelled ligand is assessed by displacement not with cold 
ligand but with a chemically-distinct agonist or antagonist. In this case the 
probability of competition between the radiolabelled ligand and the chemically- 
distinct displacing ligand for any common, non-physiological, high affinity site is 
greatly reduced. Indeed it was recommended some years ago (Bennett et al, 1978) 
that as a general rule a structurally-distinct ligand should be used for the displacement 
of specific binding. The extension of this approach is of course to displace the 
radioligand with a variety of compounds that are known from physiological 
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experiments to act at the appropriate neuroreceptor site. However in this thesis 
specific receptor binding was swamped by cold naloxone in experiments to give the 
non-specific binding of radiolabelled naloxone. The enhanced binding of 
radiolabelled naloxone in the absence of cold naloxone gave a difference 
disintegrations per minute count which was interpreted as specific binding of 
radiolabelled naloxone to opiate receptors. The effect of the Chinese Herb-Gou and 
other drugs on this receptor binding was used to see if any component of Gou 
showed specific binding to the opiate receptors. 
5.1.2.2 Separation of Free From Bound Ligand 
Seuaration Time 
Whatever the method that is finally chosen, the single most important factor is the 
time taken to achieve a separation. In the great majority of cases binding 
measurements are made at equilibrium, therefore as soon as the free ligand is 
separated from the bound ligand that equilibrium is disturbed and bound ligand will 
dissociate until a new equilibrium is reached. The equilibrium association rate 
constant we defined as k+1 and the dissociation rate constant as kl. In the majority of 
receptor binding assays, k+1 is of the order of 106 M per second. Most 
neuroreceptor binding assays are done with ligands with a KD in the range of 10'8 M 
(permitted separation time 10 sec) to 10"10 M (permitted separation time 15 min). The 
concentrations used in these experiments of this thesis were in the range of 10"9 M 
with permitted separations of the order of a minute or two. 
Vacuum Filtration 
Vacuum filtration offers possibly the fastest and most convenient method of 
achieving separation times of a few seconds. There are several commercial filtration 
chambers available; The millipore and Biorad versions are the most widely 
encountered. With such systems total filtration and washing times of 3-8 sec can be 
achieved routinely for sample volumes of up to 10 ml, using 2.5 cm diameter filters. 
Depending on the KD of the receptor-ligand pair, it may not be possible to wash the 
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retained material extensively and thus filter assays may suffer from high blank values. 
Non-specific absorption of free ligand to the filters may also be a problem. This can 
often be overcome by combinations of a variety of pre-treatments. For example the 
risk of dissociation of bound ligand during filtration and washing can be minimized by 
ensuring that all buffers are ice-cold. However even with all these precautions it is 
emphasized that satisfactory data will be obtained only if the KD is 10 M or less. 
The opioid binding assays provide direct information about the recognition of a 
ligand by the receptor protein. In terms of physiological function this is only the first 
step in what may be a complex sequence of events that couples the recognition event 
to the cellular response. It is necessary therefore to take steps to ensure that the 
binding activity is indeed an integral part of a physiological receptor mechanism. 
There are very many examples in the literature of binding assays for almost all known 
receptor types. The methods follow a common pattern in which the receptor 
preparation is exposed to a radiolabelled ligand until an equilibration is reached, after 
which time free ligand is separated from the receptor-bound ligand. Such an 
apparently simple procedure can unfortunately pose a number of practical problems. 
Thus the number of neuroreceptor sites with which the radioligand will interact in a 
specific, physiologically-relevant manner is likely to be a small proportion of the total 
number of potential binding sites in the tissue preparation. The idea of the ligand- 
binding assay should be to use purified receptors directly, but in our laboratory 
conditions such work could not be done because we did not have access to such 
receptors. Thus the following assay experiments (see Section 5.2) were designed and 
utilised to investigate the effect of the Gou aqueous extract (see Chapter 2) on the 
naloxone to opioid receptor-binding activity. In these methods the influence of Gou 
extracts was assessed by its competition with radioactivity labelled naloxone for 
binding to the opioid receptors. In this sense the binding of the Gou extract was 
assessed indirectly since it was the radioactive disintegrations per minute DPM of the 
3H-labelled naloxone which was directly measured. 
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5.1.3 The Kinetics of Opioid-receptor Binding Activity 
The kinetics of binding of a ligand to its receptor are very similar to those of enzyme- 
substrate reactions. In typical ligand binding assays, radiolabelled ligand [L*] is used 
and the receptor population [R] is provided by a membrane suspension. In such an 
experiment the following kinetics apply: 
K+1 
L*+ R L'R 
K1 
K1 [L'] [R] 
The equilibrium dissociation constant, KD == 
K+1 [L' R] 
If the total concentration of receptors in the tissue preparation is [Ro], 
[Rol = [R] + [L* R] 
[L'] [R0] 
[L* R] = (I) 
[L "I + KD 
Bound ligand [L`R] is usually separated from free ligand [L'] by filtration and the 
analysis of the radioactivity disintegration counts per minute (DPM) on the filter 
paper enables the bound ligand to be determined. In practice such DPM values (total 
DPM) will be made up of two components; DPM due to specific ligand-receptor 
binding ([LR] above) and DPM due to non-specific interactions between ligand and 
other membrane components. These two components can be separated out by 
including a large excess of unlabelled ('cold') ligand in some incubations as explained 
in section 5.1. This will displace radiolabelled ligand from all receptor sites, thus 
giving an estimate of the remaining non-specific bound DPM. Such values can then 
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be subtracted from total DPM to give specific bound DPM values, as shown in 
Figure 5.1 (Gilean et al, 1980; Cooper et al, 1986). The final curve obtained shows 
that ligand-receptor interactions are saturable, but the method assumes that there are 
vast numbers of non-specific binding sites so that, although there is a large excess of 
unlabelled ligand, there are still plenty of non-specific sites for binding radioactive 
ligand. 
total 
specific 
non-specific 
IL *1 
Figure 5.1 Theoretical Ligand Binding Curve 
By re-arranging equation (I) the familiar Scatchard equation (II) is obtained. 
[L R] [R0] [L`R] 
(n) 
[L*] KD KD 
where, again, [L`R] refers to specific binding. Thus a graph of [L*R] / [L*] (specific 
binding/free ligand) versus [L*R] (specific binding ) will (generally) produce a linear 
plot, enabling KD and Ro to be determined (see Figure 5.2). 
[LýJ, 
I-] 
[Rol 
KD 
Gradient (-1/KD) 
Specific binding [L*R] 
Figure 5.2 Theoretical Scatchard Plot 
In this chapter the radiolabelled naloxone (N-allyl-2,3 3H) which was purchased 
from NEN Ltd UK was used as the ligand for brain opiate receptors. This study was 
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designed to investigate the effect of Gou on opiate receptors. The detailed 
experimental procedures are discussed in following section (section 5.2). 
5.2 Method 
5.2.1 Preparation of Opiate Binding Receptors From Rat Brain Membranes 
(Kosterlitz et al, 1980) 
Rats (adult female wistar, 50 days old, 200g) were maintained in the University's 
Life-Science-Support unit under standard conditions. They were killed by carbon 
dioxide (C02) poisoning, decapitated and the brains rapidly removed. The tissue was 
then homogenised at low speed, using a citenco disrupter with teflon pestle, in 50 
mM of ice-cold Tris-HCI, pH 7.4,10 ml/g of wet weight of tissue. The homogenate 
was centrifuged at 49,000 g for 20 mins at 4°C. The membrane pellet was then 
gently homogenised in 20 volumes of the Tris buffer and incubated for 45 minutes at 
37°C in a shaking water bath. This suspension was then recentrifuged at 49,000 g for 
10 minutes and the pellet was then gently homogenised in 2 volumes of the Tris 
buffer. Aliquots of this suspension were assayed for protein using the Bradford 
method with Human Albumin as standard as described in chapter 3. The membrane 
suspension was then adjusted to a concentration of 10 mg/ml for use in the binding 
assay. 
5.2.2 Experimental Methods of Opiate Binding 
The ingredients were added to each tube in the order shown in the table overleaf. A 
typical incubation tube contained the following ingredients in a final volume of I ml, 
Receptor membrane suspension 1.0 mg 
[3H]naloxone 1-15 nM 
Tris-HCl buffer 50 mM sometimes with and sometimes without 
Chinese herbs (0.5 -8 mgml'1) 
Unlabelled naloxone (1-15 µM) was also included in some incubations. The reaction 
mixture was incubated in a water bath at 37°C for 30 minutes. This gave sufficient 
time for the binding to reach equilibrium at this temperature. After this time, each 
mixture was filtered through Whatman GFB filters on the millipore filter manifold 
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under vacuum. Each filter was washed with 2x5 ml of ice cold Tris buffer, and 
placed upon a piece of tissue paper. When filtration was complete the filter papers 
were placed into scintillation-vial inserts, 5 ml of Ecoscint H was added and the vials 
were left for 2 days and then placed in the scintillation counter. A `blank' vial 
containing only scintillation fluid was included as a control. From the results KD and 
Ro were calculated and the changes resulting from the influence of the Chinese herb 
Gou on the binding activity of naloxone observed. 
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RESULTS AND DISCUSSION 
5.3. The Determination of Protein Concentration in the Rat-Brain 
Membrane Preparation 
The Bradford method was adopted to assay the protein concentration of rat brain 
membranes as described in chapter 3. The results were as shown in the following 
tables. 
Table 5.2 The Bradford Method to Determine The Protein Concentration 
of Rat Brain Membrane 
The Concentration of Human Albumin (mg/ml) A595 
0.0 0.000 
0.2 0.2603±0.0218 
0.4 0.3827±0.008 
0.6 0.5163±0.014 
0.8 0.6645±0.019 
1.0 0.7713±0.018 
Rat brain membrane dilution : 1: 40 0.1293±0.025 
1: 20 0.2508±0.016 
1: 10 0.4879±0.023 
Based on these result, the standard curve was prepared as Figure 5.3. 
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Figure 5.3 The Determination of the Protein Concentration in the 
Rat Brain Membrane (Bradford Method) 
The rat-brain membrane was diluted at three dilutions. Human Albumin was used as a 
control to produce the standard curve. 
Using the rat brain membrane absorbance of Table 5.2 and the equation for the curve 
of Figure 5.3, the protein concentrations could be calculated. They were : 0.528 
mg/ml for the dilution of 1: 10, and 0.237 mg/ml for the dilution of 1: 20, and 0.107 
for the dilution of 1: 40. Thus the average protein concentration in the original rat 
brain membrane was 4.77 ±0.50 mg/ml. The final volume of rat brain membrane was 
40 mis, so the rat brain membrane contained 40x4.77 = 190.8 mg protein. The 
protein concentration of rat brain membrane was adjusted finally to 10 mg/ml. 
5.4 The Design And Establishment of Naloxone-opioid Receptor 
Binding Assay 
Before the activity of Gou was assayed, the naloxone-opioid receptor binding curve 
had to be established. In detail, 1 to 15 nM of 3H-naloxone and 1 to15 µM of cold 
naloxone were mixed separately as described in Table 5.1. In all, four batches of rat 
brain membranes were observed and all the results were as shown in Figure 5.4.1 to 
Figure 5.4.4. The Scatchard Plots were also prepared for every binding curve so 
that the KD and Ro could be obtained, assuming that independent binding (i. e. non- 
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5.4.1b Scatchard Plot Analysis of 3H-naloxone 
Figure 5.4.1 First Binding Curves to The Rat-Brain-Receptor-Preparation 
of 3H-naloxone and Related Scatchard Plot (n=3) 
(1) First Measurements of Naloxone Binding to the Rat-Brain-Receptor- 
Preparation 
Figure 5.4.1 shows results from first experiment and related Scatchard plot. From 
Figure 5.4.1a it can be found that the total binding gave the highest dpm count while 
receptor binding, i. e. specific binding, gave the lowest. Non-specific receptor binding 
was obtained from the difference between the total binding and the specific binding. 
The total binding of ligand to receptor (dpm) was very high as it was made up of two 
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components, dpm due to specific ligand receptor binding and dpm due to non-specific 
interaction between ligand and other membrane components. Non-specific binding of 
radioligand should increase linearly with increasing radioligand concentration whilst 
specific binding of radioligand and receptor was saturable. The binding curve of 
Figure 5.4.1 was not compatible with the reported results because a saturable 
specific binding curve was not obtained. The non-specific binding curve was close to 
linearity but still not ideal enough. 
Calculation For The Scatchard Plot (Scatchard_ 1949) 
By adding a large excess of unlabelled ('cold') ligand to some incubations, 
radiolabelled ligand from receptors sites were displaced and specific and non-specific 
binding of ligand was analysed. Then a graph of [L*R] /[L*] versus [L*R] was 
produced and the dissociation constant KD and the maximum Ro (total concentration 
of receptor) was determined. Then based the above data a Scatchard graph of 
specific binding /free ligand (pmoVmg protein-nM) versus specific binding (pmol/mg 
protein) was plotted (Seen in Figure 5.4.1b). The equation is: y=0.0018x + 
0.0116. According to the equation -1/KD = 0.0018 . *. KD=555.6 
The reported value of 3H-naloxone's KD was 1.66 ±0.29 (Josterlitz 1984). An 
order of magnitude less than the value calculated above even though errors were 
taken into account during the analysis. However, there were large error bars on the 
data points. The reasons for large errors was likely to be as follows: (a) The process 
lasted too long; b) The rat membrane was kept for overnight which no doubt 
inactivated some receptor sites. Therefore the experimental conditions was needed 
to specified more clearly and experimental manipulations done more quickly and 
carefully. 
(2) Later Measurement of Naloxone Binding to the Rat-Brain Receptors 
In the second experiments the rat membranes were prepared freshly and assayed 
immediately. A more accurate filtration step was also adopted so that the separation 
time could be reduced. Otherwise the results were obtained as " first binding curve " 
and the results were as shown in Figure 5.4.2. 
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Figure 5.4.2 Later Binding Curves to the Rat-Brain-Membrane-Receptor 
Preparation of 3H-naloxone and the Related Analysis (n=3) 
From Figure 5.4.2 it can be found that the specific binding became saturable while 
non-specific binding was still not ideal enough. The Scatchard plot showed that y=- 
0.189x + 0.0149, giving - 1/KD = -0.189 . '. KD = 5.29 and Ro = 0.0149/ 0.189 = 
0.0788 pmol/mg protein. According to the reference (Kosterlitz, 1985) the KD of 3H- 
naloxone was 1.66±0.29 which is still statistically different from the above 
experimental value. This suggested that the experimental conditions were still not 
accurate enough and more improvements were needed. The experiment was 
repeated several times and every step of the procedure was done as carefully as 
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possible. At the same time all the rat membranes were prepared freshly and assayed 
immediately and all the isotopes were kept at -20°C, strictly in aliquots and which 
were used one time only. The filtration vacuum pump were adjusted so that the 
separation time could be as short as possible. The following two repeated results 
were as shown in the Figure 5.4.3 and Figure 5.4.4 separately. The related 
Scatchard plots were also as shown in the above two figures. 
(3) Third Measurement of Naloxone Binding to the Rat-Brain Receptors 
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5.4.3b Scatchard Plot Analysis of 3H-naloxone 
Figure 5.4.3 A Third Set of Binding Curve to Rat-Brain-Membrane- 
Receptor-Preparation of 3H-naloxone and Related Analysis (n=3) 
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Figure 5.4.3a gave the quite good binding curve: the specific binding was saturable; 
The total binding was curved; The non-specific binding was unsaturable and 
approximately showed a straight line graph. The Scatchard plot also showed that 
y= -0.1519x + 0.0068; giving - I/KD = -0.1519 or KD = 6.58 , with an Ro value 
of Ro = 0.0068/0.1519 = 0.0448 pmol/mg protein. Compared with work of 
Kosterlitz the KD was still too high. However the error bars were still large. This 
affects the accuracy of KD and Ro values. 
(4) Fourth Measurement of Naloxone Binding to the Rat-Brain Receptors 
A fourth attempt of the experiment was made being as careful as possible to control 
the experimental conditions and the result was shown in Figure 5.4.4. 
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Figure 5.4.4 A Fourth Set of Binding Curves of 3H-naloxone to the 
Rat-Brain-membrane-Receptor-preparation and Related Analysis (n=3) 
The result presented in Figure 5.4.4 gave a much better binding curve (fourth Curve) 
finally and the error bars were also small. In this case the KD was equal to 1/0.4821= 
2.07 nM which correlated well statistically with the work of Kosterlitz with aP value 
greater than 0.05 (Student's t test). The Ro was calculated to be 0.0181/0.4821 = 
0.0375 pmol/mg protein. It seems therefore that there is a high affinity of the ligand 
naloxone to the opiate receptor and this is why only a low dose of naloxone is 
required in the clinical treatment of morphine overdose. Only one Ro value was 
obtained from the Scatchard graph, this assuming that the receptor had only one type 
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of binding site. However our experiments were restricted to only four data points. 
Therefore examination of the linearity of the Scatchard plots could not be made and 
tests for multiple binding sets and cooperative binding could not be carried out. 
It is believed that optimum experimental conditions were established as shown in 
Table 5.1 and so, based on that table, more complicated experiments were designed 
to investigate the effect of Gou on the 3H-naloxone-receptor binding reaction. 
However our experiment with the binding curves described above made it clear that 
(a) a great deal of care was needed in planning and executing the experiments and (b) 
there is a great value in repeating experiments many times in order to be fairly sure of 
the data and statistical accuracy of the results. 
123 
5.5 The Effect of Gou on Ligand-receptor Binding Activity 
After the establishment of the opioid binding assay, the effect of Gou on this assay 
was investigated. 
The following reaction mixture was prepared, 
150 µl of 0.1 µM 3H-naloxone 
5-80 µl of 100 mg/ml Gou aqueous extract 
or 150 µl of 0.1 mM cold naloxone 
100 µl of 10 mg/ml rat brain membranes 
Then 50 mM Tris-HCI buffer (pH 7.4) was added until the final volume was 1000 
µl. 
The reaction mixture was incubated at 37°C for 30 minutes and then filtered using a 
Millipore Manifold Tower under vacuum conditions. In total four batches of rat 
membranes were prepared and observed so that the enough repeatibility could be 
obtained. All the results were as shown in the graphs plotted in Figures 5.5.1,5.5.2 
and 5.5.3 and Figure 5.5.4. 
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Figure 5.5.1 Dilution Curve 1 of Gou (n=3) 
NB: The drop in the "total binding" curve from A to B showed low Gou 
concentrations in spite of an apparant trend where the "non-specific binding " 
increased. 
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Figure 5.5.4 Dilution Curve 4 of Gou (n=3) 
From Figure 5.5.1 to Figure 5.5.4 it could be found that, even if all experimental 
conditions were exactly the same so far as it could be established, the result was still 
variable to some extent. This demonstrated that the naloxone-binding assay was not 
extremely repeatable. However the results presented in Figure 5.5.1 to Figure 5.5.4 
did show trends which are strongly suggestive of an antagonistic effect of a 
component of Gou on naloxone binding. The results may be summarised as follows: 
1) In the absence of cold naloxone (the black curves of Figure 5.5) there was in all 
cases a drop in the binding of labelled naloxone from zero and going to low Gou 
concentrations. Therefore Gou competed in binding to the opiate receptors, 
suggesting that it acted as an antagonist to the 3H naloxone binding in most cases, 
except for some reason at 4 mg ml-' concentration. It seems therefore that Gou 
contains several different biologically-active compounds, some of which act as 
antagonists to naloxone binding to opiate receptors and, as indicated in Chapter 4, 
some of which inhibit proteolytic enzymes involved in the turnover of enkephalins. 
2) In the presence of cold naloxone, the effect of the Gou aqueous extract on the 3H 
naloxone binding reaction became complicated: 1 to 2 mg. ml"' of Gou seemed to be 
able to increase the non-specific binding up to three times the DPM count compared 
with the control experiment at zero concentration of Gou. However at 4 mg. ml-' 
there was no significant difference with the control group at zero Gou concentration. 
02468 
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This result was difficult to explain. However, remembering that both the Gou extract 
and the rat-brain preparations were mixtures of many compounds, these effects might 
be due to: 
a) In the absence of the Gou extract, the total binding was significantly higher than 
the non-specific binding and the binding corresponds to 35,000 DPM, which 
corresponds with the binding curve of Figure 5.4. Therefore the assay itself had no 
problem. One reason why Gou could increase the non-specific uptake of 3H 
naloxone could be because it could bind with enkephalins which possibly persisted in 
the rat-brain-membrane preparations. The enkephalins could then change the 
mechanism of the 3H naloxone-binding reaction in the mixture. How and why such a 
change could occur is still unclear and this explanation is thought to be not a good 
one since it is most unlikely that enkephalins were present in the rat-brain-membrane 
preparations. 
b) It is possible that some components of Gou reacted with the 3H naloxone itself to 
cause precipitation of the radio-labelled naloxone on the filter membranes, so 
enhancing the DPM counts in a way which would be extra to the expected non- 
specific binding. 
There is no reason to expect that the drugs which inhibit the proteolytic degradation 
of enkephalins should bind to opiate receptors. However these drugs do have similar 
effects to some components of Gou, which clearly cannot be associated with opiate- 
receptor binding, but which may cause similar precipitation effects on cold naloxone 
to those discussed above. Therefore, to see if these apparent increases in non- 
specific binding, occurred also in the presence of the drugs, the opiate-binding 
procedure was carried out three times in the presence, respectively, of Bestatin, 
Captopril and Thiorphan. 
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5.6 Comparing the Effect of Standard NEP Inhibitors and Gou On 
Naloxone-opioid Receptor Binding Assay 
In order to clarify the effect of Gou on the nonspecific binding measurements further, 
the comparison experiment of Gou and the standard inhibitors of peptidases 
(Bestatin, Captopril and Thiorphan) were investigated. The result were as shown in 
Figure 5.6. 
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Figure 5.6 The Comparison of the Effects of Standard NEP Inhibitors and 
Gou On Ligand-binding Assay (n=3) 
Figure 5.6 shows that three standard inhibitors of enkephalin-hydrolysing enzymes 
increased the non-specific binding of naloxone-opioid receptor reaction systems. 
While in Gou's case it is more complicated, for the cases of Gou at 1.0 mg/ml to 
8.0 mg/ml , the non-specific 
binding was lower than total binding. But in low 
concentration (2.0 mg /ml) the non-specific binding was higher than total binding. 
The above results suggested that the Gou preparation contains enkephalin- 
hydrolysing enzyme inhibitors which can increase the non-specific binding of 
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naloxone. But Gou might also contain other compounds which might antagonise the 
binding reaction of naloxone and opioid receptor. There seems to be a statistical 
reduction of the specific binding although so far as the author is aware there is no 
reason to expect the peptidase-inhibiting drugs to be competitive for binding to 
opiate receptors. The other effect is present also namely the increase in the 3H- 
naloxone binding to the membranes in the presence of cold naloxone. 
SUMMARY 
The opioid binding assay was designed and utilised to investigate the effect of Gou 
on the naloxone-opioid-receptor binding reaction studied earlier in this chapter. The 
result showed that the Gou seemed to be able to decrease the 3H-naloxone uptake in 
the absence of cold naloxone, thus acting as an antagonist of 3H-naloxone. The three 
standard inhibitors of enkephalin-hydrolysing enzymes appeared to increase the 
nonspecific binding. This demonstrate they have not antagonism activity to naloxone. 
Gou at low concentration also increased the non-specific binding of naloxone. The 
assay , 
however is difficult and the results not very large. 
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CHAPTER VI 
THE ISOLATION OF ACTIVE INGREDIENTS 
FROM GOU AND INVESTIGATION 
OF THEIR ACTIVITY 
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INTRODUCTION 
Although the literature has indicated that about 39 compounds have been obtained 
from Gou (Liu er al, 1991,1993), it is not clear whether of these, of any, would 
show NEP inhibitory activity. The following procedures were adopted to fractionate 
the active ingredients from Gou crude extract: - 
a) Sephadex G- 10 gel filtration, 
b) Reversed-phase preparative High Performance Liquid Chromatography (HPLC); 
c) HPLC of the Gou aqueous extract and comparison of three single known 
components (rhynchophylline (Rhy), mitraphyline and pteropodine). 
Fractions were characterised by absorption spectroscopy and activity against NEP 
The HPLC separation pattern was used to investigate the stability of the Gou extract. 
6.1 Reversed-phase Preparative High Performance Liquid Chromatography 
(HPLC) 
6.1.1 Choice of Mode or Chromatomar 
The choice of chromatographic method is summarised in Figure 6.1. 
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Figure 6.1 Flow Diagram Used for the Choice of Chromatographic Systems. 
(Riley, 1997) 
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Based on the principle shown in Figure 6.1 size-exclusion chromatography is 
traditionally recommended for the separation of compounds of molecular weight 
greater than 1000 and this is still the method of choice for the determination of the 
size distributions of biomolecules. Sephadex G-10 gel filtration was therefore chosen 
to determine the size distribution of compounds existed in Gou aqueous extract in 
this thesis. According to principle the main factors to consider in the choice of mode 
of chromatography for the separation of small molecules (RMM<1000) are ionic 
character and polarity. Ionic compounds are best separated by ion-exchange 
chromatography or reversed-phase chromatography. Therefore reversed-phase 
preparative HPLC was used to fractionate the active ingredients of Gou aqueous 
extract (Riley, 1997). 
6.1.2 Reversed-phase Liquid Chromatography (RPLC) 
Recently reversed-phase liquid chromatography has developed to be an effective and 
useful mode of chromatography for the analytical and preparative separations of 
compounds in the chemical, biological, pharmaceutical and biomedical sciences 
(Horvath et al., 1976; Schomburg, 1988; Akiyama et al., 1998). This partly derives 
from the fact that the technique requires an aqueous mobile phase and so it is 
generally compatible with most aqueous samples, samples can often be injected 
directly onto the column without pre-treatment. Even if pre-treatment of the sample 
is required, it is often relatively simple. For example the Gou crude extract was 
filtered before being injected onto the column. A wide range of polar- molecular 
analytes can be separated in this way. 
The term reversed-phase liquid chromatography derives from the fact that the mobile 
phase is more polar than the stationary phase, which is the opposite of normal-phase 
chromatography. A typical reversed-phase system employs a hydrocarbonaceous 
phase covalently bonded to a silica gel and a hydro-organic mobile phase such as a 
mixture of water and acetonitrile. 
The retention of macromolecules by the stationary phase arises from repulsion of 
non-polar (hydrophobic) regions of the solute molecules by the water molecules in 
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the mobile phase. The stationary-phase surface is saturated by molecules of polar 
solvent such as acetonitrile. Basically, all the possible solute-solvent-stationary phase 
interactions contribute to retention. For a given solute the logarithm of the capacity 
ratio is linearly related to the volume fraction of the polar solvent in the mobile phase, 
D, their equations follows can be expressed this principle log K'= logk'W, -S(D where 
k', r is the capacity ratio of solute with a completely aqueous mobile phase (i. e. (D=O) 
and S is the slope coefficient. The above equation provides a covenient framework 
for characterisation of solvent strength and stationary phase polarity. The order of 
solvent strength are: methanol<acetonitrile<tetrahydrofuran. In this thesis Octadecsi- 
yllyl Silica (S5 ODS or C18) was used as the stationary phase, and 0.075 TFA+100% 
water was used as mobile phase. Acetonitrile was the polar solvent (Riley, 1997), 
and TFA was used to keep the system always acid. 
6.1.3 Reversed-phase Preparative HPLC Instrumentation 
Briefly, the HPLC instrumental system can be described by the following diagram 
(Figure 6.2). 
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Figure 6.2 Block Diagram of An HPLC Instrument 
DETECTOR 
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In this chapter reversed-phase HPLC was used to fractionate Gou aqueous extract 
so that the active ingredients could be obtained step by step. The detailed procedures 
of HPLC are described as in section 2.5 of chapter 2 and in section 6.6.1. 
RESULTS AND DISCUSSION 
6.2 Spectral Analysis of Gou Crude Extracts 
Both organic (methanol, Gmext) and aqueous (water, Gwext) extracts (prepared as 
described in section 2.1) of Gou were dissolved in 50 mM Tris-HC1 (pH 7.4) at a 
final concentration of 100 mg/ml, then diluted with 50 mM Tris-HCI (pH7.4) until 
the final concentration was 0.5 mg/ml. In order to have an understanding for the 
spectral absorption of Gou crude extracts, the aqueous extract was measured for its 
absorption between 200 nm - 900 nm on a spectrophotometer, and the background 
absorption was designed to be subtracted on the machine. The organic extract was 
also measured for its absorption in the range of 200 nm to 900 nm. Both extracts 
showed absorption peaks only in the U. V. range (about 200 nm to 340 nm). The 
absorption curves were as presented in Figure 6.3. All the following absorption 
curves were obtained by subtracting the effect of absorption cells. 
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(A) The U. V. Spectrum of the Gou Aqueous Extract (0.5mg/ml) 
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(B) The U. V. Spectrum of the Organic Extract of Gou (0.5mg/ml) 
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Figure 6.3 U. V. Spectrum of the Gou Aqueous and Organic Extracts 
(Concentration: 100 µg /ml) 
The U. V. spectrum as presented in Figure 6.3 indicated that both Gou extracts 
showed absorption in the U. V. range. The aqueous extract was found to have 
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absorption peaks at 209 nm, 275 nm, 316 nm while the organic extract had peaks at 
211 nm, 283 nm, 322 nm. Proteins are known to have absorption peaks in the region 
of 280 nm, and alkaloids have absorption peaks at about 220 nm to 240 nm. It can 
be assumed therefore that the crude extracts of Gou might contain protein or 
alkaloids. The above results were obtained by measuring the crude extracts and 
therefore experiments were essentially needed in order to carry out such 
measurements on single fractions of Gou. 
6.3 The Fractionation of Gou By Sephadex G-10 and the Effects of the 
Fractions on NEP Activity 
Spectrophotometry analysis showed that Gou aqueous extract might contain 
alkaloids or proteins. There are many molecules which have absorption peaks in the 
280 nm range. In order to determine whether proteins were involved in NEP 
inhibitory activity, proteins were precipitated from the aqueous extract by addition of 
50% ethanol. The pellet of precipitated proteins was separated from the supernatant 
by centrifugation at 13000 rpm for 5 minutes. Then the supernatant was added onto 
a Sephadex G-10 column (volume: 5 ml) and eluted with 0.5 M sodium chloride. 
The eluted fractions were collected and their effects on NEP activity were measured. 
The hydrolysis percent of 3H(leu)-enkephalin for eluted fractions of Gou aqueous 
extract were as shown in Figure 6.4. 
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Figure 6.4 The Hydrolysis Percent for the Fraction of Gou Aqueous 
Extract from A Sepadex G-10 Gel Filtration Column. 
0.5 M sodium chloride was used to wash the binding molecules, blue 
dextran was used as the marker. Loading volume 0.25 ml. Each fraction 
was assayed as in section 2.4. The enzyme dilution was 1: 20. The 
hydrolysis percent of crude enzyme (without adding fractions) was 65.5. 
The results in Figure 6.4 indicated that all the eluted fractions of Gou aqueous 
extract showed a lower hydrolysis percent of 3H(Leu)-enkephalin than the 65.5% 
hydrolysis produced by the crude rat kidney microsomal extract rich in NEP as 
described in section 4.1. But fraction 1 to 16 showed significantly lower hydrolysis 
percent than crude rat kidney microsomal extract (P< 0.05). Fraction17 to Fraction 
34 did not show significantly lower hydrolysis percent than crude rat kidney 
microsomal extract. This suggested that the inhibitory ingredients of Gou were in the 
eluted fraction of I to 16. It also suggested Sepahdex G-10 gel filtration could not 
concentrate the active ingredients into one or two fractions. 
The effect of the precipitated proteins (pellet) on NEP activity was also tested. The 
hydrolysis percent of 3H(leu)-enkephalin for the precipitated proteins (pellet) was: 
63.6% (pellet was re-dissolved in 50 mM Tris-HCl buffer pH 7.4 and measured for 
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its effect on NEP activity) and 52.7 (in phosphate buffer). This demonstrated that the 
hydrolysis percent of precipitated proteins (pellet) was as high as crude rat kidney 
microsomal fraction (65.5%). It suggested that the precipitated proteins (pellet) 
were not the active ingredients of Gou. The active ingredients still existed in the 
supernatant---they were water and ethanol soluble. 50% ethanol pretreatment 
followed with sephadex G-10 gel filtration did not isolate the active compounds 
from the Gou crude extracts. Another specific isolation method was therefore 
needed. 
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6.4 HPLC Analysis of Gou Crude Extracts 
6.4.1 High Performance Liquid Chromatography of the Gou Aqueous 
Extract 
Aqueous extracts of Gou solutions at 10 mg/ml were applied to an HPLC column 
(C18 / S5 ODS2). The detailed procedure are given in section 2.4.2 of Chapter 
2. The HPLC chromatograph of Gou is as shown in Figure 6.5. 
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Figure 6.5 A Typical HPLC Chromatograph of the Gou Aqueous Extract 
(10mg/ml). Loading volume: 50µl; Flow rate: 1mUmin; S5 ODS-2 C18 
column; Solvent system: 0.07% TFA (Trifluoroacetic acid) / 0.07% TFA+100% 
acetonitrile. (Typical of six runs) 
The typical HPLC chromatograph presented in Figure 6.5 showed that the 
aqueous extract of Gou contained at least 16 peaks in the solvent system of 
TFA/Acetonitrile. The elution times for above 16 peaks were: Peakl at 12.09 
minutes; peak2 at 15.59 minutes; peak 3 at 16.97 minutes; peak4 at 18.21 
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minutes; peak5 at 19.03 minutes; peak6 at 20.64 minutes; peak7 at 21.94 
minutes; peak8 at 24.27 minutes; peak 9 at 25.33 minutes; peakl0 at 28.99 
minutes; Peak 11 at 32.91 minutes; peak12 at 34.29 minutes; peak13 at 36.68 
minutes; peakl4 at 38.81 minutes; peakl5 at 39.74 minutes and peakl6 at 45.51 
minutes. The S5 ODS2 column (made in Bio-Rad) and the TFA/acetonitrile 
solvent were therefore suitable for this separation system. The following HPLC 
experiments were therefore corrected out with the following parameters: Loading 
volume: 50pl; Column: S5 ODS2 (C18); Eluant A: 0.07%TFA; Eluant B: 
0.07% TFA+100% Acetonitrile; Flow rate: lmi/min; Detector: 254 nm (0.0- 
0.1); and the HPLC instrument: Bio-Rad 1350. The HPLC profile is given 
further in Appendix 4. 
6.4.2 The Comparison of Two Different Runs 
In order to investigate the stability and the repeatability of the HPLC system 
presented in Figure 6.5, two different HPLC runs were compared. The result 
was as shown in the Figure 6.6. 
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Figure 6.6 Comparison of Two Different Runs of the HPLC of Gou Aqueous 
Extract. 
Run 1: red plot; Runt: green plot. Both plots were run on the same day. 
Figure 6.6 suggested that the two different runs of Gou showed the same 
HPLC elute plots if they were run during same day. This demonstrated that the 
HPLC system itself is stable and repeatable. 
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6.4.3 The High Performance Liquid Chromatogrphy of Two Different 
Extracts (Aqueous and Organic) of Gou 
In order to find out why the two extracts of Gou (aqueous and organic) have 
different inhibitory activity on NEP (as shown in the section 4.2), the HPLC 
chromatographs of two extracts of Gou were carried out. 
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Figure 6.7 The Comparison of Two Different Extracts of the Gou on HPLC 
Absorption. Red run: Gwext (10mg/ml); Blue run: Gmext (10mg/ml). Other 
HPLC parameters were the same as shown in Figure 6.5. 
The HPLC results presented in Figure 6.7 showed that the two extracts had 
different HPLC chromatographs although five common peaks were observed. 
The elution time of the above five common peaks are as follows: peak I eluted at 
15.59 minutes, peak2 eluted at 17.25 minutes, peak3 eluted at 18.21 minutes, 
peak4 eluted at 36.68 minutes and peak5 eluted at 45.51 minutes. Other peaks 
were eluted at completely different times. 
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As the organic extract of Gou only showed limited inhibitory activity on NEP 
proteolysis (section 4.2), it is likely that the above five common peaks of the 
aqueous and organic extracts of Gou are not active. The active ingredients are 
thus likely to be contained in the other different peaks of the Gou aqueous extract 
or responsible for this limited activity. 
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6.4.4 The Time Stability Determination of Gou 
In order to investigate the time stability of Gou the same batch of Gou aqueous 
extract was divided into equal aliqouts, and kept at -20°C. One aliquot was 
run HPLC at the first day (performed on 10/06/96) and another one was run 
HPLC about one year later (performed on 20/05/97). Then two different runs 
were compared in the following figure (Figure 6.8). 
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Figure 6.8 The Determination of the Time Stability of Gou 
The result presented in the Figure 6.8 showed that at least six peaks did not 
change with time. They are: peak 1 eluted 13.98 minutes, peak 2 eluted at 16.25 
minutes, peak 3 eluted at 24.50 minutes, peak 4 eluted at 28.17 minutes, peak 5 
eluted at 33.24 minutes, peak 6 eluted at 36.96 minutes and peak eluted at 39.41 
minutes. Other peaks changed with time. All the following HPLC plots were 
obtained by means of the same batch of Gwext which was prepared on 10th June, 
1996. 
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6.4.5 The Activity of Pooled HPLC Peaks on NEP 
In order to develop the isolation of the active ingredients from Gou by the HPLC 
method, the HPLC fractions were pooled into seven parts, i. e. the eluant was 
collected as shown in figure (Figure 6.9). 
MA. 
C 
O 
0 
0 
a 
4 
Min. 0.00 ý6 26 350 66.00 
P1 P7 --r; 
Figure 6.9 The Pooled Peaks of Gou Aqueous Extract. 
As shown in the Figure 6.9 every pool of fractions was evaporated and 
concentrated to dryness. Then the dried samples were washed with distilled 
water and dried again. Each pooled powder was dissolved in 80 µl of distilled 
water and then used for NEP assay. The assay of NEP actually described in the 
section of 2.3.5. The results were as shown in Table 6.1 and charted in Figure 
6.10. 
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Table 6.1 The Effects of the different Pooled HPLC Peaks on NEP 
Activity (For the method used here was the same as section 2.4) 
Specified Groups Total DPM Specific DPM Hydrolysis % 
(H D %) 
Inhibition % 
(IN 0/6) 
Pooll (80 l) 60554.34 2930.59 4.8 +++ 
Pool2 80 1 63341.40 5039.92 8.0 +++ 
Pool 3 (80 1) 61893.73 3216.52 5.2 +++ 
Pool4 80 1 71861.51 3026.34 4.2 +++ 
Pool 5 (80 l 59172.25 38822.08 65.6 - 
Pool 6 (80 1 83439.30 4095.98 4.9 +++ 
Pool 7 80 1 70015.84 8554.39 12.2 +++ 
Gwext (80 1 69786.27 11529.53 16.5 +++ 
CE (1: 20) only 59588.09 40269.53 67.5 - 
BFC (buffer control) 64425.94 3028.02 4.7 - 
Ecoscint H control 83.2+12.2 
NB: Inhibition %_ (Specific DPM/ Total DPM) x 100%; Gwext: Gou 
aqueous (water) extract; +++ :P<0.001 
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Figure 6.10 The Effects of Pooled HPLC Peaks on NEP Activity 
The enzyme assay was the same as Chapter 3. The dilution of Crude enzyme 
(CE): 1: 20; BFC: Buffer control; Gwext: Gou aqueous (water) extract (80 
µl of I00mg/ml);. CE: Crude rat kidney microsomal extract (NEP rich). 
147 
The result presented in Table 6.1 and Figure 6.10 showed clearly that Pool 5 
had the same level of hydrolysis percent of 3H(leu)-enkephalin as the crude rat 
kidney microsomal extract. It suggested that Pool 5 did not contain NEP 
inhibitor, while the other six Pools showed lower hydrolysis percent of 3H(leu)- 
enkephalin than the crude rat kidney microsomal extract. They showed positive 
inhibitory activity on NEP. Student's t-test showed their inhibitory activities are 
significant (P< 0.001). This suggested that the active ingredients of Gou aqueous 
extract were not a single compound but a mixture. They distributed in Pool 1,2, 
3,4,6 and 7, and might belong to a large group of compounds such as alkaloids, 
which have already been isolated from Gou by Liu et al. (1993). Therefore the 
positions of the peaks isolated from Gwext on HPLC plots were compared with 
such alkaloids. 
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6.5 The Comparison Experiments of Three Single Standard Compounds 
With Gou Crude (Aqueous) Extract (Gwent) 
As mentioned in previous section, Liu et al. (1991,1993) had successfully 
isolated about 39 compounds from Gou. All of them were alkaloids. And all the 
39 compounds can be represented by the following three types of compounds: 
(1) Tetracyclic-oxindole alkaloids: rhynchophylline(Rhy) etc.; 
(2) Rauwolfia Alkaloids: hirsutine etc.; 
(3) Pentacyclic-oxindole alkaloids: pteropodine, mitraphylline etc.. 
Three compounds (Rhy, mitraphylline and pteropodine) were kindly provided by 
Professor Feng of the Chinese Materia Medical Institute. The three compounds 
were run on HPLC under exactly the same experimental conditions as that of 
Gwext in Figure 6.5. The results were as shown in the following figures (Figure 
6.1la to Figure 6.11c) and described in section 6.6.1,6.6.2 and 6.6.3. 
6.5.1 The Comparison of Rhy and Gwext 
Rhy powder was prepared at 5 mg/ml in aqueous solution and diluted until the 
final concentration was 50 µg/ml, then 50 µl was analysed by HPLC plot to give 
the Figure 6.1 la. Gwext at 10mg/ml was run HPLC as for Figure 6.5 
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Figure 6.1la The HPLC Plots of Rhy and Gwext 
As shown in the Figure 6.11a Rhy peak was eluted at the elution time of 46.5 
minutes and at this elution time one peak was obtained on the Gwext plot. Rhy 
was in the range of pool 7. 
6.5.2 The Comparison of Mitraphylline and Gwext 
Mitraphylline was prepared at 500 µg/ml in aqueous solution and diluted until the 
final concentration was 50 pg/ml, then 50 gl was analysed by HPLC to give the 
plot in Figure 6.11a. Gwext was analysed as in Figure 6.11a. Both HPLC 
plots were as shown in Figure 6.11b. 
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Figure 6.11 b The HPLC Plots of Mitraphylline and Gwext 
The plot of mitraphylline in Figure 6.11 b showed that mitraphylline was eluted at 
the elution time of 37.5 minutes. As in Figure 6.11a there was a related peak 
observed in Gwext plot at the same elution time. Mitraphylline was also in the 
Pool 7 range. 
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6.5.3 The Comparison of Pteropodine and Gwext 
Pteropodine was also prepared in aqueous solution and diluted until final 
concentration became 50 µg/ml, then 50 µl was analysed by HPLC. Gwext was 
applied to the HPLC column as before. The result were as seen in Figure 6.11c. 
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Figure 6.11c The HPLC Plots of Pteropodine and Gwext 
As shown in Figure 6.1 1c the Pteropodine was eluted at the elution time of 
39.66 minutes. The related peak was obtained at the elution time of about 38.86 
minutes on Gwext plot. It was also in the range of Pool 7. 
CONCLUSION AND SUMMARY 
6.6 Conclusion 
The three single compounds were compared with Gwext in the same graph 
as shown as Figure 6.12. 
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Figure 6.12 The HPLC Plots of Three Single Compounds with Gwext 
The results presented in the Figure 6.12 suggested that all the three single 
compounds presented in the area of Pool 7. As Pool 7 was already found to 
have inhibitory activity on NEP (section 6.6.5), above three compounds might be 
the active components of Pool 7. However, the inhibitory activity of Pools 1,2, 
3,4, and 6 are greater than that of Pool 7. Clearly the aqueous extract of Gou 
contains many compounds with NEP inhibitory activity. This is unexpected and 
suggests that several different compounds may be active. 
6.7 Summary 
In this chapter the systematic chemical study of Gou crude extract was done so 
that the active ingredients could be fractionated step by step. The spectral 
analysis showed that both Gou aqueous (water) extract (Gwext) and organic 
(methanol) extract (Gmext) have absorption only in the U. V. range. And their 
absorption peaks are different (see section 6.4); 50% ethanol pre-treatment and 
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followed with sephadex G-10 column gel filtration can not separate the active 
ingredients from other molecules of Gou. Reversed-phase preparative HPLC was 
therefore chosen to fractionate the Gou crude extract, and the results showed that 
the two different extracts of Gou showed different HPLC chromatographs too. 
Repeatability experiments showed that the HPLC system is stable and repeatable; 
Gou was found in section 6.5.4 to be somewhat unstable, but if the same batch 
of Gou was kept at -20°C for one year, its HPLC plots were relatively stable. 
HPLC comparison experiments between three single alkaloids and Gwext 
showed that the three single compounds were harvested in the Pool 7 range of 
the Gwext spectrum by reversed-phase HPLC. As Pool 7 was positive on 
inhibition of NEP the above three compounds (Rhynchophylline, Mitraphylline 
and Pteropodine) might also have inhibitory activity on NEP. Pools 1,2,3,4 and 
6 however, were found to have greater NEP inhibitory activity than Pool 7, 
suggesting that the chief active compounds have not been described yet. 
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CHAPTER 7 
CONCLUSIONS AND DISCUSSIONS 
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7.1 Known Analgesic Effects of Four Chinese Herbs 
It has been known that the endogenous opioid peptides Met- and Leu-enkephalin are 
rapidly inactivated in vivo, by neutral endopeptidase (NEP E. C. 3.4.24.11) (Malfroy et 
al., 1978; Guyon et al., 1979) and aminopeptidase N (APN E. C 3.4.11.2) (Hambrook et 
al., 1976; Hersh, 1986); a further enkephalin inactivator is angiotensin-converting 
enzymes (ACE) (Waksman et al., 1984; Giros et al., 1986). In recent years the 
inhibition of enkephalin metabolism has been extensively investigated with the aim of 
testing the hypothesis that increasing the level of endogenous enkephalins in neuronal 
pathways implicated in pain transmission could lead to a "physiological" analgesia free of 
the major side effects of morphine (Roques and Fournie-Zaluski, 1986; Chipkin., 1986). 
Inhibitors of NEP and APN increase the level of endogenous enkephalin, and potent 
physiological analgesic responses should be produced without major side effects in all 
animals in pain for which morphine is normally prescribed (Fournie-zaliski et al., 1984; 
Claude et al., 1984; Nobel et al., 1991,1992,1997; Chen et al., 1998). 
Based on the above background many scientists are interested in screening the inhibitors 
of the enkephalin-hydrolysing enzymes (including NEP, APN and ACE) and have 
obtained much knowledge in this field. French scientists are concentrating on 
biosynthesis of the enkephalin-like compounds which are sensitive to NEP, APN, DAP 
and ACE (Adjroud, 1995; Nobel et al., 1991,1992,1997). So far they have 
developed a family of analgesics devoid of opioid side effects (Chen et al., 1998; Nobel 
et a!., 1997), but no compound has actually been applied clinically. Compound RB 101 
passed through clinical trial but was only slightly active after oral administration (Nobel 
et al., 1991,1992). Another compound RB 120 is currently on clinical trial ( Nobel et 
al , 
1997). Japanese scientists are engaged in screening the natural inhibitors of these 
enzymes from micro-organisms (Kojima, 1990; Akiyama et al., 1998; Otani, 1991,1992; 
Tsurumi, 1995; Kimura, 1990; Tsuru et al., 1992). However far from satisfactory 
results were obtained. As one kind of natural resource, plants are also worth 
investigating but so far no papers have been published. Traditional Chinese Herbs 
(TCH) have been used as analgesics for thousands of years (Yang et al., 1985). Thus it 
156 
might be possible to find new analgesics by use of Chinese herbs clinically. This effect 
may be mediated by altering the metabolism of endogenous enkephalin by inhibiting NEP 
and APN, thus producing analgesia free of induced physical and psychic dependence. 
So far Chinese scientists have done much work on screening new analgesics free of 
major side effects of morphine. Yang and his colleagues (1985) have successfully 
investigated the effects of three hundred cases of Chinese herbs on drug addiction in 
vivo. They used whole-animal tests to investigate the analgesic activity of twenty herbs, 
combined with data from treating opium and heroin addicts in Hong Kong. The results 
of three hundred cases were analysed and evaluated. The effects of Chinese herbs on 
withdrawal behaviour in morphine-addicted rats were also investigated. Four herbs 
(Qiang huo, Gou teng, Chuan xiong, Yan husuo) were found to reduce the three main 
withdrawal symptoms significantly. The effect of the above four herbs in combination on 
the morphine-withdrawal signs were also compared with that of endogenous opiate-like 
peptides (endorphin, enkephalin, dynorphin) and acupuncture. The analgesic effects of 
the above herbs were also studied in mice where the writhing test (a standard analgesic 
experiment-see section of 1.2) caused a reduction of the writhing sign. Tests on the 
contraction of guinea pig ileum showed that the inhibition of the enzymes caused by the 
herbs was not blocked by naloxone. This suggested that none of the above herbs 
contained morphine-like substances showing that the analgesic activity was by a different 
mechanism. Based on the study of Yang et al (1985), it was decided in this thesis to 
investigate the effects of the above four listed herbs on enkephalin-hydrolysing enzymes 
(NEP, APN and ACE), so that the molecular mechanism for the analgesic activity of 
above four herbs might be clarified and the active ingredients identified. 
The project involved screening for selective NEP inhibitors, mixed NEP/APN inhibitors 
and mixed NEP/ACE inhibitors. NEP was the key enzyme in this screening system. 
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7.2 NEP and Other Enkephalin-hydrolysing Enzyme Inhibitory Effects of Four 
Chinese Herbs 
The crude microsomal fraction containing enkephalin-hydrolysing enzymes was therefore 
prepared from the rat kidney (section 2.3.1), and the enkephalin-hydrolysing enzymes 
assay was established (Chapter 3). By using selective NEP inhibitors or mixed inhibitors 
of NEP/APN, APN/ACE, and NEP/ACE, the inhibitory effects of four Chinese herbs 
Yan; Gou; Qiang and Chuan on NEP activity were tested and compared (Chapter 4). 
Aqueous extracts of Gou (Gwext) and Qiang (Qwext) showed significant inhibitory 
activity on NEP but results with organic extracts were not significant. Both aqueous and 
organic extracts of Yan (Ywext) and Chuan (Cwext) showed less inhibitory activity than 
Gou and Qiang. This suggested that the four herbs may have different bases for their 
analgesic activity (Yang et al., 1985,1986). Gwext showed the strongest inhibitory 
activity on NEP. The minimum concentration of Gwext needed to produce detectable 
NEP inhibition was 2.5 mg dried extract per ml and 50% inhibitory concentration (IC50) 
was 2.7 mg dried extract per ml for a digestion time of 30 minutes. The experiments 
showed that Gwext and Qwext were not only dual inhibitors but also triple 
inhibitors of NEP/APN/ACE. So far there has been no report that triple inhibitors of 
the above three enzymes could be obtained, even RB 120 is only a dual inhibitor of 
NEP/APN (Nobel et al., 1997). The above results are therefore of great interest. The 
inhibitory effect of Gwext was compared with standard inhibitors and it was found that 
Gwext in the experiment showed stronger inhibitory activity than that which was 
produced by the chemical inhibitor Thiorphan and it was even stronger than the 
combined effects of Bestain and Captopril. Therefore the following work was 
concentrated on studying Gou. 
7.3 Presence of Many Compounds with NEP Inhibitory Activity in Gou Aqueous 
Extract 
To test whether one compound in Gou had inhibitory activity on the three enzymes, or 
several compounds acting together, a crude fractionation of Gou aqueous extract was 
done so that the active ingredients could be identified step by step (Chapter 6). The 
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spectral analysis showed that both Gou aqueous (water) extract (Gwext) and organic 
(methanol) extract (Gmext) have absorption peaks in the U. V. range. Reversed-phase 
preparative HPLC was chosen to fractionate the Gou crude extract, and the results 
showed that the two different extracts of Gou showed different HPLC chromatorams. 
These results partly explain why the two different extracts of Gou have different 
inhibitory activity on NEP. The Gwext was further fractionated by HPLC and pooled 
into seven parts, and the effect of each part on NEP activity was investigated. The 
results indicated that Pool 5 had no inhibitory activity on NEP while the other six pools 
showed significant inhibitory activity on NEP proteolytic action. Three single 
compounds (Rhynchophylline, Mitraphylline and Pteropodine) isolated from Gou 
by Liu et al (1993) were compared with Gwext on HPLC plots and it was shown that 
the above three single compounds were eluted in the Pool 7 range of Gwext. This result 
suggested that above three compounds might be relevant to the inhibitory activity of 
Pool 7 on NEP proteolytic action. However, the HPLC result of Gwext showed that the 
NEP inhibitory activity of Pools 1,2,3,4, and 6 are greater than that of Pool 7. Clearly 
the aqueous extract of Gou contains many compounds with NEP inhibitory activity. 
This is unexpected and suggests that at 
least five active compounds have not yet been 
identified. 
7.4 Possible Activity on Opiate Receptor by Gwext 
In order to analyse the pharmacological action of 
Gou's analgesic activity further, the 
opiate-receptor binding assay was used to investigate the effect of 
Gou aqueous extract 
on naloxone-opioid receptor binding reaction. 
The rat brain membrane was prepared as 
section 5.2.1 and the optimum ligand binding experiments were established. 
Then the 
effect of Gou on the naloxone-opioid-receptor 
binding reaction was investigated 
(Chapter 5). The result showed that the low concentration of 
Gou aqueous extract 
seemed to be able to decrease the 
3H-naloxone uptake in the absence of cold naloxone. 
The Gou seemed to act as an antagonist of 
3H-naloxone under this condition, while at 4 
mg/ml the Gou aqueous extract increased the uptakes of 
3H-naloxone and acted as an 
agonist. These results suggested Gou aqueous extract contained several compounds 
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which showed different activity on the naloxone-receptor binding assay. Gou had 
synergistic activity with naloxone which demonstrated that Gou's effect on opioid 
receptors was different from naloxone (morphine derivatives). The three standard 
inhibitors of enkephalin-hydrolysing enzymes (bestain, captopril and thiorphan) increase 
the nonspecific binding of naloxone showing that they have no antagonised activity to 
naloxone (Figure 5.6). At the same time Gou at low concentration also increased the 
non-specific binding of naloxone. Clearly Gou contains many different compounds 
which are active in the opioid system. 
Combining with Gou's inhibitory effect on enkephalin-hydrolysing enzymes, it is 
assumed that one way for Gou's analgesic activity might be due to its inactivation of 
enkephalin-hydrolysing enzymes. This effect may be mediated by altering the metabolism 
of endogenous enkephalin by inhibiting NEP and APN. 
7.5 The Composition of Gou 
Chemical study of Gou extracts (Uncaria rhynchophyiine) has been on going for about 
ten years. So far chemists have isolated and identified about 39 single compounds from 
Gou (Liu et al., 1991,1993). Most of them are alkaloids. The chemical structure of 
above 39 compounds were shown in following figure (Figure 7.1). 
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Figure 7.1 The Chemical Structure of the Compounds Isolated from Gou (Liu et 
at., 1991) The structure of Rhynchophylline is 6, Mitraphylline and Pteropodine are 5. 
Figure 7.1 suggests that Gou has been well studied for its composition. However 
properties of the above 39 compounds are far less well studied so far. 
The biological functions of some alkaloids among the above 39 compounds have been 
reported in recent years. Liu et al (1983) reported that they observed the hemodynamic 
effects of total alkaloids of Uncaria macrophylla in anaesthetized dogs. Cardiac output 
was determined by an impedance cardiograph. Intravenous (i. v. ) infusion of the total 
alkaloids isolated from Gou produced a moderate hypotension accompanied by a marked 
bradycardia. The cardiac output increased temporarily and then decreased slightly, 
where as the stroke volume consistently elevated. The total peripheral resistance 
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diminished during initial hypotension. The possible cause of hypotension may be a 
reduction of both cardiac output and peripheral resistance. Considering NEP can 
degrade atrial natriuretic peptides (ANP) which mediate the cardiovascular system 
metabolism (Seymour, 1995; RobI et al., 1996), it may be that Gou's inhibitory activity 
on NEP is related to these observations. 
7.6 Conduding Remarks 
Taken together the results presented in this study and Liu's report in 1983 , the 
pharmacological activity of Gou can be summarised as follows. 
(1) Inhibition of NEP/APN, so that the endogenous enkephalins could be kept at a 
high level and bind with opioid receptors thus producing analgesia; 
(2) Inhibition of NEP/ACE, so the atrial natriuretic peptide (ANP) could be kept 
at a high level, thus resulting in an antihypertensive effect. Above conclusion can 
also be expressed as in following chart (Figure 7.2). 
Gou 
Selective inhibition of NEP Inhibition of NEP, APN and ACE 
Endogenous ANP 
was kept at high level 
Antihypertension 
Reduced blood pressure etc 
Endogenous Enkephalin 
was kept at high level 
Showed analgesic activity free of 
major side effect of morphine 
Figure 7.2 A Possible Basis for Gou's Action 
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7.7 Scope for Future Studies 
Future studies will be concentrated on following :- 
(1) Isolation of the 39 single compounds from Gou; 
(2) Assay of the effect of the above 39 single compounds on enkephalin-hydrolysing 
enzyme (NEP and APN) activity; 
(3) Design and utilization of a subtype opioid receptor binding assay to investigate the 
effect of the above 39 single compounds; 
(4) Design and utilization of a standard analgesic assay in animals to observe the effect of 
active compounds obtained from Gou. 
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APPENDIX I 
Amino acid abbreviations 
A ALA Alanine 
C CYS Cystine 
D ASP Aspartic acid 
E GLU Glutamic acid 
F PHE Phenylalanine 
G GLY Glycine 
H HIS Histidine 
I ILU Iso-leucine 
K LYS Lysine 
L LEU Leucine 
M MET Methionine 
N ASN Asparagin 
P PRO Proline 
Q GLN Glutamine 
R ARG Arginine 
S SER Serine 
T THR Threonine 
V VAL Valine 
W TRP Tryptophan 
Y TYR Tyrosine 
A 
APPENDIX 2 
SILVER STANING OF SDS-PAGE GELS 
* Wear gloves at all times (Wash gloves before use, to remove talc. ); 
* Staining, developing, fixing and washing of gel are carried out on a flat bed rocker; 
* Stain and developer need to be made up fresh. 
1 Clean equipment/glassware with alcohol and dH2O. 
2 Wash gel in two changes of 50% McOH. Each wash time is 15-30 minutes. 
3 STAIN; Dissolve 1 xNaOH pellet in 20 ml dH2O, add 1.5 ml neat 
ammonium hydroxide; 
Dissolve 0.8 g silver nitrate (AgNO3) in 2.5 ml dH2O; 
With vigorous stirring of the ammonium solution, slowly add the silver 
solution dropwise. If a brown precipitation appears and will not clear, add 
drops of ammonium hydroxide. Dilute this solution to 200 ml (measuring 
cylinder). 
4 Rinse gel in dH2O (few seconds). 
5 Soak in silver stain for 20-40 minutes. 
6 DEVELOPER; 2.5 ML 1% citric acid 
250 µ1 formaldehyde 
up to 500 ml (measuring cylinder). 
7 Rinse gel in 2-3 changes of dH2O. 
8 Transfer gel to glass container, add developer. Brown bands should show in a few 
minutes. If precipitation appears, or developing is taking too long, pour off 
developer and add fresh. 
9 Just before developing is complete, transfer gel to dH2O. Developing will 
continue until developer is diffused out gel. 
10 Rinse gel in 2-3 changes of dH2O. 
11 FIX; 45% McOH (225 ml) 
5% acetic acid (25 nil) 
50% dH2O (250 ml) 
12. Transfer gel to fix, leave for at least 30 minutes. 
B 
APPENDIX 3 
The Student t Distribution 
Early in this century it was shown by w. s. Gossett, writing under the name of 
'Student', that the mean of a sample from normal distribution with unknown variance 
has a distribution that is similar to, but not quite the same as a normal distribution. 
He called it as the t distribution, and we still refer it as Student's t distribution. 
As the sample size increases the sampling distribution of the mean becomes closer to 
the normal distribution for large samples there is little point in doing so, since for 
large samples the methods give virtually identical answers and it is simpler to use the 
same method regardless of the sample size. 
The t distribution has one parameter, a quantity called the degrees of freedom. The 
concept of degrees of freedom is one of the more elusive statistical ideas. In general 
the degrees of freedom are calculated as the sample size, inus the number of 
estimated 
parameters. The degrees of freedom for the t distribution relate to the estimated 
standard deviation, which is calculated as variation around the estimated mean. 
Hence for a single sample of n observations we have n -1 degrees of freedom. 
One Sample t Test 
Carry out a test of the null hypothesis that our data are a population with a specific 
'hypothesized' mean. The test is called the one sample t test, and the value of t is 
calculated as 
sample mean - hypothesized mean 
t= 
standard error of sample mean 
following the common for of hypothesis tests. If population mean is some value k, 
we can rewrite the formula as 
C 
x-k 
t= 
s/' n 
(x-k) 4n 
t= 
s 
where x and s are the mean and standard deviation of the sample of size n. The 
magnitude of t is thus the average discrepqancy of the sample values from the 
hypothetical mean, divided by the standard error of the sample mean. 
The Table B4 was used to find the P value associated with an observed value of t. 
We can ignore the sign of t for a two-sided test, and look for the largest tabulated 
value oft below the observed value, the recommended level using the usual criterion 
of P<0.05. Notice that statistical significance gives no information about the 
magnitude of energy deficit, nor the uncertainty of that estimate. 
Note that we use t to indicate the observed value of the test statistic and also a 
particular value from the theoretical t distribution. For clarity I always use a subscript 
in the latter case. For many other statistical methods we use slightly different notation 
for these two purposes. 
Confidence Interval For The Median 
The methods using the t distribution to calculate a confidence interv al or perform at 
test require the data to be approximately normally distributed. We can calculate a 
confidence interval for a sample median without making any assumption about the 
distribution of the data. The data are ranked in ascending order, and the ranks of the 
values defining the confidence interval are found from a table such as that given in 
Table B11. From that table the 95% confidence interval for the median is given by 
the data values. 
D 
For small samples the confidence interval for the median is rather wide, here being 
nearly twice as wide as the confidence interval for the mean given earlier. For larger 
samples of data that have a normal distribution the mean and median will be very 
similar and their confidence intervals will agree closely. It is preferable to use the 
median if the data are not near to normal. 
Table B4 the t distribution 
The tabulated values of the t distribution correspondend to give two-tailed P values 
for different degrees of freedom. For the two-sided hypothesis test where the test 
statistic has at distribution, the P value is less than a tabulated value of P if the test 
statistic is greater than the tabulated t value. The tabulated values are tl_ cv2 where P 
=a. 
Example: For an observed statistic test t=3.21 on 20 degrees of freedom we have 
P< 0.01. 
E 
x degrees of freedom Two-tailed probability (P) 
0.2 0.1 0.05 0.02 0.01 0.001 
1 3.078 6.314 12.706 31.821 63.657 636.619 
2 1.886 2.920 4.303 6.965 9.925 31.599 
3 1.638 2.353 3.182 4.541 5.841 12.924 
4 1.533 2.132 2.776 3.747 4.604 8.610 
5 1.476 2.015 2.571 3.365 4.032 6.869 
6 1.440 1.943 2.447 3.143 3.707 5.959 
7 1.415 1.895 2.365 2.998 3.499 5.408 
8 1.397 1.860 2.306 2.896 3.355 5.041 
9 1.383 1.833 2.262 2.821 3.250 4.781 
10 1.372 1.812 2.228 2.764 3.169 4.587 
11 1.363 1.796 2.201 2.718 3.106 4.437 
12 1.356 1.782 2.179 2.681 3.055 4.318 
13 1.350 1.771 2.160 2.650 3.012 4.221 
14 1.345 1.761 2.145 2.624 2.977 4.140 
15 1.341 1.753 2.131 2.602 2.947 4.073 
16 1.337 1.746 2.120 2.583 2.921 4.015 
17 1.333 1.740 2.110 2.567 2.898 3.965 
18 1.330 1.734 2.101 2.552 2.878 3.922 
19 1.328 1.729 2.093 2.539 2.861 3.883 
20 1.325 1.725 2.086 2.528 2.845 3.850 
21 1.323 1.721 2.080 2.518 2.831 3.819 
22 1.321 1.717 2.074 2.508 2.819 3.792 
23 1.319 1.714 2.069 2.500 2.807 3.768 
24 1.318 1.711 2.064 2.492 2.797 3.745 
25 1.316 1.708 2.060 2.485 2.787 3.725 
26 1.315 1.706 2.056 2.479 2.779 3.707 
27 1.314 1.703 2.052 2.473 2.771 3.690 
28 1.313 1.701 2.048 2.467 2.763 3.674 
29 1.311 1.699 2.045 2.462 2.756 3.659 
30 1.310 1.697 2.042 2.457 2.750 3,646 
F 
APPENDIX 4 Reversed-phase HPLC Elution Profile of Gou 
The HPLC profile of Gou aqueous extract used in Chapter 6 was shown 
in following 
table. 
Table HPLC Elution Profile of Gou Aqueous Extract 
TIME % Pump 
_ 
% Pump_ FLOW RATE 
0.00 100.00 0.00 1.00 
0.10 100.00 0.00 1.00 
5.00 100.00 0.00 1.00 
5.01 95.00 5.00 1.00 
10.00 95.00 5.00 1.00 
10.01 90,00 10.00 1.00 
15.00 89.90 10.10 1.00 
15.01 85.00 15.00 1.00 
20.00 85.00 15.00 1.00 
20.01 80.00 20.00 1.00 
25.00 80.00 20.00 1.00 
25.01 75.00 25.00 1.00 
30.00 75.00 25.00 1.00 
30.01 - 70.00 30.00 1.00 
35.00 70.00 30.00 1.00 
35.01 65.00 35.00 1.00 
40.00 65.00 35.00 1.00 
40.01 60.00 40.00 100 
45.00 60.00 40.00 1.00 
45.01 55.00 45.00 1.00 
50.00 55.00 45.00 O 
50.01 50.00 50.00 1.00 
55.00 50.00 50.00 1.00 
55.01 45.00 55.00 1.00 
60.00 45.00 55.00 1.00 
60.01 0.00 100.00 1.00 
65.00 0.00 100.00 1.00 
65.10 100.00 0.00 1.00 
G 
